<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Exp Hematol Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Exp Hematol Oncol</journal-id><journal-title-group><journal-title>Experimental Hematology &#x00026; Oncology</journal-title></journal-title-group><issn pub-type="epub">2162-3619</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39891180</article-id><article-id pub-id-type="pmc">PMC11786384</article-id><article-id pub-id-type="publisher-id">602</article-id><article-id pub-id-type="doi">10.1186/s40164-025-00602-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Zhe</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Huichao</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Yin</surname><given-names>Meilong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liu</surname><given-names>Huaizheng</given-names></name><address><email>lhz3385@csu.edu.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Emergency, The Third Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, 410013 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Oncology, NHC Key Laboratory of Cancer Proteomics, Laboratory of Structural Biology, Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, 410008 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Infectious Disease, XiangYa Hospital, </institution><institution>Central South University, </institution></institution-wrap>Changsha, 410008 China </aff></contrib-group><pub-date pub-type="epub"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>31</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>14</volume><elocation-id>11</elocation-id><history><date date-type="received"><day>20</day><month>11</month><year>2024</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Liposomes and lipid nanoparticles are common lipid-based drug delivery systems and play important roles in cancer treatment and vaccine manufacture. Although significant progress has been made with these lipid-based nanocarriers in recent years, efficient clinical translation of active targeted liposomal nanocarriers remains extremely challenging. In this review, we focus on targeted liposomes, stimuli-responsive strategy and combined therapy in cancer treatment. We also summarize advances of liposome and lipid nanoparticle applications in nucleic acid delivery and tumor vaccination. In addition, we discuss limitations and challenges in the clinical translation of these lipid nanomaterials and make recommendations for the future research in cancer therapy.</p><sec><title>Graphical Abstract</title><p id="Par238">
<graphic position="anchor" xlink:href="40164_2025_602_Figa_HTML" id="d33e191"/>
</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Liposome</kwd><kwd>Lipid nanoparticle</kwd><kwd>Cancer therapy</kwd><kwd>Targeted delivery</kwd><kwd>TME, Tumor vaccination</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004735</institution-id><institution>Natural Science Foundation of Hunan Province</institution></institution-wrap></funding-source><award-id>2023JJ30830</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; YUMED Inc. and BioMed Central Ltd. 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par2">Cancer is a disease that seriously threatens human health. In 2020, there were estimated over 19&#x000a0;million new cancer cases and nearly 10&#x000a0;million cancer deaths [<xref ref-type="bibr" rid="CR1">1</xref>]. Cancer is one of the main causes for morbidity and mortality. So far, research has revealed that complex pathological process is involved in cancer occurrence, metastasis and reoccurrence. Genomic instability and mutation are common patterns in tumorigenesis while cell death resistance, induced angiogenesis, inflammation also play important roles in cancer development [<xref ref-type="bibr" rid="CR2">2</xref>]. Treatment of cancer has always been a major spotlight in medical research. Common cancer treatment methods include surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy, hormone therapy. As a common approach vastly applied in clinical practice, chemotherapy has been proved to be effective in cancer treatment. To achieve better treatment efficacy, chemotherapy is also combined with surgery [<xref ref-type="bibr" rid="CR3">3</xref>], radiation therapy and other therapies [<xref ref-type="bibr" rid="CR4">4</xref>]. However, due to intrinsic characteristics of chemical drugs, all kinds of side effects can be caused.</p><p id="Par3">Chemotherapy inhibits rapid-growing normal cells due to indiscriminate cytotoxicity of chemical drugs. These cells include bone marrow cells, hair follicles, gastrointestinal tract cells and cells in reproductive system. Chemotherapy can also cause multi-drug resistance (MDR) because of distribution heterogeneity and non-specificity of chemical drugs [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. These side effects greatly affected the treatment outcome. In addition to chemical drugs, certain antibodies and nucleic ingredient also exhibit inspiring anti-tumor efficacy. To prolong the half-life of these therapeutic drugs and specifically deliver them to the target tumor cells, nanocarriers are studies in depth. And lipid-based drug delivery system (LBDDS) is one of the most promising nanoplatforms being researched.</p><p id="Par4">To reduce chemical drug cytotoxicity towards normal tissues and cells, lipid-based nanocarriers are applied in cancer chemotherapy. Nanocarriers used in cancer therapy are generally on the scale of 1&#x02013;100&#x000a0;nm, and lipid-based nanocarriers are vastly studied in cancer therapy. Lipid-based nanocarriers are nano-scale materials made of lipids. Liposomes, solid lipid nanoparticles (sLNP), nanostructured lipid carriers (NLC), nanoemulsions, nanosuspensions, and niosomes are currently studied lipid-based nanocarriers in medical fields. These lipid-based nanocarriers are researched to deliver drugs in various diseases including skin diseases [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>], tuberculosis [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>], Alzheimer&#x02019;s disease [<xref ref-type="bibr" rid="CR11">11</xref>], infection [<xref ref-type="bibr" rid="CR12">12</xref>], ophthalmic diseases [<xref ref-type="bibr" rid="CR13">13</xref>], cardiovascular diseases [<xref ref-type="bibr" rid="CR14">14</xref>]. lipid-based nanomaterials are also used as key vehicles in mRNA vaccines. Nanoemulsions are colloidal nanoparticles. Compared with liposomes, nanoemulsions require high temperature and pressure, making it cost more in commercial manufacture. Due to lack of understanding of chemistry in NE production, the safety should be well assessed before clinical use [<xref ref-type="bibr" rid="CR15">15</xref>].</p><p id="Par5">In the fight against coronavirus disease 2019 (COVID-19), lipid nanoparticles constitute mRNA vaccine platform [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. One of the most extensively applied area of lipid-based nanocarrier is cancer therapy. Once loaded into a lipid-based drug delivery system, chemical drugs, especially those with poor water-solubility, gain better specificity, longer half-life, improved bioavailability. Compared with plain drug solutions, drugs loaded in LBDDSs also gain better pharmacokinetics [<xref ref-type="bibr" rid="CR18">18</xref>]. With sophisticated design, controllable drug release and variable targeting capability can be achieved [<xref ref-type="bibr" rid="CR19">19</xref>].</p><p id="Par6">Common LBDDSs such as liposomes and LNPs are used to improve active pharmaceutical ingredient (API) delivery in cancer treatment. In recent years, various active targeting strategies based on antigen-antibody reactions and ligand-receptor binding have been explored in the laboratory, but few can be put into clinical use [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. We summarize advances in liposomal active targeting delivery strategies and bring up possible solutions of obstacles in clinical translation. Nucleic acids are vastly researched in cancer treatment and vaccine development. To achieve better specificity towards target cancer cells, liposome and LNP vehicles used for nucleic acid delivery in cancer treatment can be modified with ligands or moieties. Cancer vaccines encapsulated with nucleic acids are also promising approaches for cancer immunotherapy and numerous researches on mRNA-based cancer vaccines are being carried out.</p></sec><sec id="Sec2"><title>The application of common LBDDSs in cancer therapy</title><p id="Par7">There are all kinds of lipid-based drug delivery system (LBDDSs) applied in cancer therapy: Liposomes, LNPs, NLCs, nanoemulsions, nanosuspensions, and niosomes. Although these materials all consist of lipid ingredients, each of them possesses unique structure and heterogeneous characteristics. Liposomes and LNPs are the most common lipid-based nanomaterials based on amount in research and clinical applications. Liposomes have a long history and were first defined in the mid-60s. They are usually described as spheres consisting of single or multiple phospholipid bilayers [<xref ref-type="bibr" rid="CR23">23</xref>]. Size and structure are two major parameters that affect characteristics of liposomes. Liposomes with unilamellar bilayer lipid membrane can be divided into small unilamellar vesicles (SUV) with size within 100&#x000a0;nm and large unilamellar vesicles (LUV) with size over 100&#x000a0;nm [<xref ref-type="bibr" rid="CR24">24</xref>]. Multilamellar vesicles (MLV) are liposomes with more than one bilayer lipid membrane. Liposomes can also encapsule several smaller micron-sized non-concentric liposomes, in which case multivesicular liposomes (MVL) are manufactured. MVLs can provide sustained drug release when applied in non-vascular administration due to this particular structure [<xref ref-type="bibr" rid="CR25">25</xref>]. Liposomes are composed of sterols, surfactants and natural or synthetic phospholipids, such as egg yolk, soybean and hydrogenated phosphatidylcholine [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. These ingredients are biodegradable, non-toxic and suitable for industrial production. The hydrophilic core and hydrophobic phospholipid bilayer make it possible to encapsule both hydrophobic and hydrophilic drugs. Compared to free cancer chemical drugs, liposomes help reduce undesired toxicity towards normal cells and tissues, prolong half-life, enhance drug solubility, improve drug pharmacokinetics and improve drug bioavailability.</p><p id="Par8">Liposomes are broadly used in food, medicine, cosmetics and other areas [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. Liposomes, nanoparticles (NPs) and micelles are vastly used nanomaterials in clinical medicine [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. In cancer treatment, liposomes have been utilized as ideal DDSs to deliver chemical drugs. There are two factors to attend to when designing liposomal DDSs for cancer treatment: encapsuled drugs/therapeutic substances and surface modification. These nano-DDSs are phagocytized by mononuclear phagocyte system (MPS) in liver and spleen, to further prolonged drug half-life, improve drug solubility and stability, reduce drug immunogenicity and antigenicity, polyethylene glycol (PEG) is used to modify liposome surface. PEGylated liposomes are harder to be recognized by MPS therefore are delivered to cancerous areas more efficiently. To date, several liposomal DDSs have been approved in cancer treatment, and some are PEGylated. These liposomal designs have shown concrete therapeutic effects in cancer treatment. Moreover, liposomes are modified to achieve better efficiency in cancer therapeutic material delivery.</p><p id="Par9">LNPs and NLCs are LBDDSs that differ in composition and structure from liposomes. LNPs are colloidal nanocarriers among 1&#x02013;100&#x000a0;nm, and LNPs are solid particles at body temperature. NLCs consist both solid and liquid lipids. Compared with traditional liposomes, these recently developed lipid nanomaterials have prolonged release and relative higher drug stability. However, solid composition also causes unpredictable gelation tendency and leads to insufficient incorporation rates [<xref ref-type="bibr" rid="CR32">32</xref>]. LNPs and metallic nanoparticles are both nano-scale particles with diameter within 1000&#x000a0;nm. This similarity indicates they can be vehicles transporting therapeutical ingredients to tumor cells [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Unlike metallic NPs, LNPs are more easily cleared from the biological system and causes less accumulation in tissues, therefore LNPs are considered to exhibit less toxicity accumulation in the organism [<xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. Structures of various liposomes and LNPs are shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.</p><p id="Par10">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Structures of various liposomes and LNPs. <bold>a</bold> SUVs (within 100&#x000a0;nm) and LUVs (over 100&#x000a0;nm). <bold>b</bold> MLVs. <bold>c</bold> MVLs. <bold>d</bold> LNPs. LNP: Lipid nanoparticle; SUV: Small unilamellar vesicles; LUV: Large unilamellar vesicles; MLV: Multilamellar vesicles; MVL: Multivesicular liposomes</p></caption><graphic xlink:href="40164_2025_602_Fig1_HTML" id="d33e352"/></fig>
</p><p id="Par11">Nanoemulsions, nanosuspensions and niosomes are also explored in cancer therapy [<xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. Doxil is the first liposomal nano-DDS approved by FDA (Food and Drug Administration). Doxil is a liposomal DDS that encapsulates doxorubicin, it is PEGylated in the surface and used in various cancer treatment including breast, bone, ovarian, breast, lung, brain cancer, leukemia and AIDS-related Kaposi&#x02019;s sarcoma. Doxil has achieved concrete clinical success since it was developed and approved by FDA in 1995 [<xref ref-type="bibr" rid="CR41">41</xref>]. To date, almost all FDA-approved LBDDSs have been manufactured based on liposomes [<xref ref-type="bibr" rid="CR42">42</xref>], suggesting that liposomes are one of the most promising lipids nanoplatforms (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Lipid-based nanocarriers using various therapeutic approaches including chemotherapy, immunotherapy and nucleic acid drugs have also been tested by clinical trials (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>) (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/">https://clinicaltrials.gov/</ext-link>).</p><p id="Par12">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Summary of FDA-approved LBDDSs in cancer therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Brand name</th><th align="left">Pharmaceutical ingredients</th><th align="left">Indication(s)</th><th align="left">Composition</th><th align="left">Approval year</th></tr></thead><tbody><tr><td align="left">Doxil</td><td align="left">Doxorubicin (DOX)</td><td align="left">Breast, bone, ovarian, breast, lung, brain cancer, leukemia, AIDS-related Kaposi&#x02019;s sarcoma</td><td align="left">HSPC, Cholesterol, DSPE-PEG 2000</td><td char="." align="char">1995</td></tr><tr><td align="left">DaunoXome</td><td align="left">Daunorubicin</td><td align="left">Advanced HIV-associated Kaposi&#x02019;s sarcoma</td><td align="left">DSPC, Cholesterol</td><td char="." align="char">1996</td></tr><tr><td align="left">Depocyt</td><td align="left">Cytarabine</td><td align="left">Lymphomatous meningitis</td><td align="left">DOPC, DPPG, Cholesterol, Triolein</td><td char="." align="char">1999</td></tr><tr><td align="left">Marqibo</td><td align="left">Vincristine</td><td align="left">Acute Lymphoblastic Leukemia</td><td align="left">Sphingomyelin, Cholesterol</td><td char="." align="char">2012</td></tr><tr><td align="left">Onivyde</td><td align="left">Irinotecan</td><td align="left">Metastatic pancreatic cancer</td><td align="left">DSPC, MPEG-2000, DSPE</td><td char="." align="char">2015</td></tr><tr><td align="left">Vyxeos</td><td align="left">Daunorubicin and cytarabine</td><td align="left">Acute myeloid leukaemia</td><td align="left">DSPC, DSPG, Cholesterol</td><td char="." align="char">2017</td></tr></tbody></table></table-wrap>
</p><p id="Par13">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Examples of cancer LBDDSs in clinical trials (as of January 2025)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Therapy</th><th align="left">Nano-platform name</th><th align="left">Indication(s)</th><th align="left">Composition</th><th align="left">NCT number</th><th align="left">Status</th><th align="left">Outcome (year)</th></tr></thead><tbody><tr><td align="left">Chemotherapy</td><td align="left">EndTAG-1(2016)</td><td align="left">Breast cancer</td><td align="left">Liposomal paclitaxel</td><td align="left">NCT03002103</td><td align="left"><p>Phase III trial ongoing</p><p>Suspended</p></td><td align="left">Undisclosed (2024)</td></tr><tr><td align="left">Chemotherapy</td><td align="left">MM-302(2014)</td><td align="left">Breast cancer</td><td align="left">HER2-targeted liposomal doxorubicin hydrochloride</td><td align="left">NCT02213744</td><td align="left">Phase III trial terminated</td><td align="left">Negative (2017)</td></tr><tr><td align="left">Chemotherapy</td><td align="left">ThermoDox(2009)</td><td align="left">Breast cancer</td><td align="left">Thermally sensitive liposomal doxorubicin</td><td align="left">NCT00826085</td><td align="left">Phase III trial completed</td><td align="left">Positive (2017)</td></tr><tr><td align="left">Immunotherapy</td><td align="left">DPX-Survivac(2014)</td><td align="left">Lymphoma</td><td align="left">Liposomal survivin-based synthetic peptide antigens</td><td align="left">NCT02323230</td><td align="left">Phase II trial terminated</td><td align="left">Negative (2021)</td></tr><tr><td align="left">Immunotherapy</td><td align="left">PNT2258(2012)</td><td align="left">Lymphoma</td><td align="left">Liposomal DNA interference oligonucleotides PNT100</td><td align="left">NCT01733238</td><td align="left">Phase II trial completed</td><td align="left">Positive (2020)</td></tr><tr><td align="left">Nucleic acid</td><td align="left">SGT-53(2015)</td><td align="left">Pancreatic cancer</td><td align="left">Liposomal p53 plasmid</td><td align="left">NCT02340117</td><td align="left">Phase II trial recruiting</td><td align="left">Recruiting</td></tr><tr><td align="left">Nucleic acid</td><td align="left">TKM-PLK1(2010)</td><td align="left">Neuroendocrine tumors and adrenocortical carcinoma</td><td align="left">Lipid NP containing PLK1 siRNA</td><td align="left">NCT01262235</td><td align="left">Phase II trial completed</td><td align="left">Undisclosed (2015)</td></tr><tr><td align="left">Nucleic acid</td><td align="left">WGI-0301(2022)</td><td align="left">Advanced solid tumors</td><td align="left">Lipid NP Suspension of Akt-1 antisense oligonucleotide</td><td align="left">NCT05267899</td><td align="left">Phase I trial recruiting</td><td align="left">Recruiting</td></tr></tbody></table></table-wrap>
</p><p id="Par14">LNPs are colloidal particles with the ability of nucleic acid encapsulation and delivery. Genetic drugs such as mRNA, small interfering RNA (siRNA) and plasmid DNA are used in gene therapy [<xref ref-type="bibr" rid="CR43">43</xref>]. LNPs were originally designed to deliver siRNAs, and recently LNPs were used in mRNA delivery in cancer gene therapy and cancer vaccine development [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Encapsulation of these therapeutic nucleic acid helps improve their stability, facilitate internalization, limit immune activation and increase target specificity. We summarize recent advances of LNP application in cancer gene therapy and cancer vaccine development.</p></sec><sec id="Sec3"><title>Liposomes and targeted delivery</title><p id="Par15">Conventional chemical drugs are used in cancer chemotherapy. Because of indiscriminate cytotoxicity towards fast-growing cells, these free drugs exhibit various side effects. Nanomaterial based DDSs are applied to reduce these undesired side effects. Once loaded into liposomes, chemical drugs as well as other therapeutic materials gain better specificity towards cancer cells. In liposomal DDS targeting area, two major techniques are used: passive targeting and active targeting.</p><sec id="Sec4"><title>Passive targeting</title><p id="Par16">Passive targeting is primarily based on the enhanced permeability and retention (EPR) effect created by the specific structure of the cancer tissue. In comparison to normal tissue, cancer tissue forms plentiful aberrant vascular and excessive vascular permeability factors, and lack of lymphatic drainage. These features help liposomal DDSs target at cancer cells and achieve enrichment at cancerous areas. With better specificity, liposome encapsuled chemical drugs show less toxicity to normal organs or tissues, therefore lead to fewer side effects [<xref ref-type="bibr" rid="CR46">46</xref>]. Although EPR effect has been reported and studied broadly, most nanodrugs based on EPR effect show unfavorable targeting efficacy. The reason is that EPR effect has its limitations. Research showed that the frequency of gaps in tumor tissues could not fully explain nanoparticle accumulation in tumor. Further research showed that EPR effect possesses quite heterogeneity across tumor types and patient individuals [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>].</p><p id="Par17">Liposomal DDS are nanomaterials, therefore possess basic characteristics such as high surface-to-volume ratio, enhanced biocompatibility and increased permeability through biological barriers [<xref ref-type="bibr" rid="CR49">49</xref>]. However, compared with other nanomaterials such as polymeric NPs, metallic NPs, intrinsic electrical conductivity, superparamagnetic behavior or optical features of liposomes are less used in medical fields. Over the years, active targeted liposomal DDS have been vastly researched. Active targeting is commonly realized by conjugating certain ligands to liposome surface. These modified liposomes mainly target at two categories: cancer cells and tumor microenvironment (TME). TME refers to the environment setting that promotes tumor. TME includes fibroblasts, endothelial cells that associated with cancer, immune cells and extracellular matrix also interact with cancer cells [<xref ref-type="bibr" rid="CR50">50</xref>]. Research show that innate and adaptive immune cells in TME can secrete growth factors and cytokines that contribute to tumor invasion, metastasis, interactions of cancer cells and TME immune cells also attenuate antitumor immunity [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR52">52</xref>]. Surface of liposomal DDSs are modified with various molecular moieties such as antibodies, proteins, peptides, aptamers. Most of these moieties bond specifically to receptors that are highly expressed in cancer cells or TME, while some bond to enzymes that contribute to tumor growth. It should be noted that the active targeting strategy that conjugates liposome with molecular moieties is based on the EPR effect, and the moieties contribute to liposome internalization process (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>).</p><p id="Par18">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Schematic representation of passive and active targeted delivery. <bold>a</bold> Liposomal nanocarrier delivers drugs to cancer cells through EPR effect. <bold>b</bold> Illustration of liposomal active targeted delivery strategies. Liposome endocytosis and transcytosis mediated by folate-FR conjugation</p></caption><graphic xlink:href="40164_2025_602_Fig2_HTML" id="d33e686"/></fig>
</p></sec><sec id="Sec5"><title>Active targeting strategy</title><sec id="Sec6"><title>Ligands</title><p id="Par19">Ligands are commonly used in active targeting in liposome manufacture. As ligands bind to corresponding receptors, specific ligands help guide the liposomal nano-DDS to enrich in target cancerous areas. Transferrin receptor (TfR), folate receptor (FR), estrogen receptor (ER) and hyaluronic acid receptor are vastly investigated ligand-binding targets. TfRs are glycoproteins that bind to iron in blood plasma. TfR plays important roles in cellular iron uptake. In normal cells, TfR is highly expressed on placental tissue, immature erythroid cells and other rapidly dividing cells [<xref ref-type="bibr" rid="CR53">53</xref>]. Tumor cells are rapidly proliferating cells and TfR is highly expressed in many cancer cells. Researches show that TfR is heavily distributed in blood-brain barrier (BBB) and glioblastoma multiforme (GBM) cells [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. TfR is also found to be highly expressed in other solid tumors such as breast cancer and hepatocellular carcinoma. Research indicates that TfR1 overexpression can be a potential prognostic indicator of hepatocellular carcinoma [<xref ref-type="bibr" rid="CR56">56</xref>]. Zhang et al. developed a doxorubicin (Dox)-loaded liposomal nanocarrier, and the holo-lactoferrin (holo-Lf) was attached to the nano-DDS as it is a natural protein that acts as a ligand of TfR. The nanocarrier exhibited satisfactory cellular uptake [<xref ref-type="bibr" rid="CR20">20</xref>]. Compared to single target modified liposomes, some liposomes are co-modified with both TfR and penetration enhancers. These designs accomplish better specificity and endocytosis efficacy towards target cells. Desphande and coworkers developed a dual-functional liposome modified with both transferrin and octaarginine, a popular penetration enhancer by improving cell micropinocytosis. The liposomal nanocarrier loaded with Dox showed improved drug accumulation in ovary tumors [<xref ref-type="bibr" rid="CR57">57</xref>].</p><p id="Par20">Folate receptor is also a common target in active targeting strategies. Folate is converted from folic acid in the body. Folate plays important roles in nucleotide base synthesis and cell division. There are several isoforms of FRs and some FRs are expressed on the surface of epithelial cells [<xref ref-type="bibr" rid="CR58">58</xref>]. FRs are found to be overexpressed in many tumors including liver cancer, lung cancer, breast cancer, ovarian cancer, prostate cancer [<xref ref-type="bibr" rid="CR59">59</xref>&#x02013;<xref ref-type="bibr" rid="CR62">62</xref>]. In liposomal nano-DDS design, FRs are often used as practical targets to guide the nanocarrier. As folate receptor is overexpressed in lung cancer cells, many researches have conjugated folate onto the nanocarrier to gain better specificity towards lung cancer cells. Park et al. developed a pH-sensitive liposome carried with doxycycline and docetaxel in non-small cell lung cancer (NSCLC) treatment. The liposome was modified with folate in the surface to specifically target at M2 tumor-associated macrophages and NSCLC cells, and the liposome exhibited specific targeting ability and controlled release ability [<xref ref-type="bibr" rid="CR63">63</xref>]. A topotecan liposome was modified with folate and exhibited improved therapeutic efficacy against A549 lung cancer cells [<xref ref-type="bibr" rid="CR64">64</xref>]. A delicate liposome-based nano-DDS was developed by Lv and coworkers, the liposome platform was modified with folate and encapsulated with magnetic nanoparticles, gold nanorods and DOX, and the liposomal DDS could specifically bind bladder tumor cells and exert cytotoxicity [<xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par21">Another vastly studied target in active target liposome design is estrogen receptor. ER binds to estrogen that play important roles in women&#x02019;s sexual and reproductive system. There are two subtypes of ER: Er&#x003b1; and Er&#x003b2;. ER expression varies in human cancers. There are approximately 75% Er&#x003b1; positive breast cancer cases at diagnosis [<xref ref-type="bibr" rid="CR66">66</xref>]. ER is used as a potential target in ER-positive cancer treatment including breast cancer, gastric cancer and acute myeloblastic leukemia [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. Estrone targeted liposomal nano-DDS have been developed to achieve better drug efficacy. Xu et al. [<xref ref-type="bibr" rid="CR69">69</xref>] developed an estrone-targeted liposomal system to deliver mitoxantrone in human acute myeloblastic leukemia treatment, and the in vivo experiment conducted in mouse showed that the liposomal nano-DDS could be well delivered to targeted ER-expressing tumor cells. Drug circulation time was prolonged and drug side effects was reduced. Chemotherapy is the main option in advanced metastatic gastric cancer treatment [<xref ref-type="bibr" rid="CR70">70</xref>]. However, oxaliplatin, the chemo-drug used results in serious side effects including nausea, vomiting, mucosal inflammation and neurological toxicity [<xref ref-type="bibr" rid="CR71">71</xref>]. An oxaliplatin loaded, estrogen targeted PEGylated liposome was developed and exhibited concrete anti-tumor efficacy, improved metabolic behavior and reduced toxicity towards normal tissues [<xref ref-type="bibr" rid="CR72">72</xref>]. ER is also used as practical target in cervical cancer nano-DDS design. Li and coworkers designed a PEGylated liposomal nano-DDS platform for cisplatin delivery. The target specificity and metabolic behavior was improved and myelosuppression was decreased [<xref ref-type="bibr" rid="CR73">73</xref>].</p><p id="Par22">Cluster of differentiation 44 (CD44) is a glycoprotein expressed on cancer cell surface. CD44 overexpress in many tumors including breast, pancreatic, ovary, brain and lung tumors [<xref ref-type="bibr" rid="CR74">74</xref>]. CD44 specifically binds to hyaluronic acid (HA) and chondroitin sulfate (CS), therefore can be utilized as a target tool in liposomal platform design. CD44 was found to be related to various physiological and pathological functions including angiogenesis, cell differentiation, proliferation and tumor metastasis [<xref ref-type="bibr" rid="CR75">75</xref>]. A stimuli-responsive polysaccharide modified liposomal platform with CD44 targeted ability was developed. The redox-sensitive amphiphilic CS and HA were conjugated onto the liposome and therapeutic shRNA that silences the inhibitor of apoptosis was loaded into the liposome. The liposomal carrier suppressed the tumor growth and exhibited low toxicity to mice [<xref ref-type="bibr" rid="CR76">76</xref>]. Dong et al. developed an epalrestat and DOX dual-loaded liposome in triple-negative breast cancer treatment, and HA tagged on the surface provided effective target ability through CD44-HA interaction. The liposome suppressed tumor growth and metastasis [<xref ref-type="bibr" rid="CR77">77</xref>]. These ligand-receptor active targeting strategies are closed associated with receptor expression level in target cancer cells, and with specific ingredients that enhance permeability and bioavailability, ligand-based liposomal DDS exhibit satisfactory delivery efficacy.</p></sec><sec id="Sec7"><title>Proteins and peptides</title><p id="Par23">The specific antigen-antibody conjugation has been utilized to achieve better targeted ability of liposomes. Since various proteins are expressed on cancer cell and TME cell surface, antibodies of these proteins can be used to help target at desired cancerous sites. Once conjugated with corresponding antibodies, receptors on cell surface can also cause series of changes of downstream signaling and exert anti-tumor effect. Therefore, active targeting strategy can be closely related with targeted therapy that aims at specific targets in cancer targeted therapy. Epidermal growth factor receptor (EGFR) is an important signaling component that regulates various processes such as cell proliferation, differentiation, growth and inhibition of apoptosis [<xref ref-type="bibr" rid="CR78">78</xref>]. Combination with epidermal growth factor (EGF) results in downstream signal transduction, which are PI3K/AKT/mTOR, Ras/MAPK and PLC/PKC signaling or changes in expression level [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. PI3K/AKT/mTOR signaling pathway regulates cell metabolism, proliferation and cell survival. This pathway is often heavily activated as a result of EGFR mutation. LBDDSs can be designed to specifically target at EGFR and inhibit it, which leads to inhibition of PI3K/AKT/mTOR activation. Since activation of EGFR regulates signaling network and affect cancer cell proliferation, migration and apoptosis, EGFR and related proteins have become effective targets for cancer treatment. EGF can be conjugated with liposomes to enhance targeted ability of liposomal nano-carrier. Silver nanoparticles (AgNPs) are toxic therapeutic materials for both cancer and healthy cells, and to reduce toxicity towards normal cells, researchers developed an EGF-labeled AgNP loaded liposome. The liposomal nano-platform exhibited fewer toxicity against normal human fibroblasts and elevated proapoptotic effect and toxicity against EGFR-overexpressing cancer cells [<xref ref-type="bibr" rid="CR80">80</xref>]. In pancreatic cancer treatment, EGF is also used to enhance the targeted ability of liposomes. Le and coworkers fabricated an EGF-conjugated liposome containing curcumin. The liposomal nanocarrier was tested with human pancreatic cancer cell lines that express EGFR, and the EGF-decorated liposome enhanced the antitumor activity of curcumin in pancreatic cancer chemotherapy [<xref ref-type="bibr" rid="CR21">21</xref>]. Other than ligand-receptor combination similar to EGF-EGFR, antibodies of target receptors can also be used to modify liposome surfaces and used in targeted delivery. With these specific antibodies, the liposomal platform can combine chemotherapy and targeted therapy at the same time. Cetuximab is an anti-EGFR monoclonal antibody. DTX is broadly used in metastatic prostate cancer chemotherapy. Eloy et al. designed a targeted immunoliposome with cetuximab modified on the surface. And the cetuximab targeted liposome had high DTX encapsulation efficiency. Higher cellular uptake and toxicity in EGFR-overexpressing prostate cancer cells DU145 was exhibited compared to non-targeted liposomes [<xref ref-type="bibr" rid="CR81">81</xref>]. Another member of human epidermal growth factor receptor family is human epidermal growth factor receptor 2 (HER2), which is also a transmembrane glycoprotein that possesses tyrosine kinase activity. Although HER2 doesn&#x02019;t bind any ligand, it is essential in mediation of signaling pathways [<xref ref-type="bibr" rid="CR82">82</xref>]. HER2 is an important target for cancer treatment as HER2 overexpresses in many cancers and is found to be strongly associated with increased recurrence and poor prognosis [<xref ref-type="bibr" rid="CR83">83</xref>]. HER2 antibody can also be utilized in liposome surface modification. Li and coworkers built a light-sensitive liposome consisting of hydrophobically modified photosensitizer (ICG-ODA) and special phospholipid (PLsPC). DOX was encapsuled to exert anti-tumor effect while the surface was modified with HER2 antibodies to target specifically at high HER2 receptor expression tumor cells. The liposomal system showed significant accumulation in MCF7 and SKOV3 tumor cells due to mediation of HER2 antibody [<xref ref-type="bibr" rid="CR84">84</xref>]. As TfR is heavily expressed in BBB and GBM cells, TfR can also be used in active targeting strategy. A docetaxel (DTX) liposome co-modified with muscone/RI7217 was developed to treat glioma. RI7217, a mouse monoclonal antibody that possesses high affinity and selectivity for TfR, was modified in the surface of the liposome. Muscone was reported to inhibit P-glycoprotein and matrix metalloproteinase-9 expression and thereby relax the epithelial cell junction. Muscone alters BBB permeability and boosts drug uptake in the brain. The liposomal DDS exhibited improved brain targeting efficacy [<xref ref-type="bibr" rid="CR85">85</xref>].</p><p id="Par24">In active targeted liposomal manufacture, antibody fragments (Fab) and single-chain variable fragment (scFv) are also used in liposomal surface modification [<xref ref-type="bibr" rid="CR86">86</xref>]. Because antibody may contain more than one reactive group, heterogeneity can be generated when the antibody is conjugated on the liposome surface, and improper orientation towards the antigen also leads to targeted efficacy heterogeneity [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. And research show that covalent reactions that bind antibody to liposome might potentially affect the antibody or the liposome, leading to heterogeneity in targeting efficacy [<xref ref-type="bibr" rid="CR89">89</xref>]. Therefore, various modification methods have been explored to modify antibody or their peptide fragment. A recombinant Fab antibody fragment was generated, and the protein D derived from pulmonary surfactant was fused on the C-terminus of the fragment. The fused protein D can be inserted into liposome bilayer and anchored the Fab to the liposomal surface [<xref ref-type="bibr" rid="CR86">86</xref>]. Li and coworkers fabricated two immunoliposomes conjugated with anti-EGFR-Fab&#x02019;, and siRNA was encapsuled as therapeutic agents. The liposome-polycation-DNA complex (LPD) exhibited good targeting and gene silencing ability [<xref ref-type="bibr" rid="CR22">22</xref>]. Compared with the whole antibody molecule, the Fab/scFv used in these researches exhibit reduced immunogenicity and improved pharmacokinetics. Peptide fragments also have easier preparation, lower cost, decreased opsonization, lower antigenicity and better stability against enzymatic degradation [<xref ref-type="bibr" rid="CR90">90</xref>]. These properties make peptide more beneficial than whole antibodies in clinical use.</p><p id="Par25">Targeting TME is also an important active targeting strategy. Blood vessels, fibroblast, signaling molecules, extracellular matrix (ECM) and immune cells in TME are possible targets in anti-tumor liposome design [<xref ref-type="bibr" rid="CR91">91</xref>&#x02013;<xref ref-type="bibr" rid="CR93">93</xref>]. Immune checkpoint molecule is an important category in cancer immune. Regulators of immune responses can also become targets for active targeting strategies. Programmed cell death ligand 1 (PD-L1) is known as an immune checkpoint that overexpresses on tumor cells. It binds to programmed death-1 (PD-1) receptor present on activated effector T cells [<xref ref-type="bibr" rid="CR94">94</xref>]. PD-1/PD-L1 interaction down-regulates T cell antitumor activity and reduces inhibitory cytokine secretion, therefore can suppress immune function and promote tumor progression [<xref ref-type="bibr" rid="CR95">95</xref>]. Liposomes targeting on PD-1/PD-L1 axis are developed based on these researches. A dual activity immunoliposome loaded with DOX was developed and tested in melanoma murine model. A monovalent-variable fragment (Fab&#x02019;) of PD-L1 monoclonal antibody was modified onto the liposome surface. Result showed that the immune checkpoint inhibitor (ICI) modified immunoliposome bound specifically to PD-L1&#x02009;+&#x02009;cells and decreased 30-fold the IC50 compared to conventional liposomes [<xref ref-type="bibr" rid="CR96">96</xref>]. There are massive researches towards TME and receptors related to cancerous angiogenesis, vascular co-option, cell adhesion, cell migration are studies as targets for liposome design [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>]. Vascular endothelial growth factor (VEGF) is a vital regulator in cancer abnormal angiogenesis and the vascular endothelial growth factor receptor-2 (VEGFR-2) overexpresses in human breast cancer cells. A DTX encapsuled functional VEGF antibody modified liposome was fabricated in breast cancer treatment. The result showed that cellular uptake of DTX carried by liposome was significantly higher than free DTX and the liposomal nanocarrier resulted in significant reduction in tumor burden [<xref ref-type="bibr" rid="CR99">99</xref>]. Researches aiming at TME remodeling and immune regulation through liposomal delivery have also been vastly conducted [<xref ref-type="bibr" rid="CR100">100</xref>&#x02013;<xref ref-type="bibr" rid="CR102">102</xref>].</p></sec><sec id="Sec8"><title>Aptamers</title><p id="Par26">Aptamers are short single-stranded DNA (ssDNA) or single-stranded RNA (ssRNA). The in vitro approach called systematic evolution of ligands by exponential enrichment (SELEX) is a major approach to isolate evolution of synthetic ssDNA/ssRNA during aptamer production in vitro [<xref ref-type="bibr" rid="CR103">103</xref>, <xref ref-type="bibr" rid="CR104">104</xref>]. Similar to antibodies, aptamers can also specifically bind to corresponding targets with high affinity [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR106">106</xref>]. However, compared to antibodies, aptamers bear better properties including higher thermal stability, less immunogenicity. And lower production cost of aptamers allows large-scale synthesis [<xref ref-type="bibr" rid="CR107">107</xref>, <xref ref-type="bibr" rid="CR108">108</xref>]. Aptamers possess better tumor penetration and retention properties because of smaller size. Homogenous distribution also makes it ideal for modification of targeted delivery liposomes [<xref ref-type="bibr" rid="CR109">109</xref>]. Aptamers can be conjugated to surface of nanomaterials with higher density and less steric hindrance compared to antibodies fragments. To date, novel liposomal drug carriers modified with aptamers have been fabricated and tested in cancer therapy. Active pharmaceutical ingredient (API) is the key component of liposomal DDS. BRAF gene mutation is common in over 60% malignant melanomas. An active targeted liposome encapsuled with anti-BRAF siRNA (siBraf) was developed in melanomas treatment. AS1411 is an aptamer specifically binds to nucleolin and the PEGylated cationic liposome was modified with AS1411. The AS1411-PEG-liposome exhibited significant silencing activity of BRAF gene and higher siRNA accumulation compared with normal cells. The liposomal nanocarrier inhibited the melanoma growth [<xref ref-type="bibr" rid="CR110">110</xref>]. AS1411 was also utilized in other aptamer-functionalized liposomes in breast cancer and basal cell carcinoma treatment [<xref ref-type="bibr" rid="CR111">111</xref>, <xref ref-type="bibr" rid="CR112">112</xref>]. These studies suggest that aptamers have great potential in active targeted liposome design. To sum up, various materials have been utilized in active targeting strategies and achieved favorable results (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). In addition to employ various moieties to achieve active targeting, stimuli-responsive strategies can also enhance the targeting efficacy of the nano-drug.</p><p id="Par27">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Active targeted liposomes used in cancer therapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Targeted moieties</th><th align="left">API</th><th align="left">Target cancer model</th><th align="left">Anti-cancer effect</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Holo-lactoferrin (holo-Lf)</td><td align="left">Dox</td><td align="left">Murine breast cancer cell line 4T1</td><td align="left">The Lf-liposome-Dox relieved tumor hypoxic microenvironment and achieved excellent cancer treatment effect combined with radiotherapy.</td><td align="left"> [<xref ref-type="bibr" rid="CR20">20</xref>]</td></tr><tr><td align="left">Antibody RI7217</td><td align="left">DTX</td><td align="left">U87-MG glioma cells and immortalized hCMEC/D3</td><td align="left">The muscone and RI7217 modified DTX liposome showed improved brain targeting and prolonged survival time of tumor-bearing mice.</td><td align="left"> [<xref ref-type="bibr" rid="CR85">85</xref>]</td></tr><tr><td align="left">Folate</td><td align="left">Doxycycline and docetaxel</td><td align="left">Human NSCLC cell line A549</td><td align="left">Effectively inhibited tumor growth and reduced drug side effects.</td><td align="left"> [<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td align="left">Estrone</td><td align="left">Mitoxantrone</td><td align="left">Human acute myeloblastic leukaemia HL-60 cells</td><td align="left">The liposomal nanocarrier effectively entered into ER-expressing cells and accumulated, prolonged circulation time and reduced side effects.</td><td align="left"> [<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td align="left">EGF</td><td align="left">Curcumin</td><td align="left">Human pancreatic cancer cell lines, BxPC-3, Panc-1 and Mia Paca-2</td><td align="left">The curcumin loaded liposome exhibited enhanced antitumor activity with surface modified EGF.</td><td align="left"> [<xref ref-type="bibr" rid="CR21">21</xref>]</td></tr><tr><td align="left">Anti-EGFR-Fab&#x02019;</td><td align="left">siRNA</td><td align="left">Human hepatocellular carcinoma cell line SMMC-7721</td><td align="left">Immunoliposomes conjugated with anti-EGFR Fab&#x02019; showed higher luciferase gene silencing efficiency and were more effective in targeting hepatocellular carcinoma cells for siRNA delivery.</td><td align="left"> [<xref ref-type="bibr" rid="CR22">22</xref>]</td></tr><tr><td align="left">VEGF antibody</td><td align="left">DTX</td><td align="left">Human breast cancer cell line MCF-7</td><td align="left">The VEGF modified liposome exhibited enhanced cellular uptake and cytotoxicity.</td><td align="left"> [<xref ref-type="bibr" rid="CR99">99</xref>]</td></tr><tr><td align="left">AS1411</td><td align="left">siBraf</td><td align="left">Melanoma cell A375</td><td align="left">The AS1411 modified liposome showed excellent tumor-targeting ability, silencing activity and melanoma inhibition in A375 tumor xenograft mice.</td><td align="left"> [<xref ref-type="bibr" rid="CR110">110</xref>]</td></tr></tbody></table></table-wrap>
</p></sec></sec></sec><sec id="Sec9"><title>Stimuli-responsive strategy and combined therapy</title><p id="Par28">These proteinic and nucleic acid fragment provide specific active binding of modified liposomes and cancerous target based on EPR effect. Another technique studied in liposomal targeted delivery is stimuli-responsive strategy. This method is based on characteristics of TME and unique properties of modified liposomes (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>). Acid environment allows possibility of pH-responsive liposomes. As pH level in cancerous tissues is lower than normal tissues, researchers have conducted experiments in pH-sensitive liposome design. Two strategies can be taken in the process: either by aiming at choosing specific composition of the system or anchoring polymers to the liposomal membrane. To make pH-sensitive liposomes, unsaturated phosphatidylethanolamine (PE) can be used. Typical PE includes diacetylenic-phosphatidyl-ethanolamine (DAPE), palmitoyl-oleoyl-phosphatidyl ethanolamine (POPE) and dioleoyl-phosphatidyl-ethanolamine (DOPE) [<xref ref-type="bibr" rid="CR113">113</xref>]. Mildly acidic amphiphiles such as oleic acid, cholesteryl hemisuccinate (CHEMS) and N-palmitoyl-l-homocysteine (PHC) are combined with DOPE and stabilize the liposome at neutral pH. In acid environment, carboxyl groups of acidic amphiphiles are protonated and eventually result in membrane destabilization of pH-sensitive liposomes and release of encapsulated cargo. Another common approach is to conjugate pH-sensitive peptide/proteins or synthetic polymers to liposomal surface [<xref ref-type="bibr" rid="CR114">114</xref>]. GALA peptide (WEAALAEALAEALAEHLAEALAEALEALAA), listeriolysin O and the N-terminus of hemagglutinin are available pH-sensitive peptide/proteins. These ligands are inactive in neutral pH environment and undergo conformational changes in lower pH environment, which leads to fusion of liposomal membrane and cell membrane [<xref ref-type="bibr" rid="CR115">115</xref>]. pH-responsive feature is utilized in liposome design in researches [<xref ref-type="bibr" rid="CR99">99</xref>]. Zhang et al. used the inorganic nanomaterial MnO<sub>2</sub> to construct sustained-release liposome. Since MnO<sub>2</sub> responses to low pH and GSH, the nano-platform exhibited good tumor-specific responses. The liposome consisted of hydrophilic MnO<sub>2</sub>, gefitinib and bevacizumab and was tested in NSCLC treatment. The result showed that the liposomal nano-drug inhibited A549 cell progression with excellent biocompatibility [<xref ref-type="bibr" rid="CR116">116</xref>].</p><p id="Par30">Oxidative extracellular environment caused by hypoxia in cancerous tissues allows function of redox-responsive liposomal platforms [<xref ref-type="bibr" rid="CR117">117</xref>]. A novel redox responsive liposomal formulation was manufactured and tested in breast cancer and lung cancer treatment. 7-Ethyl-10-hydroxycamptothecin (SN38) is a camptothecin derivative that targets specifically at DNA topoisomerase I cleavage complexes and has shown great potential in solid tumor treatment. To improve its poor solubility, chemical and metabolic stability, a liposomal nano-DDS was fabricated. SN38 was conjugated with lysophospholipid and release of the parent drug can be triggered by high GSH condition. The liposomal platform showed lower systemic toxicity and improved tumor inhibition [<xref ref-type="bibr" rid="CR118">118</xref>]. As there are some enzymes exhibit higher expression level in TME compared with normal tissues, enzyme-responsive liposomes can be fabricated with improved target ability. As mentioned before, many enzymes significantly overexpress in cancerous tissues, which is the basis of enzyme-responsive liposomes design. Two main enzymes are vastly researched in this category: matrix metalloproteinase (MMP) and phospholipase enzymes. MMPs are a group of proteases that play important roles in protein degradation in the extracellular matrix. MMPs are closely associated with tumor invasion, metastasis and angiogenesis, and expression level of MMPs is elevated in many cancers. To enable liposome with MMP-responsive ability, MMP-responsive peptides are synthesized and conjugated to the liposome membrane. Once the liposome reaches cancerous sites with high MMP expression, the liposome releases encapsulated API. It was reported that a HER-2 targeted liposome was conjugated with PEG layer. And a protease-sensitive cleavable peptide linker was inserted in the PEG base. MMPs can cleave the PEG and result in substantial oxaliplatin release [<xref ref-type="bibr" rid="CR119">119</xref>]. Light, ultrasound, heat and magnetism can also be used to design stimuli-responsive liposomes [<xref ref-type="bibr" rid="CR120">120</xref>]. Conventional cancer chemotherapy causes various undesired side effects, and liposomal nanocarrier reduces these side effects. Besides chemical drugs, RNA, small molecule inhibitors and metallic materials are also common antitumor compound. Combined therapy based on co-delivery of API has been an important approach to achieve higher therapeutic efficacy in liposome research. However, API co-delivery and combined therapy has only been explored in experiments and few has been approved in clinical use. To enhance therapeutic efficacy of the nano-DDS and gain improved side effects, many liposomal platforms are designed with complex compositions and therefore bear multiple features. These novel liposomal vehicles might be conjugated with active targeting ligands, encapsuled with several therapeutic APIs, and unique components enable stimuli-release feature.</p><p id="Par31">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Stimuli-responsive strategies applied in targeted delivery. <bold>a</bold> pH-sensitive liposomes release anti-tumor drugs in low pH cancer cell environment. After entering the acid environment in cancer cells, the DOPE disassembles and releases the ingredients. <bold>b</bold> Ultrasound-sensitive liposomes release anti-tumor drugs under ultrasound stimulate. <bold>c</bold> Illustration of light-sensitive liposome induced PTT and PDT therapy. The lipid was resolved upon light stimulate and release the drug cargo. <bold>d</bold> Schematic representation of magnetic guided liposomes encapsulated with nanoparticle core. The nanocarrier was attracted by the magnetic field and enriched in cancerous sites</p></caption><graphic xlink:href="40164_2025_602_Fig3_HTML" id="d33e1116"/></fig>
</p><p id="Par32">Deng and coworkers developed a liposomal spherical nucleic acid encapsulated with DOX and CPG that increases infiltration of immune cells in TME by binding to Toll-like receptor 9 (TLF-9) in the endosome. By incorporating MMP-9-responsive peptide into the lipid nanocarrier, the nanoplatform can response to MMP-9 enzyme in cancer tissues and release therapeutic cargos. The result showed that the MMP-9 responsive-liposome achieved synergistic therapeutic effect by delivering chemical drugs and adjuvants with reduced side effect compared with free drugs [<xref ref-type="bibr" rid="CR121">121</xref>]. Arsenic trioxide (ATO) is a therapeutic chemical against hepatocellular carcinoma. However, clinical application of ATO has been severely hindered because of its poor distribution and high toxicity [<xref ref-type="bibr" rid="CR122">122</xref>, <xref ref-type="bibr" rid="CR123">123</xref>]. A liposomal drug delivery system was developed to overcome the drawbacks. The nanoplatform consists of arsenic prodrug, MMP2-responsive cleaved cell-penetrating peptide and folate. The calcium arsenate nanoparticle was coated with liposome. The liposomal nanocarrier exhibited better tumor targeting specificity and therapeutic efficacy both in vitro and in vivo [<xref ref-type="bibr" rid="CR124">124</xref>]. Another target enzyme is phospholipase and subtype secretory phospholipase A2 (sPLA2) is overexpressed up to 22-fold in metastatic prostate cancers [<xref ref-type="bibr" rid="CR125">125</xref>]. Experiments were conducted using sPLA2 sensitive phospholipids and confirmed the stimuli-responsive feature in cancer treatment [<xref ref-type="bibr" rid="CR126">126</xref>]. However, there are researches indicate that though sPLA2 responsive liposomes might exhibit anti-tumor effects in vitro, the therapeutic index of sPLA2 triggered release is narrow and may cause severe systemic toxicity in vivo [<xref ref-type="bibr" rid="CR127">127</xref>&#x02013;<xref ref-type="bibr" rid="CR129">129</xref>]. Therefore, stability and toxicity of phospholipase sensitive liposomes should be more carefully evaluated.</p><p id="Par33">For stimuli-responsive strategies, consistent and concrete controlled release is always desired. Unfortunately, the environmental signatures these liposomes rely on are often heterogeneous and dynamic, which leads to unsatisfactory specificity in some circumstances. Therefore, design of delicate liposomes that react to physiological trigger remains a fascinating challenge. Heat, light and ultrasound are common endogenous factors used in these stimuli-responsive strategies. In cancer treatment, photothermal therapy (PTT) and photodynamic therapy (PDT) are two promising strategies in recent years. PTT and PDT are often applied synergistically with surgery and chemotherapy. PTT are commonly realized by materials with high photothermal conversion efficiency that generates heat under near-infrared (NIR) light radiation. In liposomal platform design, PTT can be combined with NIR-triggered API release. Phospholipids undergo phase transition at a certain temperature, by using proper phospholipids such as DPPC, DSPC, the liposome can response to heat generated by NIR light radiation and release the loaded API above transition temperature (Tm) at which the liposome changes from solid phase to liquid phase. PDT therapy are usually realized by photosensitizer accumulated in cancer tissues by liposomal targeted delivery. The photosensitizer interacts with oxygen under light radiation of particular wave length and leads to a series of chemical reaction. During the process, toxic reactive oxygen species (ROS), superoxide oxygen O2 and &#x000b7;OH are produced, which leads to death of target cancer cells [<xref ref-type="bibr" rid="CR130">130</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. Haeri and coworkers developed a thermosensitive liposomal system. The thermosensitive liposome (TSL) was further modified with Fab&#x02019; fragments of EGFR antibody cetuximab (Fab&#x02019;-TSL) and EGFR specific peptide GE11 (GE11-TSL). The Fab&#x02019;-TSL exhibited adequate stability at 37&#x000a0;&#x000b0;C and a temperature dependent release manner when above 40&#x000a0;&#x000b0;C in serum. The result showed that hyperthermia and Fab&#x02019;-conjugation enhanced the cytotoxicity of DOX-loaded liposome [<xref ref-type="bibr" rid="CR132">132</xref>]. A delicate gold wrapped immunoliposome was designed to treat breast cancer. The liposome was modified with HER2 antibody and loaded with antitumor medicine cyclopamine. &#x0201c;Petal-like&#x0201d; gold nanocluster was modified on the liposomal surface to provide photothermal conversion under NIR radiation. With the heat provided by NIR radiation and photothermal conversion feature, the thermosensitive liposome shows controlled release ability. The presence of gold nanoparticle also makes multimodal imaging possible. The result showed that the liposome possessed good colloidal stability, NIR-sensitive drug release feature and Photothermal treatment effect [<xref ref-type="bibr" rid="CR133">133</xref>]. To enhance PDT effect in cancer treatment, a new photosensitizer (BODIPY-I-35) was developed and encapsulated into liposomes, and the liposome was incubated with urea to enhance production of ROS. The result showed that the synergistic effect of liposome and urea provided significantly higher phototoxicity than liposome alone in Hela cells and lowered the dose needed in PDT therapy [<xref ref-type="bibr" rid="CR134">134</xref>]. In a word, liposome is vastly studied in PTT and PDT therapy and might be promising combined cancer therapy nanoplatform with thermosensitive stimuli-release feature.</p><p id="Par34">Efforts have been made to improve specificity of API-loaded liposomes and reduce off-target effect. Ultrasound (US) and magnetic field are two possible strategies. Acoustic cavitation is the main mechanism of ultrasound-sensitive liposomes. Perfluorocarbon (PFC) is used in these liposomes and causes phase transition from liquid to gas when exposed to US pulses. The liposomal bilayer will be disrupted during the process thus release the encapsulated drugs [<xref ref-type="bibr" rid="CR135">135</xref>]. Magnetic field can be used to guide magnetic liposomes consisting of iron oxide nanoparticles to target areas. Dwivedi [<xref ref-type="bibr" rid="CR136">136</xref>] developed a liposome-microbubble conjugate with enhanced delivery in cancer therapies. The liposome can be activated by US and has magnetic targeting ability with citrate-stabilized iron oxide nanoparticles. The in vitro studies showed that the liposomal platform promoted apoptosis under US pulses, and the liposome was highly effective in killing pancreatic cancer cells at a low dose. Liposomes with ultrasound triggered release feature has been extensively studied in cancer therapy and could be a promising approach to improve drug delivery specificity [<xref ref-type="bibr" rid="CR137">137</xref>&#x02013;<xref ref-type="bibr" rid="CR139">139</xref>].</p><p id="Par35">Based on heterogeneous characteristics of TME and nanomaterials, various stimuli-responsive liposomes are developed. These novel liposomal nanoplatforms exhibit good bioavailability, prolonged drug half-life, improved specificity in cancerous areas and synergistic effect with various APIs. However, performance of these liposomes has merely been tested in cell lines and mouses, and human body is an extremely complex system and requires further research to achieve concrete drug efficacy and toxicity information with the corresponding stimuli needed.</p></sec><sec id="Sec10"><title>Recent advances of common LBDDS application in nucleic acid delivery</title><p id="Par36">Lipid-based drug delivery systems (LBDDSs) have been vastly researched in nucleic acid delivery. Nucleic acids are being used to develop vaccines, treat cancer and other diseases caused by gene defects such as cystic fibrosis, muscular atrophy, hemophilia and sickle cell disease [<xref ref-type="bibr" rid="CR140">140</xref>&#x02013;<xref ref-type="bibr" rid="CR145">145</xref>]. In cancer gene therapy, siRNA can induce degradation of specific messenger RNA (mRNA) and is commonly used to silence expression of specific genes. And cancer immunotherapy uses mRNA as ingredients for vaccines. Modified virus is an option for effective gene delivery. However, application of viral vectors is limited due to the immunogenicity, potential oncogenicity and relatively small capacity [<xref ref-type="bibr" rid="CR146">146</xref>]. LBDDS exhibit less immunogenicity and mutagenesis compared with viral vectors. Liposome and LNP are two common vehicles for nucleic acid delivery. As siRNA delivery requires high specificity towards cancer cells, immunoliposomes with active targeting ability or stimuli-responsive liposomes are vastly studies in vivo and in vitro [<xref ref-type="bibr" rid="CR110">110</xref>, <xref ref-type="bibr" rid="CR147">147</xref>&#x02013;<xref ref-type="bibr" rid="CR149">149</xref>]. Liposomes are also used to fabricate mRNA tumor vaccines [<xref ref-type="bibr" rid="CR150">150</xref>]. Since nucleic acids are negatively charged, cationic liposomes were used to effectively deliver nucleic acids initially [<xref ref-type="bibr" rid="CR151">151</xref>]. 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) and 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) are two commonly used cationic lipids [<xref ref-type="bibr" rid="CR152">152</xref>]. However, cationic liposomes are easily purged by the mononuclear phagocyte system (MPS) which consists of cells in liver and spleen. Cationic charges induce cytotoxicity and are more likely to stimulate the immune system and cause aggregation in blood [<xref ref-type="bibr" rid="CR153">153</xref>].</p><p id="Par37">As a new generation LBDDS, LNP has shown impressive delivery efficacy and bioavailability in nucleic acid delivery. Similar to liposomes, LNPs is composed of lipids, phospholipids, cholesterol and PEG. These materials form 80&#x02013;200&#x000a0;nm nanoparticles and deliver nucleic acids into the cells through endocytosis [<xref ref-type="bibr" rid="CR154">154</xref>]. LNP is broadly explored in siRNA and mRNA delivery. Ionizable lipids are the main lipids used in LNPs. These lipids are neutral at physiological pH and protonated at low pH. LNPs with neutral lipids have less interactions with anionic membranes of blood cells and exhibit better biocompatibility and less cytotoxicity than cationic liposomes [<xref ref-type="bibr" rid="CR155">155</xref>]. LNPs are used to deliver siRNA and mRNA. siRNA is able to silence expression of target proteins in liver targets, and researches show that the adsorb apolipoprotein E (ApoE) expressed mainly on livers is important in the process [<xref ref-type="bibr" rid="CR156">156</xref>]. Mennati and coworkers manufactured a hybrid LNP loaded with siRNA and lycopene. The siRNA was used to silence insulin-like growth factor-1 receptor (IGF-1R), and researches showed that blockage of IGF-1R signal reduces cell proliferation and leads to programmed cell death. Lycopene is a chemical with anti-tumor effect. The result showed that the LNP significantly induced apoptosis and arrested cell cycle in breast cancer MCF-7 cell line [<xref ref-type="bibr" rid="CR157">157</xref>]. siRNA is also used to knock down long non-coding RNAs (lncRNAs) selectively expressed with oncogenic functions. A delicate LNP nanocarrier was developed loaded with novel oncogenic lncRNA LINC01257 to treat children with acute myeloid leukemia (AML). The characterization of the LNP was carefully designed and measured and researchers verified that the LNP-siRNAs were taken up by cancer cells. The result showed that the expression of LINC01257 was significantly reduced [<xref ref-type="bibr" rid="CR158">158</xref>]. However, delivery of these siRNAs in cancer gene therapy still faces off-target and potential safe issue and demands further research.</p><p id="Par38">For mRNA delivery, LNP is the most advanced nano-platform. Exogenous mRNAs lead to expression of the target protein in the desired cells and stimulate specific immune response, and generate antibodies that achieve vaccine effects. mRNA vaccine for COVID-19 has been put into emergency use and LNP is the key carrier in the system. Cancer immunotherapy includes immune checkpoint blockade, chimeric antigen receptor (CAR)-T cell therapy, immune system modulator and cancer vaccine [<xref ref-type="bibr" rid="CR159">159</xref>]. These therapies all involve function of immune system and mRNA loaded LNP is a promising strategy of cancer vaccines. mRNAs used in these LNP vaccines mainly encode tumor associated proteins (TAAs) and tumor specific antigens (TSAs). By encapsulating these mRNAs into carefully designed LNPs, degradation of mRNA is reduced and mRNA can pass through the cell membrane by endocytosis. The process of tumor vaccination induced by mRNA loaded LNP is shown in Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>. A clinical trial was conducted to induce therapeutic vaccinations in gastrointestinal cancer. Antigen-related genes and mutations of driver gene were concatenated into a mRNA and the mRNA was loaded into a LNP and used to vaccinate metastatic gastrointestinal cancer patients. The result showed that the vaccine was safe and corresponding mutation-specific T cell responses were elicited [<xref ref-type="bibr" rid="CR160">160</xref>]. Zhang et al. developed a mRNA vaccine with lipid-like material. A special LNP that could activate Toll-like receptor 4 (TLR4) and induce T cell activation was designed and screened. The result showed that the C1-mRNA vaccine delivered mRNA to DCs and promoted antigen presentation. The LNP also exhibited self-adjuvant property [<xref ref-type="bibr" rid="CR161">161</xref>]. Despite these inspiring advances in LNP-based mRNA vaccines, the targeting ability of LNPs needs to be further researched. Intravenously (IV) administered LNPs tend to accumulate in the liver [<xref ref-type="bibr" rid="CR162">162</xref>], and strategies have been utilized to break this limit. LoPresti reported that by replacing helper lipids with charged alternatives, the nanoparticle can be targeted to the spleen and lungs. In the experiment, DOPE was replaced by neutral lipids, anionic lipids and cationic lipids. The result exhibited a method to target LNPs at the spleen or lungs [<xref ref-type="bibr" rid="CR163">163</xref>]. A special LNP with selective organ targeting (SORT) component was developed and conjugated to LNP surface. CRISPR-Cas is a power tool to edit genes. However, the off-target effect limited the application of CRISPR-cas. A research showed that by encapsuling CRISPR-Cas system into the LNP system, the nanocarrier can distribute specifically in target cancer tissues. By adding specific antibodies, the nanocarrier reduced off- targeting and enhanced the targeting ability [<xref ref-type="bibr" rid="CR164">164</xref>]. By adding SORT molecule, the LNP can target at spleen, lungs and other organs [<xref ref-type="bibr" rid="CR165">165</xref>]. This shows that compared with plain LNPs, the coated SORT molecule could greatly enhance the targeting ability of LNPs.These research on mRNA vaccines showed that nucleic acid delivery through LNPs is a promising way in fabricating tumor vaccines as well as cancer immunotherapy.</p><p id="Par39">
<fig id="Fig4"><label>Fig. 4</label><caption><p>LNP based mRNA vaccines induce tumor vaccination. mRNAs are encapsuled in the LNP nanocarrier and released in the cytoplasm, TAAs and TSAs are synthesized by the ribosome and released from the cytoplasm. TAAs and TSAs activate the immune cells and eventually induce tumor vaccination</p></caption><graphic xlink:href="40164_2025_602_Fig4_HTML" id="d33e1265"/></fig>
</p><p id="Par40">In addition to liposomes and LNPs, other LBDDSs including nanoemulsions, nanosuspensions and niosomes have also been explored to deliver nucleic acids, and these lipid nanomaterials exhibit unique advantages. These materials are also researched to be used in cancer vaccines. Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref> shows examples of these materials that are applied in cancer treatment and cancer vaccines. When developing nucleic acid loaded LBDDSs, the ethical issue and potential socio-economic impacts should also be evaluated. As nucleic acid vaccines directly interfere with gene transcription and translation, patients&#x02019; informed consent, autonomy and privacy should be well taken care of. Moreover, the potential impact of gene vaccines on human body should be well monitored and evaluated [<xref ref-type="bibr" rid="CR166">166</xref>, <xref ref-type="bibr" rid="CR167">167</xref>]. The relatively high price of lipid-based gene vaccines could result in injustice in terms of cancer immune [<xref ref-type="bibr" rid="CR168">168</xref>, <xref ref-type="bibr" rid="CR169">169</xref>]. These issues should be constantly evaluated during vaccine development and government policy formulation.</p><p id="Par41">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Examples of LBDDS applied in cancer treatment and cancer vaccines</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Lipid nanocarrier</th><th align="left">Pharmaceutical ingredients</th><th align="left">Applications</th><th align="left">Outcome</th><th align="left">References</th></tr></thead><tbody><tr><td align="left">Liposome</td><td align="left">mRNA encoding cytokeratin 19</td><td align="left">Lung cancer vaccine</td><td align="left">The vaccine provoked a strong cellular immune response and tumor growth was slowed in an aggressive Lewis lung cancer model.</td><td align="left"> [<xref ref-type="bibr" rid="CR150">150</xref>]</td></tr><tr><td align="left">LNP</td><td align="left">siRNA and lycopene</td><td align="left">Breast cancer treatment</td><td align="left">The LNP induced apoptosis and arrested cell cycle in the MCF-7 tumor cell lines.</td><td align="left"> [<xref ref-type="bibr" rid="CR157">157</xref>]</td></tr><tr><td align="left">LNP</td><td align="left">mRNA</td><td align="left">Gastrointestinal cancer vaccine</td><td align="left">The vaccine was safe and elicited mutation-specific T cell responses against predicted neoepitopes not detected before vaccination.</td><td align="left"> [<xref ref-type="bibr" rid="CR160">160</xref>]</td></tr><tr><td align="left">Nanoemulsion</td><td align="left">TLR7/8 agonist (R848)</td><td align="left">Cancer vaccine</td><td align="left">NE (R848) induced tumor-specific T cell activation and mitigating T cell exhaustion and showed systemic antitumor immune responses in mouse lung cancer models.</td><td align="left"> [<xref ref-type="bibr" rid="CR170">170</xref>]</td></tr><tr><td align="left">Nanosuspensions</td><td align="left">Glioma cell membrane and DTX</td><td align="left">Anti-glioma therapy</td><td align="left">The nanosuspension exhibited effective glioma cell targeting ability and induced efficient antigen presentation and downstream immune.</td><td align="left"> [<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr><tr><td align="left">Niosome</td><td align="left">Artemether</td><td align="left">Breast cancer treatment</td><td align="left">The artemether-loaded noisome caused superior tumor necrosis and smaller tumor volume compared to artemether group.</td><td align="left"> [<xref ref-type="bibr" rid="CR171">171</xref>]</td></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec11"><title>Limitations and challenges</title><sec id="Sec12"><title>Protein corona on LBDDSs</title><p id="Par42">Despite vast number of researches on common LBDDSs including liposomes and LNPs in cancer treatment, there are still concerning issues in clinical translation. APIs of liposomal drugs that are applied in clinical use are mostly chemical drugs, and these liposomes are barely decorated with active targeting ligands. Research show that the ligands used to modify the system may lead to formation of protein corona (PC). When the LBDDS is absorbed to blood circulations through various methods, the nanocarrier interacts with blood cells and plasma proteins and forms a PC with an average thickness of 50&#x02013;80&#x000a0;nm on liposomal surface [<xref ref-type="bibr" rid="CR172">172</xref>, <xref ref-type="bibr" rid="CR173">173</xref>]. After entering the biological blood circulation, the nanocarrier is instantly coated by proteins with high abundance and low affinity in blood and forms the &#x0201c;soft corona&#x0201d;. With the residence time increases, the &#x0201c;hard corona&#x0201d; composed of proteins with high affinity is formed on the outer surface [<xref ref-type="bibr" rid="CR174">174</xref>]. The formation of PC is considered a consequence of minimization of free enthalpy, and it is also related to van der Waals forces, hydrogen bonding and hydrophobic interactions [<xref ref-type="bibr" rid="CR175">175</xref>].</p><p id="Par43">By changing the interacting surface of the LBDDS, PC affects properties including circulation and retention time in the system, distribution and release of encapsulated drugs, cell uptake and clearance [<xref ref-type="bibr" rid="CR176">176</xref>]. Moreover, formation of PC in liposomal surface alters zeta potential of the system, and the proteins could contribute to solubilization of the lipids therefore disrupt the phospholipid bilayer. Adsorption of proteins may also lead to aggregation [<xref ref-type="bibr" rid="CR177">177</xref>]. For active targeted liposomes, the molecules and ligands on the surface induce more potential binding of plasma proteins compared with passive targeted liposomes. However, whether formation of PC enhances macrophage function still needs further research [<xref ref-type="bibr" rid="CR178">178</xref>]. The effect of PC on lipid nanoplatform internalization is associated with liposome composition and the bioenvironment of the nanoplatform [<xref ref-type="bibr" rid="CR179">179</xref>&#x02013;<xref ref-type="bibr" rid="CR181">181</xref>].</p><p id="Par44">The pharmacokinetic influence of PC has been broadly researched in recent years. Prolonged circulation enhances the therapeutic effect of the nano-drug. Proteins constituting the PC can be divided into two types, which are opsonins and dysopsonins [<xref ref-type="bibr" rid="CR182">182</xref>]. Opsonins include immunoglobulins and complement proteins, and these proteins enhance MPS capture of the nanocarrier. On the other hand, dysopsonins such as albumin and apolipoproteins can promote the circulation period [<xref ref-type="bibr" rid="CR183">183</xref>]. For active targeting strategies, PC can also cover the ligand binding site potentially therefore leads to reduction of targeting efficacy. For instance, folate receptor is overexpressed in glioma cells and folic acid (FA) was modified on some liposomal nanocarriers. Due to undesired adsorption of plasma proteins especially natural IgM, the FA modified liposomes mainly accumulate in microphages, and the liposome tend to accumulate more in liver and spleen instead of tumor cells [<xref ref-type="bibr" rid="CR184">184</xref>, <xref ref-type="bibr" rid="CR185">185</xref>].</p><p id="Par45">Two approaches have been explored to reduce the formation of PC formation and minimize unintended protein adsorption. The first approach is reducing PC formation on LBDDS surface. PEG modification on liposomes have been proved to form a hydrated layer and reduce protein adsorption. By stealth coating, the PEGylation greatly reduces protein adsorption in blood circulation, therefore improves the pharmacokinetics and reduces immunogenicity [<xref ref-type="bibr" rid="CR186">186</xref>, <xref ref-type="bibr" rid="CR187">187</xref>]. However, conventional PEG induces anti-PEG antibody and decreases long circulation ability of the nanocarrier. The Fc domain of anti-PEG antibody activates endocytosis and complement effect, leading to increased blood clearance of nanocarriers and accumulation in liver and spleen. The immunoreaction can also affect the nanoplatform structure [<xref ref-type="bibr" rid="CR188">188</xref>&#x02013;<xref ref-type="bibr" rid="CR190">190</xref>]. Researches have been conducted to overcome these drawbacks. It was reported that an anti-PEG single-chain variable fragment (PEG-scFv) was coated onto liposomes. Compared with full PEG ligand, the PEG-scFv exhibited reduced binding with anti-PEG IgM while preserving the PEG stealth coating function in rats with pre-existing anti-PEG antibodies [<xref ref-type="bibr" rid="CR191">191</xref>]. Another typical stealth material is the zwitterionic polymer. Characterized by electrostatic interactions with water molecules, the zwitterionic polymer can form a hydrated layer that reduces nonspecific adsorption [<xref ref-type="bibr" rid="CR192">192</xref>, <xref ref-type="bibr" rid="CR193">193</xref>].</p><p id="Par46">To minimize the unfavored result of PC formation, researches have also been conducted to modify the PC constitution. Kim and coworkers designed a siRNA carrier coated with polydopamine, and proteomics analysis identified that the main PC constitution was albumin. Albumin mediated nanocarrier endocytosis and the nanocarrier significantly attenuated CT26 tumor growth [<xref ref-type="bibr" rid="CR194">194</xref>]. Research shows that apolipoproteins promote nanocarrier delivery to the brain through low density lipoprotein receptor (LDLR). Surface polysorbate modification causes apolipoprotein adsorption therefore improves delivery to the brain [<xref ref-type="bibr" rid="CR195">195</xref>].</p><p id="Par47">The protein corona formed on the LBDDS affects the biological characteristics. To better predict PC formation, artificial intelligence (AI) has been used in analyzing the interaction between the nanocarrier and PC. AI technology main includes machine learning (ML), deep learning (DL) and artificial neural networks (ANN) [<xref ref-type="bibr" rid="CR196">196</xref>, <xref ref-type="bibr" rid="CR197">197</xref>]. These promising technologies showed great potential in nano-platform design, early cancer diagnosis and analyzing drug distribution and efficacy. Since the PC is mainly composed of various plasma proteins, it is extremely hard to test the composition in vivo [<xref ref-type="bibr" rid="CR198">198</xref>]. Compared with in vivo studies, nanocarriers tend to adsorb less proteins in the surface due to the monotonous cell culture environment [<xref ref-type="bibr" rid="CR174">174</xref>].Based on reported documents of protein corona, AI technology can predict possible PC elements and endosomatic biological effect. Traditional linear regression model showed unfavorable prediction ability with low <italic>R</italic><sup><italic>2</italic></sup> (less than 0.40). By applying a machine learning model and meta-analysis, Ban et al. constructed a model that precisely predicts the functional protein compositions including immune proteins, complement proteins and apolipoproteins [<xref ref-type="bibr" rid="CR199">199</xref>]. Another research applied a ferritin nanocage loaded with drugs and tracers to various tumor models, and the nanoparticle permeability in cancerous vasculatures were predicted by image segmentation-based machine learning techniques. This research refined the design of the nano-drug and improved the drug permeability to solid tumors [<xref ref-type="bibr" rid="CR200">200</xref>].</p><p id="Par48">Recent studies also reveal that change of incubation environment from 90% fetal bovine serum to 82% murine plasma significantly alters the test result of targeting capability that associates with PC formation. This suggests that to study the effect of PC formation in liposomal platforms, the experimental setting should be as close as possible to the actual environment. PC formation is an important issue hindering clinical translation of LBDDS and requires further research. AI is a powerful tool in PC prediction and nano-platform design improvement. Focusing on specially modified LBDDS surface design to either reduce PC formation or induce specific protein adsorption to refine nano-drug pharmacokinetics and immunogenicity are also promising mitigation strategies.</p></sec><sec id="Sec13"><title>Obstacles in clinical translation</title><p id="Par49">Other major obstacles in the clinical translation of LBDDSs lies in large-scale manufacturing, government regulations and intellectual property issues. Although various active targeting and stimuli-responsive strategy have been broadly studied, the currently approved LBDDSs are all designed with passive targeting strategies. In other words, clinical translation of liposomes and LNPs based on active targeting and stimuli-release was hindered by certain reasons. Quality control and cost control are two major issues when it comes to clinical translation. Compared with plain liposomes, liposomes and LNPs with specific ligands that lead to designed immunoreaction faces more difficulties in quality control. More procedures are required to integrate these components into the nano-platform, making it more difficult to maintain uniform nano-drug characteristics [<xref ref-type="bibr" rid="CR201">201</xref>, <xref ref-type="bibr" rid="CR202">202</xref>]. And evaluating the pharmacokinetics, toxicity and pharmacodynamics becomes more complicated. PC formed on these nanocarriers are also more complicated than plain liposomes [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR141">141</xref>]. Cost of the production procedure also increases as the nanocarrier becomes more complicated. Different from laboratory design, massive production in factories of lipid-based nanomaterials always faces plenty of challenges. With more extra modifications and moieties, the fabrication and storage cost increase. The government regulations make a difference in LBDDS clinical translation. The intellectual property also influences the clinical translation of LBDDSs, as the current intellectual property restricts the knowledge share of LBDDSs and may increase the cost of LNP design and manufacture. To overcome these obstacles, reports of relative studies should be as detailed as possible to increase the repetition rate of the experiments. More open policies of LBDDS regulations and intellectual property should be proposed after concrete consultation with academia, industry and law. These measures will speed up the clinical translation of LBDDSs.</p><p id="Par50">liposomal clinical use is lack of authoritative criteria that can evaluate the efficacy and safety of LBDDS universally. Especially for active targeted and stimuli-responsive nano systems. In the active targeting strategy, the ideal scenario that the delicate moiety placed on the liposomal surface guide the system towards cancerous areas is impeded by PC formation. Since the incubation environment affects the evaluation of targeting capability, a standard procedure is needed to make the test result demonstrate the actual situation in human body. Proteomics-based mass spectrometry (MS) is a powerful tool to examine the PC component and could be made a standard procedure in active targeted lipid-based nanocarrier design. Similar to these concerns, aggregation of liposomes can be resulted from proportion of each component, surface charge and density of ligands decorated on the surface. Test of the aggregation should also be carried out with a unified criterion. Compared with traditional chemotherapy and passive targeted liposomes, off-target effect and consequent toxicity towards normal cells caused by active-targeted liposomes are also concerning obstacles between lab and clinic use. Caracciolo and coworkers found out that there is significant difference of liposome PC in mice and humans [<xref ref-type="bibr" rid="CR203">203</xref>], indicating tests of active targeted liposomes should not only be tested in cell lines and mice, but also in organoid or mammal models. Safety issue is also a limitation of many gene-delivery lipid carriers. Tumor gene therapies use nucleic acid as API and aim to express or inhibit expression of specific proteins in target cells, the off-target effect and potential concern towards gene transfection are important issues that limit the clinical translation of these drug platforms. To overcome this limitation, further researches on active targeting LBDDS should be conducted.</p></sec></sec><sec id="Sec14"><title>Perspectives</title><p id="Par51">Over the years, liposomes, LNPs and other lipid-based nanocarriers have become a powerful weapon against cancer. Various chemical drug-encapsulated liposomes have been applied to clinical use. Liposomes and LNPs possess ideal bioavailability and biocompatibility and few toxicities. Tons of studies proved that by using these materials, therapeutic drugs can be specifically delivered to tumor sites with prolonged half-life, deep penetration and effective cellular internalization. However, further work should be carried out to establish standard effectiveness evaluation criteria in active targeted lipid nanocarriers. Mass spectrometry techniques can be utilized to studies the composition and formation of protein corona and eventually enhance the active target ability.</p></sec><sec id="Sec15"><title>Conclusion</title><p id="Par52">Lipid-based drug delivery systems are promising anti-tumor drug carriers. To achieve better clinical translation and more promising therapeutic results, future research can be conducted focusing on active targeting strategies and overcoming off-target effects. By refining the combination of PEG with active targeting moieties and improving stimuli-release approach based on the biological characteristics of the cancerous tissue, the targeting efficacy can be elevated. AI and machine learning can also be used to improve LBDDS design and reduce unfavorable influence of PC formation, therefore overcoming off-target effects. and it is hoped that these nanocarriers will be used clinically in near future with more promising therapeutic results.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>HL conceived and supervised the project; ZC wrote the paper; HH and MY provided critical suggestions; ZC revised the paper. All authors read and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was financially supported by the Natural Science Foundation of Hunan Province (No. 2023JJ30830).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par54">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par55">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par56">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>ANN</term><def><p id="Par60">Artificial neural networks</p></def></def-item><def-item><term>AI</term><def><p id="Par61">Artificial intelligence</p></def></def-item><def-item><term>COVID-19</term><def><p id="Par62">Coronavirus disease 2019</p></def></def-item><def-item><term>CHEMS</term><def><p id="Par63">Cholesteryl hemisuccinate</p></def></def-item><def-item><term>DAPE</term><def><p id="Par64">Diacetylenic-phosphatidyl-ethanolamine</p></def></def-item><def-item><term>DL</term><def><p id="Par65">Deep learning</p></def></def-item><def-item><term>DOPE</term><def><p id="Par66">Dioleoyl-phosphatidyl-ethanolamine</p></def></def-item><def-item><term>LNP</term><def><p id="Par67">Lipid nanoparticles</p></def></def-item><def-item><term>ML</term><def><p id="Par68">Machine learning</p></def></def-item><def-item><term>MDR</term><def><p id="Par69">Chemotherapy can also cause multi-drug resistance</p></def></def-item><def-item><term>NLC</term><def><p id="Par70">Nanostructured lipid carriers</p></def></def-item><def-item><term>POPE</term><def><p id="Par71">Palmitoyl-oleoyl-phosphatidyl ethanolamine</p></def></def-item><def-item><term>PHC</term><def><p id="Par72">N-palmitoyl-l-homocysteine</p></def></def-item><def-item><term>LBDDS</term><def><p id="Par73">Lipid-based drug delivery system</p></def></def-item><def-item><term>SUV</term><def><p id="Par74">Small unilamellar vesicles</p></def></def-item><def-item><term>LUV</term><def><p id="Par75">Large unilamellar vesicles</p></def></def-item><def-item><term>MLV</term><def><p id="Par76">Multilamellar vesicles</p></def></def-item><def-item><term>MVL</term><def><p id="Par77">Multivesicular liposomes</p></def></def-item><def-item><term>NP</term><def><p id="Par78">Nanoparticle</p></def></def-item><def-item><term>MPS</term><def><p id="Par79">Mononuclear phagocyte system</p></def></def-item><def-item><term>PEG</term><def><p id="Par80">Polyethylene glycol</p></def></def-item><def-item><term>FDA</term><def><p id="Par81">Food and Drug Administration</p></def></def-item><def-item><term>EPR</term><def><p id="Par82">Enhanced permeability and retention</p></def></def-item><def-item><term>TME</term><def><p id="Par83">Tumor microenvironment</p></def></def-item><def-item><term>TfR</term><def><p id="Par84">Transferrin receptor</p></def></def-item><def-item><term>FR</term><def><p id="Par85">Folate receptor</p></def></def-item><def-item><term>ER</term><def><p id="Par86">Estrogen receptor</p></def></def-item><def-item><term>BBB</term><def><p id="Par87">Blood-brain barrier</p></def></def-item><def-item><term>GBM</term><def><p id="Par88">Glioblastoma multiforme</p></def></def-item><def-item><term>Dox</term><def><p id="Par89">Doxorubicin</p></def></def-item><def-item><term>DTX</term><def><p id="Par90">Docetaxel</p></def></def-item><def-item><term>NSCLC</term><def><p id="Par91">Non-small cell lung cancer</p></def></def-item><def-item><term>CD44</term><def><p id="Par92">Cluster of differentiation 44</p></def></def-item><def-item><term>HA</term><def><p id="Par93">Hyaluronic acid; CS: Chondroitin sulfate</p></def></def-item><def-item><term>EGFR</term><def><p id="Par94">Epidermal growth factor receptor</p></def></def-item><def-item><term>EGF</term><def><p id="Par95">Epidermal growth factor</p></def></def-item><def-item><term>AgNPs</term><def><p id="Par96">Silver nanoparticles</p></def></def-item><def-item><term>HER2</term><def><p id="Par97">Human epidermal growth factor receptor 2</p></def></def-item><def-item><term>ECM</term><def><p id="Par98">Extracellular matrix</p></def></def-item><def-item><term>PD-L1</term><def><p id="Par99">Programmed cell death ligand 1</p></def></def-item><def-item><term>ICI</term><def><p id="Par100">Immunocheckpoint inhibitor</p></def></def-item><def-item><term>VEGF</term><def><p id="Par101">Vascular endothelial growth factor</p></def></def-item><def-item><term>VEGFR-2</term><def><p id="Par102">Vascular endothelial growth factor receptor-2</p></def></def-item><def-item><term>ssDNA</term><def><p id="Par103">Short single-stranded DNA</p></def></def-item><def-item><term>ssRNA</term><def><p id="Par104">Single-stranded RNA</p></def></def-item><def-item><term>SELEX</term><def><p id="Par105">Systematic evolution of ligands by exponential enrichment</p></def></def-item><def-item><term>API</term><def><p id="Par106">Active pharmaceutical ingredient</p></def></def-item><def-item><term>PE</term><def><p id="Par107">Phosphatidylethanolamine</p></def></def-item><def-item><term>MMP</term><def><p id="Par108">Matrix metalloproteinase</p></def></def-item><def-item><term>TLF-9</term><def><p id="Par109">Toll-like receptor 9</p></def></def-item><def-item><term>ATO</term><def><p id="Par110">Arsenic trioxide</p></def></def-item><def-item><term>PTT</term><def><p id="Par111">Photothermal therapy</p></def></def-item><def-item><term>PDT</term><def><p id="Par112">Photodynamic therapy</p></def></def-item><def-item><term>NIR</term><def><p id="Par113">Near-infrared</p></def></def-item><def-item><term>ROS</term><def><p id="Par114">Reactive oxygen species</p></def></def-item><def-item><term>TSL</term><def><p id="Par115">Thermosensitive liposome</p></def></def-item><def-item><term>US</term><def><p id="Par116">Ultrasound</p></def></def-item><def-item><term>PFC</term><def><p id="Par117">Perfluorocarbon</p></def></def-item><def-item><term>MPS</term><def><p id="Par118">Mononuclear phagocyte system</p></def></def-item><def-item><term>IGF-1R</term><def><p id="Par119">Insulin-like growth factor-1 receptor</p></def></def-item><def-item><term>AML</term><def><p id="Par120">Acute myeloid leukemia</p></def></def-item><def-item><term>TAAs</term><def><p id="Par121">Tumor associated proteins</p></def></def-item><def-item><term>TSAs</term><def><p id="Par122">Tumor specific antigens</p></def></def-item><def-item><term>TLR4</term><def><p id="Par123">Toll-like receptor 4</p></def></def-item><def-item><term>SORT</term><def><p id="Par124">Selective organ targeting</p></def></def-item><def-item><term>PC</term><def><p id="Par125">Protein corona</p></def></def-item><def-item><term>MS</term><def><p id="Par126">Mass spectrometry</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2021</year><volume>71</volume><issue>3</issue><fpage>209</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209&#x02013;49.<pub-id pub-id-type="pmid">33538338</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name><name><surname>Weinberg</surname><given-names>RA</given-names></name></person-group><article-title>Hallmarks of cancer: the next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><issue>5</issue><fpage>646</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646&#x02013;74.<pub-id pub-id-type="pmid">21376230</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Zhang Z, Zhang H, Li C, Xiang Q, Xu L, Liu Q et al. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer. Thorac Cancer. 2021.</mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Zhao W, Xie Q. Exosomal lncRNA-Mediated intercellular communication promotes Glioblastoma Chemoresistance. Cancer Immunol Res. 2021.</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>D</given-names></name></person-group><article-title>Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches</article-title><source>Cancer Lett</source><year>2014</year><volume>347</volume><issue>2</issue><fpage>159</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2014.03.013</pub-id><pub-id pub-id-type="pmid">24657660</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Wu Q, Yang Z, Nie Y, Shi Y, Fan D. Multi-drug resistance in cancer chemotherapeutics: mechanisms and lab approaches. Cancer Lett. 2014;347(2):159&#x02013;66.<pub-id pub-id-type="pmid">24657660</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez-Herrero</surname><given-names>E</given-names></name><name><surname>Fern&#x000e1;ndez-Medarde</surname><given-names>A</given-names></name></person-group><article-title>Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy</article-title><source>Eur J Pharm Biopharm</source><year>2015</year><volume>93</volume><fpage>52</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2015.03.018</pub-id><pub-id pub-id-type="pmid">25813885</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">P&#x000e9;rez-Herrero E, Fern&#x000e1;ndez-Medarde A. Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm. 2015;93:52&#x02013;79.<pub-id pub-id-type="pmid">25813885</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>El-Zaafarany</surname><given-names>GM</given-names></name><name><surname>Nasr</surname><given-names>M</given-names></name></person-group><article-title>Insightful exploring of advanced nanocarriers for the topical/transdermal treatment of skin diseases</article-title><source>Pharm Dev Technol</source><year>2021</year><volume>26</volume><issue>10</issue><fpage>1136</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1080/10837450.2021.2004606</pub-id><pub-id pub-id-type="pmid">34751091</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">El-Zaafarany GM, Nasr M. Insightful exploring of advanced nanocarriers for the topical/transdermal treatment of skin diseases. Pharm Dev Technol. 2021;26(10):1136&#x02013;57.<pub-id pub-id-type="pmid">34751091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Sguizzato M, Esposito E, Cortesi R. Lipid-Based Nanosystems as a Tool to overcome skin barrier. Int J Mol Sci. 2021;22(15).</mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Buya AB, Witika BA, Bapolisi AM, Mwila C, Mukubwa GK, Memvanga PB et al. Application of lipid-based nanocarriers for Antitubercular Drug Delivery: a review. Pharmaceutics. 2021;13(12).</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Obinu A, Porcu EP, Piras S, Ibba R, Carta A, Molicotti P et al. Solid lipid nanoparticles as Formulative Strategy to increase oral permeation of a molecule active in Multidrug-Resistant Tuberculosis Management. Pharmaceutics. 2020;12(12).</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Tripathi</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>U</given-names></name><name><surname>Ujjwal</surname><given-names>RR</given-names></name><name><surname>Yadav</surname><given-names>AK</given-names></name></person-group><article-title>Nano-lipidic formulation and therapeutic strategies for Alzheimer&#x02019;s disease via intranasal route</article-title><source>J Microencapsul</source><year>2021</year><volume>38</volume><issue>7&#x02013;8</issue><fpage>572</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1080/02652048.2021.1986585</pub-id><pub-id pub-id-type="pmid">34591731</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Tripathi S, Gupta U, Ujjwal RR, Yadav AK. Nano-lipidic formulation and therapeutic strategies for Alzheimer&#x02019;s disease via intranasal route. J Microencapsul. 2021;38(7&#x02013;8):572&#x02013;93.<pub-id pub-id-type="pmid">34591731</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Mungroo MR, Khan NA, Anwar A, Siddiqui R. Nanovehicles in the improved treatment of infections due to brain-eating amoebae. Int Microbiol. 2021.</mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="other">Puglia C, Santonocito D, Romeo G, Intagliata S, Romano GL, Strettoi E et al. Lipid nanoparticles Traverse Non-corneal path to Reach the posterior Eye Segment: in vivo evidence. Molecules. 2021;26(15).</mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Sahoo RK, Singh H, Thakur K, Gupta U, Goyal AK. Theranostic applications of nanomaterials in the Field of Cardiovascular diseases. Curr Pharm Des. 2021.</mixed-citation></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Gorain</surname><given-names>B</given-names></name><name><surname>Choudhury</surname><given-names>H</given-names></name><name><surname>Nair</surname><given-names>AB</given-names></name><name><surname>Dubey</surname><given-names>SK</given-names></name><name><surname>Kesharwani</surname><given-names>P</given-names></name></person-group><article-title>Theranostic application of nanoemulsions in chemotherapy</article-title><source>Drug Discov Today</source><year>2020</year><volume>25</volume><issue>7</issue><fpage>1174</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2020.04.013</pub-id><pub-id pub-id-type="pmid">32344042</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Gorain B, Choudhury H, Nair AB, Dubey SK, Kesharwani P. Theranostic application of nanoemulsions in chemotherapy. Drug Discov Today. 2020;25(7):1174&#x02013;88.<pub-id pub-id-type="pmid">32344042</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>TC</given-names></name><name><surname>Li</surname><given-names>XF</given-names></name><name><surname>Zhang</surname><given-names>NN</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><etal/></person-group><article-title>Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>438</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00861-4</pub-id><pub-id pub-id-type="pmid">34952914</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Zhao H, Wang TC, Li XF, Zhang NN, Li L, Zhou C, et al. Long-term stability and protection efficacy of the RBD-targeting COVID-19 mRNA vaccine in nonhuman primates. Signal Transduct Target Ther. 2021;6(1):438.<pub-id pub-id-type="pmid">34952914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Park H, Otte A, Park K. Evolution of drug delivery systems: from 1950 to 2020 and beyond. J Control Release. 2021.</mixed-citation></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Gabizon</surname><given-names>A</given-names></name><name><surname>Papahadjopoulos</surname><given-names>D</given-names></name></person-group><article-title>Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors</article-title><source>Proc Natl Acad Sci U S A</source><year>1988</year><volume>85</volume><issue>18</issue><fpage>6949</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1073/pnas.85.18.6949</pub-id><pub-id pub-id-type="pmid">3413128</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Gabizon A, Papahadjopoulos D. Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. Proc Natl Acad Sci U S A. 1988;85(18):6949&#x02013;53.<pub-id pub-id-type="pmid">3413128</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><name><surname>Yeo</surname><given-names>Y</given-names></name></person-group><article-title>Controlled drug release from Pharmaceutical Nanocarriers</article-title><source>Chem Eng Sci</source><year>2015</year><volume>125</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.ces.2014.08.046</pub-id><pub-id pub-id-type="pmid">25684779</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lee JH, Yeo Y. Controlled drug release from Pharmaceutical Nanocarriers. Chem Eng Sci. 2015;125:75&#x02013;84.<pub-id pub-id-type="pmid">25684779</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Min</surname><given-names>Q</given-names></name><name><surname>Ling</surname><given-names>C</given-names></name><name><surname>Maiti</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Holo-Lactoferrin Modified Liposome for relieving Tumor Hypoxia and Enhancing Radiochemotherapy of Cancer</article-title><source>Small</source><year>2019</year><volume>15</volume><issue>6</issue><fpage>e1803703</fpage><pub-id pub-id-type="doi">10.1002/smll.201803703</pub-id><pub-id pub-id-type="pmid">30645056</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Zhang Z, Yang J, Min Q, Ling C, Maiti D, Xu J, et al. Holo-Lactoferrin Modified Liposome for relieving Tumor Hypoxia and Enhancing Radiochemotherapy of Cancer. Small. 2019;15(6):e1803703.<pub-id pub-id-type="pmid">30645056</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>UM</given-names></name><name><surname>Hartman</surname><given-names>A</given-names></name><name><surname>Pillai</surname><given-names>G</given-names></name></person-group><article-title>Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFR-overexpressed pancreatic cancer cells</article-title><source>J Drug Target</source><year>2018</year><volume>26</volume><issue>8</issue><fpage>676</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2017.1408114</pub-id><pub-id pub-id-type="pmid">29157028</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Le UM, Hartman A, Pillai G. Enhanced selective cellular uptake and cytotoxicity of epidermal growth factor-conjugated liposomes containing curcumin on EGFR-overexpressed pancreatic cancer cells. J Drug Target. 2018;26(8):676&#x02013;83.<pub-id pub-id-type="pmid">29157028</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Jing</surname><given-names>X</given-names></name><name><surname>Ke</surname><given-names>X</given-names></name><name><surname>Lian</surname><given-names>J</given-names></name><etal/></person-group><article-title>Comparison of anti-EGFR-Fab&#x02019; conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells</article-title><source>Int J Nanomed</source><year>2013</year><volume>8</volume><fpage>3271</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.2147/IJN.S47597</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Deng L, Zhang Y, Ma L, Jing X, Ke X, Lian J, et al. Comparison of anti-EGFR-Fab&#x02019; conjugated immunoliposomes modified with two different conjugation linkers for siRNa delivery in SMMC-7721 cells. Int J Nanomed. 2013;8:3271&#x02013;83.</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Akbarzadeh</surname><given-names>A</given-names></name><name><surname>Rezaei-Sadabady</surname><given-names>R</given-names></name><name><surname>Davaran</surname><given-names>S</given-names></name><name><surname>Joo</surname><given-names>SW</given-names></name><name><surname>Zarghami</surname><given-names>N</given-names></name><name><surname>Hanifehpour</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Liposome: classification, preparation, and applications</article-title><source>Nanoscale Res Lett</source><year>2013</year><volume>8</volume><issue>1</issue><fpage>102</fpage><pub-id pub-id-type="doi">10.1186/1556-276X-8-102</pub-id><pub-id pub-id-type="pmid">23432972</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifehpour Y, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102.<pub-id pub-id-type="pmid">23432972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>TM</given-names></name><name><surname>Davidson</surname><given-names>PM</given-names></name><name><surname>Bruce</surname><given-names>BD</given-names></name><name><surname>Weiss</surname><given-names>J</given-names></name></person-group><article-title>Liposomal nanocapsules in food science and agriculture</article-title><source>Crit Rev Food Sci Nutr</source><year>2005</year><volume>45</volume><issue>7&#x02013;8</issue><fpage>587</fpage><lpage>605</lpage><pub-id pub-id-type="doi">10.1080/10408390591001135</pub-id><pub-id pub-id-type="pmid">16371329</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Taylor TM, Davidson PM, Bruce BD, Weiss J. Liposomal nanocapsules in food science and agriculture. Crit Rev Food Sci Nutr. 2005;45(7&#x02013;8):587&#x02013;605.<pub-id pub-id-type="pmid">16371329</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Chaurasiya A, Gorajiya A, Panchal K, Katke S, Singh AK. A review on multivesicular liposomes for pharmaceutical applications: preparation, characterization, and translational challenges. Drug Deliv Transl Res. 2021.</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Ahmed</surname><given-names>KS</given-names></name><name><surname>Hussein</surname><given-names>SA</given-names></name><name><surname>Ali</surname><given-names>AH</given-names></name><name><surname>Korma</surname><given-names>SA</given-names></name><name><surname>Lipeng</surname><given-names>Q</given-names></name><name><surname>Jinghua</surname><given-names>C</given-names></name></person-group><article-title>Liposome: composition, characterisation, preparation, and recent innovation in clinical applications</article-title><source>J Drug Target</source><year>2019</year><volume>27</volume><issue>7</issue><fpage>742</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1080/1061186X.2018.1527337</pub-id><pub-id pub-id-type="pmid">30239255</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ahmed KS, Hussein SA, Ali AH, Korma SA, Lipeng Q, Jinghua C. Liposome: composition, characterisation, preparation, and recent innovation in clinical applications. J Drug Target. 2019;27(7):742&#x02013;61.<pub-id pub-id-type="pmid">30239255</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Large</surname><given-names>DE</given-names></name><name><surname>Abdelmessih</surname><given-names>RG</given-names></name><name><surname>Fink</surname><given-names>EA</given-names></name><name><surname>Auguste</surname><given-names>DT</given-names></name></person-group><article-title>Liposome composition in drug delivery design, synthesis, characterization, and clinical application</article-title><source>Adv Drug Deliv Rev</source><year>2021</year><volume>176</volume><fpage>113851</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2021.113851</pub-id><pub-id pub-id-type="pmid">34224787</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Large DE, Abdelmessih RG, Fink EA, Auguste DT. Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev. 2021;176:113851.<pub-id pub-id-type="pmid">34224787</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Mu&#x000f1;oz-Shugul&#x000ed;</surname><given-names>C</given-names></name><name><surname>Vidal</surname><given-names>CP</given-names></name><name><surname>Cantero-L&#x000f3;pez</surname><given-names>P</given-names></name><name><surname>Lopez-Polo</surname><given-names>J</given-names></name></person-group><article-title>Encapsulation of plant extract compounds using cyclodextrin inclusion complexes, liposomes, electrospinning and their combinations for food purposes</article-title><source>Trends Food Sci Technol</source><year>2021</year><volume>108</volume><fpage>177</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.tifs.2020.12.020</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Mu&#x000f1;oz-Shugul&#x000ed; C, Vidal CP, Cantero-L&#x000f3;pez P, Lopez-Polo J. Encapsulation of plant extract compounds using cyclodextrin inclusion complexes, liposomes, electrospinning and their combinations for food purposes. Trends Food Sci Technol. 2021;108:177&#x02013;86.</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="other">Say&#x00131;t G, Tanr&#x00131;verdi ST, &#x000d6;zer &#x000d6;, &#x000d6;zdo&#x0011f;an E. Preparation of allantoin loaded liposome formulations and application for cosmetic textile production. J Text Inst. 2021:1&#x02013;12.</mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="other">Mukherjee A, Paul M, Mukherjee S. Recent progress in the Theranostics application of Nanomedicine in Lung Cancer. Cancers (Basel). 2019;11(5).</mixed-citation></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Palazzolo</surname><given-names>S</given-names></name><name><surname>Bayda</surname><given-names>S</given-names></name><name><surname>Hadla</surname><given-names>M</given-names></name><name><surname>Caligiuri</surname><given-names>I</given-names></name><name><surname>Corona</surname><given-names>G</given-names></name><name><surname>Toffoli</surname><given-names>G</given-names></name><etal/></person-group><article-title>The clinical translation of Organic nanomaterials for Cancer Therapy: a Focus on Polymeric nanoparticles, Micelles, liposomes and exosomes</article-title><source>Curr Med Chem</source><year>2018</year><volume>25</volume><issue>34</issue><fpage>4224</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.2174/0929867324666170830113755</pub-id><pub-id pub-id-type="pmid">28875844</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Palazzolo S, Bayda S, Hadla M, Caligiuri I, Corona G, Toffoli G, et al. The clinical translation of Organic nanomaterials for Cancer Therapy: a Focus on Polymeric nanoparticles, Micelles, liposomes and exosomes. Curr Med Chem. 2018;25(34):4224&#x02013;68.<pub-id pub-id-type="pmid">28875844</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Chaudhury</surname><given-names>A</given-names></name></person-group><article-title>Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery</article-title><source>AAPS PharmSciTech</source><year>2011</year><volume>12</volume><issue>1</issue><fpage>62</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1208/s12249-010-9563-0</pub-id><pub-id pub-id-type="pmid">21174180</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Das S, Chaudhury A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech. 2011;12(1):62&#x02013;76.<pub-id pub-id-type="pmid">21174180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Din</surname><given-names>FU</given-names></name><name><surname>Aman</surname><given-names>W</given-names></name><name><surname>Ullah</surname><given-names>I</given-names></name><name><surname>Qureshi</surname><given-names>OS</given-names></name><name><surname>Mustapha</surname><given-names>O</given-names></name><name><surname>Shafique</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors</article-title><source>Int J Nanomed</source><year>2017</year><volume>12</volume><fpage>7291</fpage><lpage>309</lpage><pub-id pub-id-type="doi">10.2147/IJN.S146315</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Din FU, Aman W, Ullah I, Qureshi OS, Mustapha O, Shafique S, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Int J Nanomed. 2017;12:7291&#x02013;309.</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Skwarecki</surname><given-names>AS</given-names></name><name><surname>Milewski</surname><given-names>S</given-names></name><name><surname>Schielmann</surname><given-names>M</given-names></name><name><surname>Milewska</surname><given-names>MJ</given-names></name></person-group><article-title>Antimicrobial molecular nanocarrier-drug conjugates</article-title><source>Nanomedicine</source><year>2016</year><volume>12</volume><issue>8</issue><fpage>2215</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2016.06.002</pub-id><pub-id pub-id-type="pmid">27339783</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Skwarecki AS, Milewski S, Schielmann M, Milewska MJ. Antimicrobial molecular nanocarrier-drug conjugates. Nanomedicine. 2016;12(8):2215&#x02013;40.<pub-id pub-id-type="pmid">27339783</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Dobrovolskaia</surname><given-names>MA</given-names></name><name><surname>Shurin</surname><given-names>M</given-names></name><name><surname>Shvedova</surname><given-names>AA</given-names></name></person-group><article-title>Current understanding of interactions between nanoparticles and the immune system</article-title><source>Toxicol Appl Pharmacol</source><year>2016</year><volume>299</volume><fpage>78</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1016/j.taap.2015.12.022</pub-id><pub-id pub-id-type="pmid">26739622</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Dobrovolskaia MA, Shurin M, Shvedova AA. Current understanding of interactions between nanoparticles and the immune system. Toxicol Appl Pharmacol. 2016;299:78&#x02013;89.<pub-id pub-id-type="pmid">26739622</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Panahi</surname><given-names>Y</given-names></name><name><surname>Farshbaf</surname><given-names>M</given-names></name><name><surname>Mohammadhosseini</surname><given-names>M</given-names></name><name><surname>Mirahadi</surname><given-names>M</given-names></name><name><surname>Khalilov</surname><given-names>R</given-names></name><name><surname>Saghfi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications</article-title><source>Artif Cells Nanomed Biotechnol</source><year>2017</year><volume>45</volume><issue>4</issue><fpage>788</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1080/21691401.2017.1282496</pub-id><pub-id pub-id-type="pmid">28278586</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Panahi Y, Farshbaf M, Mohammadhosseini M, Mirahadi M, Khalilov R, Saghfi S, et al. Recent advances on liposomal nanoparticles: synthesis, characterization and biomedical applications. Artif Cells Nanomed Biotechnol. 2017;45(4):788&#x02013;99.<pub-id pub-id-type="pmid">28278586</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Tan</surname><given-names>T</given-names></name><name><surname>Chu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy</article-title><source>Drug Deliv</source><year>2022</year><volume>29</volume><issue>1</issue><fpage>75</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1080/10717544.2021.2018523</pub-id><pub-id pub-id-type="pmid">34964421</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Li B, Tan T, Chu W, Zhang Y, Ye Y, Wang S, et al. Co-delivery of paclitaxel (PTX) and docosahexaenoic acid (DHA) by targeting lipid nanoemulsions for cancer therapy. Drug Deliv. 2022;29(1):75&#x02013;88.<pub-id pub-id-type="pmid">34964421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>W</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery</article-title><source>J Nanobiotechnol</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>378</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-01110-0</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Hao W, Cui Y, Fan Y, Chen M, Yang G, Wang Y, et al. Hybrid membrane-coated nanosuspensions for multi-modal anti-glioma therapy via drug and antigen delivery. J Nanobiotechnol. 2021;19(1):378.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="other">Fan Y, Hao W, Cui Y, Chen M, Chu X, Yang Y et al. Cancer Cell membrane-coated nanosuspensions for Enhanced Chemotherapeutic Treatment of Glioma. Molecules. 2021;26(16).</mixed-citation></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Akbarzadeh</surname><given-names>I</given-names></name><name><surname>Farid</surname><given-names>M</given-names></name><name><surname>Javidfar</surname><given-names>M</given-names></name><name><surname>Zabet</surname><given-names>N</given-names></name><name><surname>Shokoohian</surname><given-names>B</given-names></name><name><surname>Arki</surname><given-names>MK</given-names></name><etal/></person-group><article-title>The optimized formulation of tamoxifen-loaded niosomes efficiently Induced apoptosis and cell cycle arrest in breast Cancer cells</article-title><source>AAPS PharmSciTech</source><year>2022</year><volume>23</volume><issue>1</issue><fpage>57</fpage><pub-id pub-id-type="doi">10.1208/s12249-022-02212-0</pub-id><pub-id pub-id-type="pmid">35048234</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Akbarzadeh I, Farid M, Javidfar M, Zabet N, Shokoohian B, Arki MK, et al. The optimized formulation of tamoxifen-loaded niosomes efficiently Induced apoptosis and cell cycle arrest in breast Cancer cells. AAPS PharmSciTech. 2022;23(1):57.<pub-id pub-id-type="pmid">35048234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">Thi TTH, Suys EJA, Lee JS, Nguyen DH, Park KD, Truong NP. Lipid-based nanoparticles in the clinic and clinical trials: from Cancer Nanomedicine to COVID-19 vaccines. Vaccines (Basel). 2021;9(4).</mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Shah S, Dhawan V, Holm R, Nagarsenker MS, Perrie Y, Liposomes. Advancements and innovation in the manufacturing process. Adv Drug Deliv Rev. 2020;154&#x02013;5:102&#x02013;22.</mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Cullis</surname><given-names>PR</given-names></name><name><surname>Hope</surname><given-names>MJ</given-names></name></person-group><article-title>Lipid nanoparticle systems for enabling Gene therapies</article-title><source>Mol Ther</source><year>2017</year><volume>25</volume><issue>7</issue><fpage>1467</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.03.013</pub-id><pub-id pub-id-type="pmid">28412170</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Cullis PR, Hope MJ. Lipid nanoparticle systems for enabling Gene therapies. Mol Ther. 2017;25(7):1467&#x02013;75.<pub-id pub-id-type="pmid">28412170</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccine for cancer immunotherapy</article-title><source>Mol Cancer</source><year>2021</year><volume>20</volume><issue>1</issue><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmid">33632261</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Miao L, Zhang Y, Huang L. mRNA vaccine for cancer immunotherapy. Mol Cancer. 2021;20(1):41.<pub-id pub-id-type="pmid">33632261</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>JA</given-names></name><name><surname>Witzigmann</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Cullis</surname><given-names>PR</given-names></name><name><surname>van der Meel</surname><given-names>R</given-names></name></person-group><article-title>Lipid nanoparticle technology for clinical translation of siRNA therapeutics</article-title><source>Acc Chem Res</source><year>2019</year><volume>52</volume><issue>9</issue><fpage>2435</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1021/acs.accounts.9b00368</pub-id><pub-id pub-id-type="pmid">31397996</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Kulkarni JA, Witzigmann D, Chen S, Cullis PR, van der Meel R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc Chem Res. 2019;52(9):2435&#x02013;44.<pub-id pub-id-type="pmid">31397996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Zhang Z, Deng Q, Xiao C, Li Z, Yang X. Rational design of Nanotherapeutics based on the five features Principle for Potent Elimination of Cancer Stem cells. Acc Chem Res. 2022.</mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Danhier</surname><given-names>F</given-names></name></person-group><article-title>To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine?</article-title><source>J Control Release</source><year>2016</year><volume>244</volume><issue>Pt A</issue><fpage>108</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2016.11.015</pub-id><pub-id pub-id-type="pmid">27871992</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Danhier F. To exploit the tumor microenvironment: since the EPR effect fails in the clinic, what is the future of nanomedicine? J Control Release. 2016;244(Pt A):108&#x02013;21.<pub-id pub-id-type="pmid">27871992</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Sindhwani</surname><given-names>S</given-names></name><name><surname>Syed</surname><given-names>AM</given-names></name><name><surname>Ngai</surname><given-names>J</given-names></name><name><surname>Kingston</surname><given-names>BR</given-names></name><name><surname>Maiorino</surname><given-names>L</given-names></name><name><surname>Rothschild</surname><given-names>J</given-names></name><etal/></person-group><article-title>The entry of nanoparticles into solid tumours</article-title><source>Nat Mater</source><year>2020</year><volume>19</volume><issue>5</issue><fpage>566</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1038/s41563-019-0566-2</pub-id><pub-id pub-id-type="pmid">31932672</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566&#x02013;75.<pub-id pub-id-type="pmid">31932672</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>P</given-names></name><name><surname>Bhargava</surname><given-names>M</given-names></name></person-group><article-title>Applications and characteristics of nanomaterials in industrial environment</article-title><source>Res Dev (IJCSEIERD)</source><year>2013</year><volume>3</volume><issue>4</issue><fpage>63</fpage><lpage>72</lpage></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Sharma P, Bhargava M. Applications and characteristics of nanomaterials in industrial environment. Res Dev (IJCSEIERD). 2013;3(4):63&#x02013;72.</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Belli</surname><given-names>C</given-names></name><name><surname>Trapani</surname><given-names>D</given-names></name><name><surname>Viale</surname><given-names>G</given-names></name><name><surname>D&#x02019;Amico</surname><given-names>P</given-names></name><name><surname>Duso</surname><given-names>BA</given-names></name><name><surname>Della Vigna</surname><given-names>P</given-names></name><etal/></person-group><article-title>Targeting the microenvironment in solid tumors</article-title><source>Cancer Treat Rev</source><year>2018</year><volume>65</volume><fpage>22</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2018.02.004</pub-id><pub-id pub-id-type="pmid">29502037</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Belli C, Trapani D, Viale G, D&#x02019;Amico P, Duso BA, Della Vigna P, et al. Targeting the microenvironment in solid tumors. Cancer Treat Rev. 2018;65:22&#x02013;32.<pub-id pub-id-type="pmid">29502037</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Gun</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>SWL</given-names></name><name><surname>Sieow</surname><given-names>JL</given-names></name><name><surname>Wong</surname><given-names>SC</given-names></name></person-group><article-title>Targeting immune cells for cancer therapy</article-title><source>Redox Biol</source><year>2019</year><volume>25</volume><fpage>101174</fpage><pub-id pub-id-type="doi">10.1016/j.redox.2019.101174</pub-id><pub-id pub-id-type="pmid">30917934</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Gun SY, Lee SWL, Sieow JL, Wong SC. Targeting immune cells for cancer therapy. Redox Biol. 2019;25:101174.<pub-id pub-id-type="pmid">30917934</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Binnewies</surname><given-names>M</given-names></name><name><surname>Roberts</surname><given-names>EW</given-names></name><name><surname>Kersten</surname><given-names>K</given-names></name><name><surname>Chan</surname><given-names>V</given-names></name><name><surname>Fearon</surname><given-names>DF</given-names></name><name><surname>Merad</surname><given-names>M</given-names></name><etal/></person-group><article-title>Understanding the tumor immune microenvironment (TIME) for effective therapy</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><issue>5</issue><fpage>541</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/s41591-018-0014-x</pub-id><pub-id pub-id-type="pmid">29686425</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541&#x02013;50.<pub-id pub-id-type="pmid">29686425</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Ponka</surname><given-names>P</given-names></name><name><surname>Lok</surname><given-names>CN</given-names></name></person-group><article-title>The transferrin receptor: role in health and disease</article-title><source>Int J Biochem Cell Biol</source><year>1999</year><volume>31</volume><issue>10</issue><fpage>1111</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/S1357-2725(99)00070-9</pub-id><pub-id pub-id-type="pmid">10582342</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Ponka P, Lok CN. The transferrin receptor: role in health and disease. Int J Biochem Cell Biol. 1999;31(10):1111&#x02013;37.<pub-id pub-id-type="pmid">10582342</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Johnsen</surname><given-names>KB</given-names></name><name><surname>Burkhart</surname><given-names>A</given-names></name><name><surname>Thomsen</surname><given-names>LB</given-names></name><name><surname>Andresen</surname><given-names>TL</given-names></name><name><surname>Moos</surname><given-names>T</given-names></name></person-group><article-title>Targeting the transferrin receptor for brain drug delivery</article-title><source>Prog Neurobiol</source><year>2019</year><volume>181</volume><fpage>101665</fpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2019.101665</pub-id><pub-id pub-id-type="pmid">31376426</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T. Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol. 2019;181:101665.<pub-id pub-id-type="pmid">31376426</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Calzolari</surname><given-names>A</given-names></name><name><surname>Larocca</surname><given-names>LM</given-names></name><name><surname>Deaglio</surname><given-names>S</given-names></name><name><surname>Finisguerra</surname><given-names>V</given-names></name><name><surname>Boe</surname><given-names>A</given-names></name><name><surname>Raggi</surname><given-names>C</given-names></name><etal/></person-group><article-title>Transferrin receptor 2 is frequently and highly expressed in glioblastomas</article-title><source>Transl Oncol</source><year>2010</year><volume>3</volume><issue>2</issue><fpage>123</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1593/tlo.09274</pub-id><pub-id pub-id-type="pmid">20360937</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Calzolari A, Larocca LM, Deaglio S, Finisguerra V, Boe A, Raggi C, et al. Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl Oncol. 2010;3(2):123&#x02013;34.<pub-id pub-id-type="pmid">20360937</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Adachi</surname><given-names>M</given-names></name><name><surname>Kai</surname><given-names>K</given-names></name><name><surname>Yamaji</surname><given-names>K</given-names></name><name><surname>Ide</surname><given-names>T</given-names></name><name><surname>Noshiro</surname><given-names>H</given-names></name><name><surname>Kawaguchi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma</article-title><source>Histopathology</source><year>2019</year><volume>75</volume><issue>1</issue><fpage>63</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1111/his.13847</pub-id><pub-id pub-id-type="pmid">30811632</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Adachi M, Kai K, Yamaji K, Ide T, Noshiro H, Kawaguchi A, et al. Transferrin receptor 1 overexpression is associated with tumour de-differentiation and acts as a potential prognostic indicator of hepatocellular carcinoma. Histopathology. 2019;75(1):63&#x02013;73.<pub-id pub-id-type="pmid">30811632</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Deshpande</surname><given-names>P</given-names></name><name><surname>Jhaveri</surname><given-names>A</given-names></name><name><surname>Pattni</surname><given-names>B</given-names></name><name><surname>Biswas</surname><given-names>S</given-names></name><name><surname>Torchilin</surname><given-names>V</given-names></name></person-group><article-title>Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer</article-title><source>Drug Deliv</source><year>2018</year><volume>25</volume><issue>1</issue><fpage>517</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1080/10717544.2018.1435747</pub-id><pub-id pub-id-type="pmid">29433357</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Deshpande P, Jhaveri A, Pattni B, Biswas S, Torchilin V. Transferrin and octaarginine modified dual-functional liposomes with improved cancer cell targeting and enhanced intracellular delivery for the treatment of ovarian cancer. Drug Deliv. 2018;25(1):517&#x02013;32.<pub-id pub-id-type="pmid">29433357</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Low</surname><given-names>PS</given-names></name><name><surname>Kularatne</surname><given-names>SA</given-names></name></person-group><article-title>Folate-targeted therapeutic and imaging agents for cancer</article-title><source>Curr Opin Chem Biol</source><year>2009</year><volume>13</volume><issue>3</issue><fpage>256</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.cbpa.2009.03.022</pub-id><pub-id pub-id-type="pmid">19419901</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol. 2009;13(3):256&#x02013;62.<pub-id pub-id-type="pmid">19419901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1)</article-title><source>J Nanobiotechnol</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>323</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-01063-4</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Zhang Z, Zhang J, Tian J, Li H. A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1). J Nanobiotechnol. 2021;19(1):323.</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><mixed-citation publication-type="other">Dominguez-Martinez I, Joaquin-Ovalle F, Ferrer-Acosta Y, Griebenow KH. Folate-decorated cross-linked cytochrome c nanoparticles for active targeting of Non-small Cell Lung Carcinoma (NSCLC). Pharmaceutics. 2022;14(3).</mixed-citation></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Damrongrak</surname><given-names>K</given-names></name><name><surname>Kloysawat</surname><given-names>K</given-names></name><name><surname>Bunsupa</surname><given-names>S</given-names></name><name><surname>Sakchasri</surname><given-names>K</given-names></name><name><surname>Wongrakpanich</surname><given-names>A</given-names></name><name><surname>Taresco</surname><given-names>V</given-names></name><etal/></person-group><article-title>Delivery of acetogenin-enriched Annona muricata Linn leaf extract by folic acid-conjugated and triphenylphosphonium-conjugated poly(glycerol adipate) nanoparticles to enhance toxicity against ovarian cancer cells</article-title><source>Int J Pharm</source><year>2022</year><volume>618</volume><fpage>121636</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2022.121636</pub-id><pub-id pub-id-type="pmid">35259439</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Damrongrak K, Kloysawat K, Bunsupa S, Sakchasri K, Wongrakpanich A, Taresco V, et al. Delivery of acetogenin-enriched Annona muricata Linn leaf extract by folic acid-conjugated and triphenylphosphonium-conjugated poly(glycerol adipate) nanoparticles to enhance toxicity against ovarian cancer cells. Int J Pharm. 2022;618:121636.<pub-id pub-id-type="pmid">35259439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Pilch J, Kowalik P, Kowalczyk A, Bujak P, Kasprzak A, Paluszkiewicz E et al. Foliate-Targeting Quantum Dots-&#x003b2;-Cyclodextrin nanocarrier for efficient delivery of Unsymmetrical Bisacridines to lung and prostate Cancer cells. Int J Mol Sci. 2022;23(3).</mixed-citation></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>YI</given-names></name><name><surname>Kwon</surname><given-names>SH</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Motoyama</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>MW</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><etal/></person-group><article-title>pH-sensitive multi-drug liposomes targeting folate receptor &#x003b2; for efficient treatment of non-small cell lung cancer</article-title><source>J Control Release</source><year>2021</year><volume>330</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.12.011</pub-id><pub-id pub-id-type="pmid">33321157</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Park YI, Kwon SH, Lee G, Motoyama K, Kim MW, Lin M, et al. pH-sensitive multi-drug liposomes targeting folate receptor &#x003b2; for efficient treatment of non-small cell lung cancer. J Control Release. 2021;330:1&#x02013;14.<pub-id pub-id-type="pmid">33321157</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Xue</surname><given-names>G</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>Improved therapeutic efficacy of Topotecan Against A549 Lung Cancer Cells with folate-targeted Topotecan liposomes</article-title><source>Curr Drug Metab</source><year>2020</year><volume>21</volume><issue>11</issue><fpage>902</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.2174/1389200221999200820163337</pub-id><pub-id pub-id-type="pmid">32851958</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Zhang J, Shi W, Xue G, Ma Q, Cui H, Zhang L. Improved therapeutic efficacy of Topotecan Against A549 Lung Cancer Cells with folate-targeted Topotecan liposomes. Curr Drug Metab. 2020;21(11):902&#x02013;9.<pub-id pub-id-type="pmid">32851958</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>S</given-names></name><name><surname>Jing</surname><given-names>R</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><etal/></person-group><article-title>One-step Microfluidic fabrication of Multi-responsive liposomes for targeted delivery of Doxorubicin Synergism with Photothermal Effect</article-title><source>Int J Nanomed</source><year>2021</year><volume>16</volume><fpage>7759</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.2147/IJN.S329621</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Lv S, Jing R, Liu X, Shi H, Shi Y, Wang X, et al. One-step Microfluidic fabrication of Multi-responsive liposomes for targeted delivery of Doxorubicin Synergism with Photothermal Effect. Int J Nanomed. 2021;16:7759&#x02013;72.</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Allred</surname><given-names>DC</given-names></name><name><surname>Brown</surname><given-names>P</given-names></name><name><surname>Medina</surname><given-names>D</given-names></name></person-group><article-title>The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer</article-title><source>Breast Cancer Res</source><year>2004</year><volume>6</volume><issue>6</issue><fpage>240</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1186/bcr938</pub-id><pub-id pub-id-type="pmid">15535853</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Allred DC, Brown P, Medina D. The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer. Breast Cancer Res. 2004;6(6):240&#x02013;5.<pub-id pub-id-type="pmid">15535853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Ryu</surname><given-names>WS</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Jang</surname><given-names>YJ</given-names></name><name><surname>Park</surname><given-names>SS</given-names></name><name><surname>Um</surname><given-names>JW</given-names></name><name><surname>Park</surname><given-names>SH</given-names></name><etal/></person-group><article-title>Expression of estrogen receptors in gastric cancer and their clinical significance</article-title><source>J Surg Oncol</source><year>2012</year><volume>106</volume><issue>4</issue><fpage>456</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1002/jso.23097</pub-id><pub-id pub-id-type="pmid">22422271</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Ryu WS, Kim JH, Jang YJ, Park SS, Um JW, Park SH, et al. Expression of estrogen receptors in gastric cancer and their clinical significance. J Surg Oncol. 2012;106(4):456&#x02013;61.<pub-id pub-id-type="pmid">22422271</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Kauss</surname><given-names>MA</given-names></name><name><surname>Reiterer</surname><given-names>G</given-names></name><name><surname>Bunaciu</surname><given-names>RP</given-names></name><name><surname>Yen</surname><given-names>A</given-names></name></person-group><article-title>Human myeloblastic leukemia cells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation</article-title><source>Exp Cell Res</source><year>2008</year><volume>314</volume><issue>16</issue><fpage>2999</fpage><lpage>3006</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2008.07.015</pub-id><pub-id pub-id-type="pmid">18692045</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Kauss MA, Reiterer G, Bunaciu RP, Yen A. Human myeloblastic leukemia cells (HL-60) express a membrane receptor for estrogen that signals and modulates retinoic acid-induced cell differentiation. Exp Cell Res. 2008;314(16):2999&#x02013;3006.<pub-id pub-id-type="pmid">18692045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>G</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Estrone-targeted liposomes for mitoxantrone delivery via estrogen receptor: in vivo targeting efficacy, antitumor activity, acute toxicity and pharmacokinetics</article-title><source>Eur J Pharm Sci</source><year>2021</year><volume>161</volume><fpage>105780</fpage><pub-id pub-id-type="doi">10.1016/j.ejps.2021.105780</pub-id><pub-id pub-id-type="pmid">33667664</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Xu G, Tang H, Chen J, Zhu M, Xie Y, Li Y, et al. Estrone-targeted liposomes for mitoxantrone delivery via estrogen receptor: in vivo targeting efficacy, antitumor activity, acute toxicity and pharmacokinetics. Eur J Pharm Sci. 2021;161:105780.<pub-id pub-id-type="pmid">33667664</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>AD</given-names></name><name><surname>Syn</surname><given-names>NL</given-names></name><name><surname>Moehler</surname><given-names>M</given-names></name><name><surname>Grothe</surname><given-names>W</given-names></name><name><surname>Yong</surname><given-names>WP</given-names></name><name><surname>Tai</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Chemotherapy for advanced gastric cancer</article-title><source>Cochrane Database Syst Rev</source><year>2017</year><volume>8</volume><issue>8</issue><fpage>Cd004064</fpage><pub-id pub-id-type="pmid">28850174</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):Cd004064.<pub-id pub-id-type="pmid">28850174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Tu</surname><given-names>J</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name></person-group><article-title>Long-circulating Thermosensitive liposomes for the targeted drug delivery of Oxaliplatin</article-title><source>Int J Nanomed</source><year>2020</year><volume>15</volume><fpage>6721</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2147/IJN.S250773</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Li Y, Xu P, He D, Xu B, Tu J, Shen Y. Long-circulating Thermosensitive liposomes for the targeted drug delivery of Oxaliplatin. Int J Nanomed. 2020;15:6721&#x02013;34.</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Luan</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>In vitro and in vivo evaluation of a Novel Estrogen-targeted PEGylated oxaliplatin liposome for gastric Cancer</article-title><source>Int J Nanomed</source><year>2021</year><volume>16</volume><fpage>8279</fpage><lpage>303</lpage><pub-id pub-id-type="doi">10.2147/IJN.S340180</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Sun Y, Xie Y, Tang H, Ren Z, Luan X, Zhang Y, et al. In vitro and in vivo evaluation of a Novel Estrogen-targeted PEGylated oxaliplatin liposome for gastric Cancer. Int J Nanomed. 2021;16:8279&#x02013;303.</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Li Q, Zhu M, Li Y, Tang H, Wang Z, Zhang Y et al. Estrone-targeted PEGylated liposomal nanoparticles for cisplatin (DDP) delivery in Cervical Cancer. Eur J Pharm Sci. 2022:106187.</mixed-citation></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Kesharwani</surname><given-names>P</given-names></name><name><surname>Banerjee</surname><given-names>S</given-names></name><name><surname>Padhye</surname><given-names>S</given-names></name><name><surname>Sarkar</surname><given-names>FH</given-names></name><name><surname>Iyer</surname><given-names>AK</given-names></name></person-group><article-title>Hyaluronic Acid Engineered Nanomicelles loaded with 3,4-Difluorobenzylidene curcumin for targeted killing of CD44&#x02009;+&#x02009;stem-like Pancreatic Cancer cells</article-title><source>Biomacromolecules</source><year>2015</year><volume>16</volume><issue>9</issue><fpage>3042</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.5b00941</pub-id><pub-id pub-id-type="pmid">26302089</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Kesharwani P, Banerjee S, Padhye S, Sarkar FH, Iyer AK. Hyaluronic Acid Engineered Nanomicelles loaded with 3,4-Difluorobenzylidene curcumin for targeted killing of CD44&#x02009;+&#x02009;stem-like Pancreatic Cancer cells. Biomacromolecules. 2015;16(9):3042&#x02013;53.<pub-id pub-id-type="pmid">26302089</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy</article-title><source>Carbohydr Polym</source><year>2021</year><volume>251</volume><fpage>117103</fpage><pub-id pub-id-type="doi">10.1016/j.carbpol.2020.117103</pub-id><pub-id pub-id-type="pmid">33142641</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Li M, Sun J, Zhang W, Zhao Y, Zhang S, Zhang S. Drug delivery systems based on CD44-targeted glycosaminoglycans for cancer therapy. Carbohydr Polym. 2021;251:117103.<pub-id pub-id-type="pmid">33142641</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhi</surname><given-names>D</given-names></name><name><surname>Cui</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>E</given-names></name><etal/></person-group><article-title>Stimuli-Responsive Polysaccharide Enveloped Liposome for Targeting and penetrating delivery of survivin-shRNA into breast tumor</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><issue>19</issue><fpage>22074</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1021/acsami.9b22440</pub-id><pub-id pub-id-type="pmid">32083833</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Chen H, Fan X, Zhao Y, Zhi D, Cui S, Zhang E, et al. Stimuli-Responsive Polysaccharide Enveloped Liposome for Targeting and penetrating delivery of survivin-shRNA into breast tumor. ACS Appl Mater Interfaces. 2020;12(19):22074&#x02013;87.<pub-id pub-id-type="pmid">32083833</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Bi</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>R</given-names></name><name><surname>Hao</surname><given-names>F</given-names></name><etal/></person-group><article-title>Dual-loaded liposomes tagged with Hyaluronic Acid have synergistic effects in Triple-negative breast Cancer</article-title><source>Small</source><year>2022</year><volume>18</volume><issue>16</issue><fpage>e2107690</fpage><pub-id pub-id-type="doi">10.1002/smll.202107690</pub-id><pub-id pub-id-type="pmid">35277914</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Dong S, Bi Y, Sun X, Zhao Y, Sun R, Hao F, et al. Dual-loaded liposomes tagged with Hyaluronic Acid have synergistic effects in Triple-negative breast Cancer. Small. 2022;18(16):e2107690.<pub-id pub-id-type="pmid">35277914</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other">Wee P, Wang Z. Epidermal growth factor receptor cell Proliferation Signaling pathways. Cancers (Basel). 2017;9(5).</mixed-citation></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Oda</surname><given-names>K</given-names></name><name><surname>Matsuoka</surname><given-names>Y</given-names></name><name><surname>Funahashi</surname><given-names>A</given-names></name><name><surname>Kitano</surname><given-names>H</given-names></name></person-group><article-title>A comprehensive pathway map of epidermal growth factor receptor signaling</article-title><source>Mol Syst Biol</source><year>2005</year><volume>1</volume><fpage>20050010</fpage><pub-id pub-id-type="doi">10.1038/msb4100014</pub-id></element-citation><mixed-citation id="mc-CR79" publication-type="journal">Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 2005;1:20050010.</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Sk&#x000f3;ra</surname><given-names>B</given-names></name><name><surname>Piechowiak</surname><given-names>T</given-names></name><name><surname>Szychowski</surname><given-names>KA</given-names></name></person-group><article-title>Epidermal growth factor-labeled liposomes as a way to target the toxicity of silver nanoparticles into EGFR-overexpressing cancer cells in vitro</article-title><source>Toxicol Appl Pharmacol</source><year>2022</year><volume>443</volume><fpage>116009</fpage><pub-id pub-id-type="doi">10.1016/j.taap.2022.116009</pub-id><pub-id pub-id-type="pmid">35385781</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Sk&#x000f3;ra B, Piechowiak T, Szychowski KA. Epidermal growth factor-labeled liposomes as a way to target the toxicity of silver nanoparticles into EGFR-overexpressing cancer cells in vitro. Toxicol Appl Pharmacol. 2022;443:116009.<pub-id pub-id-type="pmid">35385781</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Eloy</surname><given-names>JO</given-names></name><name><surname>Ruiz</surname><given-names>A</given-names></name><name><surname>de Lima</surname><given-names>FT</given-names></name><name><surname>Petrilli</surname><given-names>R</given-names></name><name><surname>Raspantini</surname><given-names>G</given-names></name><name><surname>Nogueira</surname><given-names>KAB</given-names></name><etal/></person-group><article-title>EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells</article-title><source>Colloids Surf B Biointerfaces</source><year>2020</year><volume>194</volume><fpage>111185</fpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2020.111185</pub-id><pub-id pub-id-type="pmid">32574928</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Eloy JO, Ruiz A, de Lima FT, Petrilli R, Raspantini G, Nogueira KAB, et al. EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells. Colloids Surf B Biointerfaces. 2020;194:111185.<pub-id pub-id-type="pmid">32574928</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Citri</surname><given-names>A</given-names></name><name><surname>Yarden</surname><given-names>Y</given-names></name></person-group><article-title>EGF-ERBB signalling: towards the systems level</article-title><source>Nat Rev Mol Cell Biol</source><year>2006</year><volume>7</volume><issue>7</issue><fpage>505</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1038/nrm1962</pub-id><pub-id pub-id-type="pmid">16829981</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006;7(7):505&#x02013;16.<pub-id pub-id-type="pmid">16829981</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Tai</surname><given-names>W</given-names></name><name><surname>Mahato</surname><given-names>R</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name></person-group><article-title>The role of HER2 in cancer therapy and targeted drug delivery</article-title><source>J Control Release</source><year>2010</year><volume>146</volume><issue>3</issue><fpage>264</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2010.04.009</pub-id><pub-id pub-id-type="pmid">20385184</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release. 2010;146(3):264&#x02013;75.<pub-id pub-id-type="pmid">20385184</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Di</surname><given-names>H</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><etal/></person-group><article-title>A photosensitive liposome with NIR light triggered doxorubicin release as a combined photodynamic-chemo therapy system</article-title><source>J Control Release</source><year>2018</year><volume>277</volume><fpage>114</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2018.02.001</pub-id><pub-id pub-id-type="pmid">29408424</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Li Q, Li W, Di H, Luo L, Zhu C, Yang J, et al. A photosensitive liposome with NIR light triggered doxorubicin release as a combined photodynamic-chemo therapy system. J Control Release. 2018;277:114&#x02013;25.<pub-id pub-id-type="pmid">29408424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Duan</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Feng</surname><given-names>J</given-names></name><name><surname>Qi</surname><given-names>N</given-names></name></person-group><article-title>Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma</article-title><source>Theranostics</source><year>2020</year><volume>10</volume><issue>10</issue><fpage>4308</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.7150/thno.41322</pub-id><pub-id pub-id-type="pmid">32292496</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Kang S, Duan W, Zhang S, Chen D, Feng J, Qi N. Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma. Theranostics. 2020;10(10):4308&#x02013;22.<pub-id pub-id-type="pmid">32292496</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Ohradanova-Repic</surname><given-names>A</given-names></name><name><surname>Nogueira</surname><given-names>E</given-names></name><name><surname>Hartl</surname><given-names>I</given-names></name><name><surname>Gomes</surname><given-names>AC</given-names></name><name><surname>Preto</surname><given-names>A</given-names></name><name><surname>Steinhuber</surname><given-names>E</given-names></name><etal/></person-group><article-title>Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells</article-title><source>Nanomedicine</source><year>2018</year><volume>14</volume><issue>1</issue><fpage>123</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2017.09.003</pub-id><pub-id pub-id-type="pmid">28939491</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Ohradanova-Repic A, Nogueira E, Hartl I, Gomes AC, Preto A, Steinhuber E, et al. Fab antibody fragment-functionalized liposomes for specific targeting of antigen-positive cells. Nanomedicine. 2018;14(1):123&#x02013;30.<pub-id pub-id-type="pmid">28939491</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Sawant</surname><given-names>RR</given-names></name><name><surname>Torchilin</surname><given-names>VP</given-names></name></person-group><article-title>Challenges in development of targeted liposomal therapeutics</article-title><source>Aaps j</source><year>2012</year><volume>14</volume><issue>2</issue><fpage>303</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1208/s12248-012-9330-0</pub-id><pub-id pub-id-type="pmid">22415612</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Sawant RR, Torchilin VP. Challenges in development of targeted liposomal therapeutics. Aaps j. 2012;14(2):303&#x02013;15.<pub-id pub-id-type="pmid">22415612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>R</given-names></name><name><surname>Xiao</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery</article-title><source>Int J Nanomed</source><year>2012</year><volume>7</volume><fpage>4185</fpage><lpage>98</lpage></element-citation><mixed-citation id="mc-CR88" publication-type="journal">Wang R, Xiao R, Zeng Z, Xu L, Wang J. Application of poly(ethylene glycol)-distearoylphosphatidylethanolamine (PEG-DSPE) block copolymers and their derivatives as nanomaterials in drug delivery. Int J Nanomed. 2012;7:4185&#x02013;98.</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Nobs</surname><given-names>L</given-names></name><name><surname>Buchegger</surname><given-names>F</given-names></name><name><surname>Gurny</surname><given-names>R</given-names></name><name><surname>All&#x000e9;mann</surname><given-names>E</given-names></name></person-group><article-title>Current methods for attaching targeting ligands to liposomes and nanoparticles</article-title><source>J Pharm Sci</source><year>2004</year><volume>93</volume><issue>8</issue><fpage>1980</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1002/jps.20098</pub-id><pub-id pub-id-type="pmid">15236448</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Nobs L, Buchegger F, Gurny R, All&#x000e9;mann E. Current methods for attaching targeting ligands to liposomes and nanoparticles. J Pharm Sci. 2004;93(8):1980&#x02013;92.<pub-id pub-id-type="pmid">15236448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Ruoslahti</surname><given-names>E</given-names></name></person-group><article-title>Peptides as targeting elements and tissue penetration devices for nanoparticles</article-title><source>Adv Mater</source><year>2012</year><volume>24</volume><issue>28</issue><fpage>3747</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1002/adma.201200454</pub-id><pub-id pub-id-type="pmid">22550056</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Ruoslahti E. Peptides as targeting elements and tissue penetration devices for nanoparticles. Adv Mater. 2012;24(28):3747&#x02013;56.<pub-id pub-id-type="pmid">22550056</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR91"><label>91.</label><citation-alternatives><element-citation id="ec-CR91" publication-type="journal"><person-group person-group-type="author"><name><surname>Joyce</surname><given-names>JA</given-names></name><name><surname>Fearon</surname><given-names>DT</given-names></name></person-group><article-title>T cell exclusion, immune privilege, and the tumor microenvironment</article-title><source>Science</source><year>2015</year><volume>348</volume><issue>6230</issue><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1126/science.aaa6204</pub-id><pub-id pub-id-type="pmid">25838376</pub-id>
</element-citation><mixed-citation id="mc-CR91" publication-type="journal">Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science. 2015;348(6230):74&#x02013;80.<pub-id pub-id-type="pmid">25838376</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR92"><label>92.</label><citation-alternatives><element-citation id="ec-CR92" publication-type="journal"><person-group person-group-type="author"><name><surname>Spill</surname><given-names>F</given-names></name><name><surname>Reynolds</surname><given-names>DS</given-names></name><name><surname>Kamm</surname><given-names>RD</given-names></name><name><surname>Zaman</surname><given-names>MH</given-names></name></person-group><article-title>Impact of the physical microenvironment on tumor progression and metastasis</article-title><source>Curr Opin Biotechnol</source><year>2016</year><volume>40</volume><fpage>41</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.copbio.2016.02.007</pub-id><pub-id pub-id-type="pmid">26938687</pub-id>
</element-citation><mixed-citation id="mc-CR92" publication-type="journal">Spill F, Reynolds DS, Kamm RD, Zaman MH. Impact of the physical microenvironment on tumor progression and metastasis. Curr Opin Biotechnol. 2016;40:41&#x02013;8.<pub-id pub-id-type="pmid">26938687</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR93"><label>93.</label><mixed-citation publication-type="other">Gilabert-Oriol R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB. Liposomal formulations to modulate the Tumour Microenvironment and Antitumour Immune Response. Int J Mol Sci. 2018;19(10).</mixed-citation></ref><ref id="CR94"><label>94.</label><citation-alternatives><element-citation id="ec-CR94" publication-type="journal"><person-group person-group-type="author"><name><surname>Merelli</surname><given-names>B</given-names></name><name><surname>Massi</surname><given-names>D</given-names></name><name><surname>Cattaneo</surname><given-names>L</given-names></name><name><surname>Mandal&#x000e0;</surname><given-names>M</given-names></name></person-group><article-title>Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities</article-title><source>Crit Rev Oncol Hematol</source><year>2014</year><volume>89</volume><issue>1</issue><fpage>140</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2013.08.002</pub-id><pub-id pub-id-type="pmid">24029602</pub-id>
</element-citation><mixed-citation id="mc-CR94" publication-type="journal">Merelli B, Massi D, Cattaneo L, Mandal&#x000e0; M. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities. Crit Rev Oncol Hematol. 2014;89(1):140&#x02013;65.<pub-id pub-id-type="pmid">24029602</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR95"><label>95.</label><citation-alternatives><element-citation id="ec-CR95" publication-type="journal"><person-group person-group-type="author"><name><surname>Robert</surname><given-names>C</given-names></name><name><surname>Soria</surname><given-names>JC</given-names></name><name><surname>Eggermont</surname><given-names>AM</given-names></name></person-group><article-title>Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies</article-title><source>Eur J Cancer</source><year>2013</year><volume>49</volume><issue>14</issue><fpage>2968</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1016/j.ejca.2013.07.001</pub-id><pub-id pub-id-type="pmid">23907003</pub-id>
</element-citation><mixed-citation id="mc-CR95" publication-type="journal">Robert C, Soria JC, Eggermont AM. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies. Eur J Cancer. 2013;49(14):2968&#x02013;71.<pub-id pub-id-type="pmid">23907003</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR96"><label>96.</label><citation-alternatives><element-citation id="ec-CR96" publication-type="journal"><person-group person-group-type="author"><name><surname>Merino</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>T</given-names></name><name><surname>Casares</surname><given-names>N</given-names></name><name><surname>Lana</surname><given-names>H</given-names></name><name><surname>Troconiz</surname><given-names>IF</given-names></name><name><surname>Ten Hagen</surname><given-names>TLM</given-names></name><etal/></person-group><article-title>Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model</article-title><source>J Nanobiotechnol</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>102</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-00846-z</pub-id></element-citation><mixed-citation id="mc-CR96" publication-type="journal">Merino M, Lozano T, Casares N, Lana H, Troconiz IF, Ten Hagen TLM, et al. Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. J Nanobiotechnol. 2021;19(1):102.</mixed-citation></citation-alternatives></ref><ref id="CR97"><label>97.</label><citation-alternatives><element-citation id="ec-CR97" publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><article-title>Hallmarks of Cancer: New dimensions</article-title><source>Cancer Discov</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>31</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id><pub-id pub-id-type="pmid">35022204</pub-id>
</element-citation><mixed-citation id="mc-CR97" publication-type="journal">Hanahan D. Hallmarks of Cancer: New dimensions. Cancer Discov. 2022;12(1):31&#x02013;46.<pub-id pub-id-type="pmid">35022204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR98"><label>98.</label><citation-alternatives><element-citation id="ec-CR98" publication-type="journal"><person-group person-group-type="author"><name><surname>Ribatti</surname><given-names>D</given-names></name><name><surname>Pezzella</surname><given-names>F</given-names></name></person-group><article-title>Vascular co-option and other alternative modalities of growth of Tumor vasculature in Glioblastoma</article-title><source>Front Oncol</source><year>2022</year><volume>12</volume><fpage>874554</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.874554</pub-id><pub-id pub-id-type="pmid">35433447</pub-id>
</element-citation><mixed-citation id="mc-CR98" publication-type="journal">Ribatti D, Pezzella F. Vascular co-option and other alternative modalities of growth of Tumor vasculature in Glioblastoma. Front Oncol. 2022;12:874554.<pub-id pub-id-type="pmid">35433447</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR99"><label>99.</label><citation-alternatives><element-citation id="ec-CR99" publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Deore</surname><given-names>SV</given-names></name><name><surname>Ghadi</surname><given-names>R</given-names></name><name><surname>Chaudhari</surname><given-names>D</given-names></name><name><surname>Kuche</surname><given-names>K</given-names></name><name><surname>Katiyar</surname><given-names>SS</given-names></name></person-group><article-title>Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy</article-title><source>Mater Sci Eng C Mater Biol Appl</source><year>2021</year><volume>121</volume><fpage>111832</fpage><pub-id pub-id-type="doi">10.1016/j.msec.2020.111832</pub-id><pub-id pub-id-type="pmid">33579470</pub-id>
</element-citation><mixed-citation id="mc-CR99" publication-type="journal">Jain S, Deore SV, Ghadi R, Chaudhari D, Kuche K, Katiyar SS. Tumor microenvironment responsive VEGF-antibody functionalized pH sensitive liposomes of docetaxel for augmented breast cancer therapy. Mater Sci Eng C Mater Biol Appl. 2021;121:111832.<pub-id pub-id-type="pmid">33579470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR100"><label>100.</label><mixed-citation publication-type="other">Tang T, Huang B, Liu F, Cui R, Zhang M, Sun T. Enhanced delivery of theranostic liposomes through NO-mediated tumor microenvironment remodeling. Nanoscale. 2022.</mixed-citation></ref><ref id="CR101"><label>101.</label><citation-alternatives><element-citation id="ec-CR101" publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name></person-group><article-title>Sustained drug release from liposomes for the remodeling of systemic Immune Homeostasis and the Tumor Microenvironment</article-title><source>Front Immunol</source><year>2022</year><volume>13</volume><fpage>829391</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.829391</pub-id><pub-id pub-id-type="pmid">35493504</pub-id>
</element-citation><mixed-citation id="mc-CR101" publication-type="journal">Zheng A, Xie F, Shi S, Liu S, Long J, Xu Y. Sustained drug release from liposomes for the remodeling of systemic Immune Homeostasis and the Tumor Microenvironment. Front Immunol. 2022;13:829391.<pub-id pub-id-type="pmid">35493504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR102"><label>102.</label><citation-alternatives><element-citation id="ec-CR102" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Dahiru</surname><given-names>NS</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><etal/></person-group><article-title>A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy</article-title><source>J Control Release</source><year>2022</year><volume>346</volume><fpage>212</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.04.015</pub-id><pub-id pub-id-type="pmid">35461965</pub-id>
</element-citation><mixed-citation id="mc-CR102" publication-type="journal">Chen Q, Zhou S, Ding Y, Chen D, Dahiru NS, Tang H, et al. A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy. J Control Release. 2022;346:212&#x02013;25.<pub-id pub-id-type="pmid">35461965</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR103"><label>103.</label><citation-alternatives><element-citation id="ec-CR103" publication-type="journal"><person-group person-group-type="author"><name><surname>Tuerk</surname><given-names>C</given-names></name><name><surname>MacDougal</surname><given-names>S</given-names></name><name><surname>Gold</surname><given-names>L</given-names></name></person-group><article-title>RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase</article-title><source>Proc Natl Acad Sci U S A</source><year>1992</year><volume>89</volume><issue>15</issue><fpage>6988</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1073/pnas.89.15.6988</pub-id><pub-id pub-id-type="pmid">1379730</pub-id>
</element-citation><mixed-citation id="mc-CR103" publication-type="journal">Tuerk C, MacDougal S, Gold L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci U S A. 1992;89(15):6988&#x02013;92.<pub-id pub-id-type="pmid">1379730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR104"><label>104.</label><citation-alternatives><element-citation id="ec-CR104" publication-type="journal"><person-group person-group-type="author"><name><surname>Beutel</surname><given-names>BA</given-names></name><name><surname>Gold</surname><given-names>L</given-names></name></person-group><article-title>In vitro evolution of intrinsically bent DNA</article-title><source>J Mol Biol</source><year>1992</year><volume>228</volume><issue>3</issue><fpage>803</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/0022-2836(92)90865-H</pub-id><pub-id pub-id-type="pmid">1469714</pub-id>
</element-citation><mixed-citation id="mc-CR104" publication-type="journal">Beutel BA, Gold L. In vitro evolution of intrinsically bent DNA. J Mol Biol. 1992;228(3):803&#x02013;12.<pub-id pub-id-type="pmid">1469714</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR105"><label>105.</label><citation-alternatives><element-citation id="ec-CR105" publication-type="journal"><person-group person-group-type="author"><name><surname>Maier</surname><given-names>KE</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name></person-group><article-title>From selection hits to clinical leads: progress in aptamer discovery</article-title><source>Mol Ther Methods Clin Dev</source><year>2016</year><volume>5</volume><fpage>16014</fpage><pub-id pub-id-type="doi">10.1038/mtm.2016.14</pub-id><pub-id pub-id-type="pmid">27088106</pub-id>
</element-citation><mixed-citation id="mc-CR105" publication-type="journal">Maier KE, Levy M. From selection hits to clinical leads: progress in aptamer discovery. Mol Ther Methods Clin Dev. 2016;5:16014.<pub-id pub-id-type="pmid">27088106</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR106"><label>106.</label><citation-alternatives><element-citation id="ec-CR106" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Ye</surname><given-names>M</given-names></name><name><surname>Donovan</surname><given-names>MJ</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name></person-group><article-title>Nucleic acid aptamers: an emerging frontier in cancer therapy</article-title><source>Chem Commun (Camb)</source><year>2012</year><volume>48</volume><issue>85</issue><fpage>10472</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1039/c2cc35042d</pub-id><pub-id pub-id-type="pmid">22951893</pub-id>
</element-citation><mixed-citation id="mc-CR106" publication-type="journal">Zhu G, Ye M, Donovan MJ, Song E, Zhao Z, Tan W. Nucleic acid aptamers: an emerging frontier in cancer therapy. Chem Commun (Camb). 2012;48(85):10472&#x02013;80.<pub-id pub-id-type="pmid">22951893</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR107"><label>107.</label><citation-alternatives><element-citation id="ec-CR107" publication-type="journal"><person-group person-group-type="author"><name><surname>Matsunaga</surname><given-names>K</given-names></name><name><surname>Kimoto</surname><given-names>M</given-names></name><name><surname>Hanson</surname><given-names>C</given-names></name><name><surname>Sanford</surname><given-names>M</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Hirao</surname><given-names>I</given-names></name></person-group><article-title>Architecture of high-affinity unnatural-base DNA aptamers toward pharmaceutical applications</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>18478</fpage><pub-id pub-id-type="doi">10.1038/srep18478</pub-id><pub-id pub-id-type="pmid">26690672</pub-id>
</element-citation><mixed-citation id="mc-CR107" publication-type="journal">Matsunaga K, Kimoto M, Hanson C, Sanford M, Young HA, Hirao I. Architecture of high-affinity unnatural-base DNA aptamers toward pharmaceutical applications. Sci Rep. 2015;5:18478.<pub-id pub-id-type="pmid">26690672</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR108"><label>108.</label><citation-alternatives><element-citation id="ec-CR108" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>X</given-names></name><name><surname>Lu</surname><given-names>PY</given-names></name><name><surname>Rosato</surname><given-names>RR</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Zu</surname><given-names>Y</given-names></name></person-group><article-title>Oligonucleotide aptamers: new tools for targeted cancer therapy</article-title><source>Mol Ther Nucleic Acids</source><year>2014</year><volume>3</volume><issue>8</issue><fpage>e182</fpage><pub-id pub-id-type="doi">10.1038/mtna.2014.32</pub-id><pub-id pub-id-type="pmid">25093706</pub-id>
</element-citation><mixed-citation id="mc-CR108" publication-type="journal">Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther Nucleic Acids. 2014;3(8):e182.<pub-id pub-id-type="pmid">25093706</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR109"><label>109.</label><citation-alternatives><element-citation id="ec-CR109" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>D</given-names></name><name><surname>Zheng</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>SF</given-names></name><name><surname>Qiao</surname><given-names>S</given-names></name><name><surname>Tran</surname><given-names>PH</given-names></name><name><surname>Pu</surname><given-names>C</given-names></name><etal/></person-group><article-title>Superior Performance of Aptamer in Tumor penetration over antibody: implication of Aptamer-based theranostics in solid tumors</article-title><source>Theranostics</source><year>2015</year><volume>5</volume><issue>10</issue><fpage>1083</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.7150/thno.11711</pub-id><pub-id pub-id-type="pmid">26199647</pub-id>
</element-citation><mixed-citation id="mc-CR109" publication-type="journal">Xiang D, Zheng C, Zhou SF, Qiao S, Tran PH, Pu C, et al. Superior Performance of Aptamer in Tumor penetration over antibody: implication of Aptamer-based theranostics in solid tumors. Theranostics. 2015;5(10):1083&#x02013;97.<pub-id pub-id-type="pmid">26199647</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR110"><label>110.</label><citation-alternatives><element-citation id="ec-CR110" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas</article-title><source>Biomaterials</source><year>2014</year><volume>35</volume><issue>12</issue><fpage>3840</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2014.01.019</pub-id><pub-id pub-id-type="pmid">24486214</pub-id>
</element-citation><mixed-citation id="mc-CR110" publication-type="journal">Li L, Hou J, Liu X, Guo Y, Wu Y, Zhang L, et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials. 2014;35(12):3840&#x02013;50.<pub-id pub-id-type="pmid">24486214</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR111"><label>111.</label><citation-alternatives><element-citation id="ec-CR111" publication-type="journal"><person-group person-group-type="author"><name><surname>Xing</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Hwang</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yin</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Selective delivery of an Anticancer drug with aptamer-functionalized liposomes to breast Cancer cells in Vitro and in vivo</article-title><source>J Mater Chem B</source><year>2013</year><volume>1</volume><issue>39</issue><fpage>5288</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1039/c3tb20412j</pub-id><pub-id pub-id-type="pmid">24159374</pub-id>
</element-citation><mixed-citation id="mc-CR111" publication-type="journal">Xing H, Tang L, Yang X, Hwang K, Wang W, Yin Q, et al. Selective delivery of an Anticancer drug with aptamer-functionalized liposomes to breast Cancer cells in Vitro and in vivo. J Mater Chem B. 2013;1(39):5288&#x02013;97.<pub-id pub-id-type="pmid">24159374</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR112"><label>112.</label><mixed-citation publication-type="other">Cadinoiu AN, Rata DM, Atanase LI, Daraba OM, Gherghel D, Vochita G et al. Aptamer-functionalized liposomes as a potential treatment for basal cell carcinoma. Polym (Basel). 2019;11(9).</mixed-citation></ref><ref id="CR113"><label>113.</label><citation-alternatives><element-citation id="ec-CR113" publication-type="journal"><person-group person-group-type="author"><name><surname>Evjen</surname><given-names>TJ</given-names></name><name><surname>Nilssen</surname><given-names>EA</given-names></name><name><surname>Fowler</surname><given-names>RA</given-names></name><name><surname>R&#x000f8;gnvaldsson</surname><given-names>S</given-names></name><name><surname>Brandl</surname><given-names>M</given-names></name><name><surname>Fossheim</surname><given-names>SL</given-names></name></person-group><article-title>Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound</article-title><source>Int J Pharm</source><year>2011</year><volume>406</volume><issue>1&#x02013;2</issue><fpage>114</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2010.12.026</pub-id><pub-id pub-id-type="pmid">21185927</pub-id>
</element-citation><mixed-citation id="mc-CR113" publication-type="journal">Evjen TJ, Nilssen EA, Fowler RA, R&#x000f8;gnvaldsson S, Brandl M, Fossheim SL. Lipid membrane composition influences drug release from dioleoylphosphatidylethanolamine-based liposomes on exposure to ultrasound. Int J Pharm. 2011;406(1&#x02013;2):114&#x02013;6.<pub-id pub-id-type="pmid">21185927</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR114"><label>114.</label><citation-alternatives><element-citation id="ec-CR114" publication-type="journal"><person-group person-group-type="author"><name><surname>Abri Aghdam</surname><given-names>M</given-names></name><name><surname>Bagheri</surname><given-names>R</given-names></name><name><surname>Mosafer</surname><given-names>J</given-names></name><name><surname>Baradaran</surname><given-names>B</given-names></name><name><surname>Hashemzaei</surname><given-names>M</given-names></name><name><surname>Baghbanzadeh</surname><given-names>A</given-names></name><etal/></person-group><article-title>Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release</article-title><source>J Control Release</source><year>2019</year><volume>315</volume><fpage>1</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.09.018</pub-id><pub-id pub-id-type="pmid">31647978</pub-id>
</element-citation><mixed-citation id="mc-CR114" publication-type="journal">Abri Aghdam M, Bagheri R, Mosafer J, Baradaran B, Hashemzaei M, Baghbanzadeh A, et al. Recent advances on thermosensitive and pH-sensitive liposomes employed in controlled release. J Control Release. 2019;315:1&#x02013;22.<pub-id pub-id-type="pmid">31647978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR115"><label>115.</label><citation-alternatives><element-citation id="ec-CR115" publication-type="journal"><person-group person-group-type="author"><name><surname>Mastrobattista</surname><given-names>E</given-names></name><name><surname>Koning</surname><given-names>GA</given-names></name><name><surname>van Bloois</surname><given-names>L</given-names></name><name><surname>Filipe</surname><given-names>AC</given-names></name><name><surname>Jiskoot</surname><given-names>W</given-names></name><name><surname>Storm</surname><given-names>G</given-names></name></person-group><article-title>Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins</article-title><source>J Biol Chem</source><year>2002</year><volume>277</volume><issue>30</issue><fpage>27135</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1074/jbc.M200429200</pub-id><pub-id pub-id-type="pmid">12021269</pub-id>
</element-citation><mixed-citation id="mc-CR115" publication-type="journal">Mastrobattista E, Koning GA, van Bloois L, Filipe AC, Jiskoot W, Storm G. Functional characterization of an endosome-disruptive peptide and its application in cytosolic delivery of immunoliposome-entrapped proteins. J Biol Chem. 2002;277(30):27135&#x02013;43.<pub-id pub-id-type="pmid">12021269</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR116"><label>116.</label><citation-alternatives><element-citation id="ec-CR116" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>E</given-names></name></person-group><article-title>The combination of MnO(2)@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer</article-title><source>Drug Deliv</source><year>2022</year><volume>29</volume><issue>1</issue><fpage>466</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1080/10717544.2022.2032872</pub-id><pub-id pub-id-type="pmid">35147070</pub-id>
</element-citation><mixed-citation id="mc-CR116" publication-type="journal">Zhang J, Xu L, Hu H, Chen E. The combination of MnO(2)@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer. Drug Deliv. 2022;29(1):466&#x02013;77.<pub-id pub-id-type="pmid">35147070</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR117"><label>117.</label><citation-alternatives><element-citation id="ec-CR117" publication-type="journal"><person-group person-group-type="author"><name><surname>Candiani</surname><given-names>G</given-names></name><name><surname>Pezzoli</surname><given-names>D</given-names></name><name><surname>Ciani</surname><given-names>L</given-names></name><name><surname>Chiesa</surname><given-names>R</given-names></name><name><surname>Ristori</surname><given-names>S</given-names></name></person-group><article-title>Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action</article-title><source>PLoS ONE</source><year>2010</year><volume>5</volume><issue>10</issue><fpage>e13430</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0013430</pub-id><pub-id pub-id-type="pmid">20976172</pub-id>
</element-citation><mixed-citation id="mc-CR117" publication-type="journal">Candiani G, Pezzoli D, Ciani L, Chiesa R, Ristori S. Bioreducible liposomes for gene delivery: from the formulation to the mechanism of action. PLoS ONE. 2010;5(10):e13430.<pub-id pub-id-type="pmid">20976172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR118"><label>118.</label><citation-alternatives><element-citation id="ec-CR118" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>W</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation</article-title><source>Int J Pharm</source><year>2021</year><volume>606</volume><fpage>120856</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120856</pub-id><pub-id pub-id-type="pmid">34229071</pub-id>
</element-citation><mixed-citation id="mc-CR118" publication-type="journal">He W, Du Y, Wang T, Wang J, Cheng L, Li X. Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation. Int J Pharm. 2021;606:120856.<pub-id pub-id-type="pmid">34229071</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR119"><label>119.</label><citation-alternatives><element-citation id="ec-CR119" publication-type="journal"><person-group person-group-type="author"><name><surname>Chaudhuri</surname><given-names>A</given-names></name><name><surname>Naveen Kumar</surname><given-names>D</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name><name><surname>Kumar Agrawal</surname><given-names>A</given-names></name></person-group><article-title>Functionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer</article-title><source>Eur J Pharm Biopharm</source><year>2024</year><volume>201</volume><fpage>114386</fpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2024.114386</pub-id><pub-id pub-id-type="pmid">38950717</pub-id>
</element-citation><mixed-citation id="mc-CR119" publication-type="journal">Chaudhuri A, Naveen Kumar D, Kumar D, Kumar Agrawal A. Functionalized solid lipid nanoparticles combining docetaxel and erlotinib synergize the anticancer efficacy against triple-negative breast cancer. Eur J Pharm Biopharm. 2024;201:114386.<pub-id pub-id-type="pmid">38950717</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR120"><label>120.</label><mixed-citation publication-type="other">Lee Y, Thompson DH. Stimuli-responsive liposomes for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2017;9(5).</mixed-citation></ref><ref id="CR121"><label>121.</label><citation-alternatives><element-citation id="ec-CR121" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>B</given-names></name><name><surname>Ma</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>P</given-names></name><name><surname>Leng</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><etal/></person-group><article-title>Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment</article-title><source>J Nanobiotechnol</source><year>2022</year><volume>20</volume><issue>1</issue><fpage>140</fpage><pub-id pub-id-type="doi">10.1186/s12951-022-01353-5</pub-id></element-citation><mixed-citation id="mc-CR121" publication-type="journal">Deng B, Ma B, Ma Y, Cao P, Leng X, Huang P, et al. Doxorubicin and CpG loaded liposomal spherical nucleic acid for enhanced Cancer treatment. J Nanobiotechnol. 2022;20(1):140.</mixed-citation></citation-alternatives></ref><ref id="CR122"><label>122.</label><citation-alternatives><element-citation id="ec-CR122" publication-type="journal"><person-group person-group-type="author"><name><surname>Dilda</surname><given-names>PJ</given-names></name><name><surname>Hogg</surname><given-names>PJ</given-names></name></person-group><article-title>Arsenical-based cancer drugs</article-title><source>Cancer Treat Rev</source><year>2007</year><volume>33</volume><issue>6</issue><fpage>542</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1016/j.ctrv.2007.05.001</pub-id><pub-id pub-id-type="pmid">17624680</pub-id>
</element-citation><mixed-citation id="mc-CR122" publication-type="journal">Dilda PJ, Hogg PJ. Arsenical-based cancer drugs. Cancer Treat Rev. 2007;33(6):542&#x02013;64.<pub-id pub-id-type="pmid">17624680</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR123"><label>123.</label><citation-alternatives><element-citation id="ec-CR123" publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Wei-Qi</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>D</given-names></name></person-group><article-title>New insights on sorafenib resistance in liver cancer with correlation of individualized therapy</article-title><source>Biochim Biophys Acta Rev Cancer</source><year>2020</year><volume>1874</volume><issue>1</issue><fpage>188382</fpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188382</pub-id><pub-id pub-id-type="pmid">32522600</pub-id>
</element-citation><mixed-citation id="mc-CR123" publication-type="journal">Cheng Z, Wei-Qi J, Jin D. New insights on sorafenib resistance in liver cancer with correlation of individualized therapy. Biochim Biophys Acta Rev Cancer. 2020;1874(1):188382.<pub-id pub-id-type="pmid">32522600</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR124"><label>124.</label><citation-alternatives><element-citation id="ec-CR124" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><name><surname>Yue</surname><given-names>T</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><etal/></person-group><article-title>MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma</article-title><source>Int J Pharm</source><year>2021</year><volume>609</volume><fpage>121209</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.121209</pub-id><pub-id pub-id-type="pmid">34678398</pub-id>
</element-citation><mixed-citation id="mc-CR124" publication-type="journal">Li C, Zhang K, Liu A, Yue T, Wei Y, Zheng H, et al. MMP2-responsive dual-targeting drug delivery system for valence-controlled arsenic trioxide prodrug delivery against hepatic carcinoma. Int J Pharm. 2021;609:121209.<pub-id pub-id-type="pmid">34678398</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR125"><label>125.</label><citation-alternatives><element-citation id="ec-CR125" publication-type="journal"><person-group person-group-type="author"><name><surname>Quach</surname><given-names>ND</given-names></name><name><surname>Mock</surname><given-names>JN</given-names></name><name><surname>Scholpa</surname><given-names>NE</given-names></name><name><surname>Eggert</surname><given-names>MW</given-names></name><name><surname>Payr&#x000e9;</surname><given-names>C</given-names></name><name><surname>Lambeau</surname><given-names>G</given-names></name><etal/></person-group><article-title>Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells</article-title><source>Mol Pharm</source><year>2014</year><volume>11</volume><issue>10</issue><fpage>3443</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1021/mp500174p</pub-id><pub-id pub-id-type="pmid">25189995</pub-id>
</element-citation><mixed-citation id="mc-CR125" publication-type="journal">Quach ND, Mock JN, Scholpa NE, Eggert MW, Payr&#x000e9; C, Lambeau G, et al. Role of the phospholipase A2 receptor in liposome drug delivery in prostate cancer cells. Mol Pharm. 2014;11(10):3443&#x02013;51.<pub-id pub-id-type="pmid">25189995</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR126"><label>126.</label><citation-alternatives><element-citation id="ec-CR126" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Mock</surname><given-names>JN</given-names></name><name><surname>Aljuffali</surname><given-names>I</given-names></name><name><surname>Cummings</surname><given-names>BS</given-names></name><name><surname>Arnold</surname><given-names>RD</given-names></name></person-group><article-title>Secretory phospholipase A&#x02082; responsive liposomes</article-title><source>J Pharm Sci</source><year>2011</year><volume>100</volume><issue>8</issue><fpage>3146</fpage><lpage>59</lpage><pub-id pub-id-type="doi">10.1002/jps.22530</pub-id><pub-id pub-id-type="pmid">21455978</pub-id>
</element-citation><mixed-citation id="mc-CR126" publication-type="journal">Zhu G, Mock JN, Aljuffali I, Cummings BS, Arnold RD. Secretory phospholipase A&#x02082; responsive liposomes. J Pharm Sci. 2011;100(8):3146&#x02013;59.<pub-id pub-id-type="pmid">21455978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR127"><label>127.</label><citation-alternatives><element-citation id="ec-CR127" publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d8;strem</surname><given-names>RG</given-names></name><name><surname>Parhamifar</surname><given-names>L</given-names></name><name><surname>Pourhassan</surname><given-names>H</given-names></name><name><surname>Clergeaud</surname><given-names>G</given-names></name><name><surname>Nielsen</surname><given-names>OL</given-names></name><name><surname>Kj&#x000e6;r</surname><given-names>A</given-names></name><etal/></person-group><article-title>Secretory phospholipase A(2) responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo</article-title><source>J Control Release</source><year>2017</year><volume>262</volume><fpage>212</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.07.031</pub-id><pub-id pub-id-type="pmid">28754610</pub-id>
</element-citation><mixed-citation id="mc-CR127" publication-type="journal">&#x000d8;strem RG, Parhamifar L, Pourhassan H, Clergeaud G, Nielsen OL, Kj&#x000e6;r A, et al. Secretory phospholipase A(2) responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo. J Control Release. 2017;262:212&#x02013;21.<pub-id pub-id-type="pmid">28754610</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR128"><label>128.</label><citation-alternatives><element-citation id="ec-CR128" publication-type="journal"><person-group person-group-type="author"><name><surname>Pourhassan</surname><given-names>H</given-names></name><name><surname>Clergeaud</surname><given-names>G</given-names></name><name><surname>Hansen</surname><given-names>AE</given-names></name><name><surname>&#x000d8;strem</surname><given-names>RG</given-names></name><name><surname>Fliedner</surname><given-names>FP</given-names></name><name><surname>Melander</surname><given-names>F</given-names></name><etal/></person-group><article-title>Revisiting the use of sPLA(2)-sensitive liposomes in cancer therapy</article-title><source>J Control Release</source><year>2017</year><volume>261</volume><fpage>163</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2017.06.024</pub-id><pub-id pub-id-type="pmid">28662900</pub-id>
</element-citation><mixed-citation id="mc-CR128" publication-type="journal">Pourhassan H, Clergeaud G, Hansen AE, &#x000d8;strem RG, Fliedner FP, Melander F, et al. Revisiting the use of sPLA(2)-sensitive liposomes in cancer therapy. J Control Release. 2017;261:163&#x02013;73.<pub-id pub-id-type="pmid">28662900</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR129"><label>129.</label><mixed-citation publication-type="other">Kobanenko MK, Tretiakova DS, Shchegravina ES, Antipova NV, Boldyrev IA, Fedorov AY et al. Liposomal formulation of a PLA2-Sensitive phospholipid-allocolchicinoid conjugate: Stability and Activity studies in Vitro. Int J Mol Sci. 2022;23(3).</mixed-citation></ref><ref id="CR130"><label>130.</label><citation-alternatives><element-citation id="ec-CR130" publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ni</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>XJ</given-names></name><etal/></person-group><article-title>Metal-based Nanocatalyst for Combined Cancer therapeutics</article-title><source>Bioconjug Chem</source><year>2020</year><volume>31</volume><issue>5</issue><fpage>1247</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1021/acs.bioconjchem.0c00194</pub-id><pub-id pub-id-type="pmid">32319762</pub-id>
</element-citation><mixed-citation id="mc-CR130" publication-type="journal">Han Y, Gao S, Zhang Y, Ni Q, Li Z, Liang XJ, et al. Metal-based Nanocatalyst for Combined Cancer therapeutics. Bioconjug Chem. 2020;31(5):1247&#x02013;58.<pub-id pub-id-type="pmid">32319762</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR131"><label>131.</label><citation-alternatives><element-citation id="ec-CR131" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhen</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><etal/></person-group><article-title>One-Dimensional Fe(2) P acts as a Fenton Agent in response to NIR II light and Ultrasound for Deep Tumor Synergetic Theranostics</article-title><source>Angew Chem Int Ed Engl</source><year>2019</year><volume>58</volume><issue>8</issue><fpage>2407</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1002/anie.201813702</pub-id><pub-id pub-id-type="pmid">30600877</pub-id>
</element-citation><mixed-citation id="mc-CR131" publication-type="journal">Liu Y, Zhen W, Wang Y, Liu J, Jin L, Zhang T, et al. One-Dimensional Fe(2) P acts as a Fenton Agent in response to NIR II light and Ultrasound for Deep Tumor Synergetic Theranostics. Angew Chem Int Ed Engl. 2019;58(8):2407&#x02013;12.<pub-id pub-id-type="pmid">30600877</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR132"><label>132.</label><citation-alternatives><element-citation id="ec-CR132" publication-type="journal"><person-group person-group-type="author"><name><surname>Haeri</surname><given-names>A</given-names></name><name><surname>Zalba</surname><given-names>S</given-names></name><name><surname>Ten Hagen</surname><given-names>TL</given-names></name><name><surname>Dadashzadeh</surname><given-names>S</given-names></name><name><surname>Koning</surname><given-names>GA</given-names></name></person-group><article-title>EGFR targeted thermosensitive liposomes: a novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery</article-title><source>Colloids Surf B Biointerfaces</source><year>2016</year><volume>146</volume><fpage>657</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.colsurfb.2016.06.012</pub-id><pub-id pub-id-type="pmid">27434152</pub-id>
</element-citation><mixed-citation id="mc-CR132" publication-type="journal">Haeri A, Zalba S, Ten Hagen TL, Dadashzadeh S, Koning GA. EGFR targeted thermosensitive liposomes: a novel multifunctional platform for simultaneous tumor targeted and stimulus responsive drug delivery. Colloids Surf B Biointerfaces. 2016;146:657&#x02013;69.<pub-id pub-id-type="pmid">27434152</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR133"><label>133.</label><citation-alternatives><element-citation id="ec-CR133" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Petal-like size-tunable gold wrapped immunoliposome to enhance tumor deep penetration for multimodal guided two-step strategy</article-title><source>J Nanobiotechnol</source><year>2021</year><volume>19</volume><issue>1</issue><fpage>293</fpage><pub-id pub-id-type="doi">10.1186/s12951-021-01004-1</pub-id></element-citation><mixed-citation id="mc-CR133" publication-type="journal">Li Y, Song W, Hu Y, Xia Y, Li Z, Lu Y, et al. Petal-like size-tunable gold wrapped immunoliposome to enhance tumor deep penetration for multimodal guided two-step strategy. J Nanobiotechnol. 2021;19(1):293.</mixed-citation></citation-alternatives></ref><ref id="CR134"><label>134.</label><citation-alternatives><element-citation id="ec-CR134" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Shi</surname><given-names>R</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>X</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The photodynamic/photothermal synergistic therapeutic effect of BODIPY-I-35 liposomes with urea</article-title><source>Photodiagnosis Photodyn Ther</source><year>2022</year><volume>37</volume><fpage>102723</fpage><pub-id pub-id-type="doi">10.1016/j.pdpdt.2022.102723</pub-id><pub-id pub-id-type="pmid">35032702</pub-id>
</element-citation><mixed-citation id="mc-CR134" publication-type="journal">Wang N, Wang Y, Shi R, Lin Y, Jiang X, Feng Y, et al. The photodynamic/photothermal synergistic therapeutic effect of BODIPY-I-35 liposomes with urea. Photodiagnosis Photodyn Ther. 2022;37:102723.<pub-id pub-id-type="pmid">35032702</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR135"><label>135.</label><citation-alternatives><element-citation id="ec-CR135" publication-type="journal"><person-group person-group-type="author"><name><surname>Pitt</surname><given-names>WG</given-names></name><name><surname>Singh</surname><given-names>RN</given-names></name><name><surname>Perez</surname><given-names>KX</given-names></name><name><surname>Husseini</surname><given-names>GA</given-names></name><name><surname>Jack</surname><given-names>DR</given-names></name></person-group><article-title>Phase transitions of perfluorocarbon nanoemulsion induced with ultrasound: a mathematical model</article-title><source>Ultrason Sonochem</source><year>2014</year><volume>21</volume><issue>2</issue><fpage>879</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.ultsonch.2013.08.005</pub-id><pub-id pub-id-type="pmid">24035720</pub-id>
</element-citation><mixed-citation id="mc-CR135" publication-type="journal">Pitt WG, Singh RN, Perez KX, Husseini GA, Jack DR. Phase transitions of perfluorocarbon nanoemulsion induced with ultrasound: a mathematical model. Ultrason Sonochem. 2014;21(2):879&#x02013;91.<pub-id pub-id-type="pmid">24035720</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR136"><label>136.</label><citation-alternatives><element-citation id="ec-CR136" publication-type="journal"><person-group person-group-type="author"><name><surname>Dwivedi</surname><given-names>P</given-names></name><name><surname>Kiran</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Dwivedi</surname><given-names>M</given-names></name><name><surname>Khatik</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>R</given-names></name><etal/></person-group><article-title>Magnetic targeting and Ultrasound activation of Liposome-Microbubble Conjugate for enhanced delivery of Anticancer therapies</article-title><source>ACS Appl Mater Interfaces</source><year>2020</year><volume>12</volume><issue>21</issue><fpage>23737</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1021/acsami.0c05308</pub-id><pub-id pub-id-type="pmid">32374147</pub-id>
</element-citation><mixed-citation id="mc-CR136" publication-type="journal">Dwivedi P, Kiran S, Han S, Dwivedi M, Khatik R, Fan R, et al. Magnetic targeting and Ultrasound activation of Liposome-Microbubble Conjugate for enhanced delivery of Anticancer therapies. ACS Appl Mater Interfaces. 2020;12(21):23737&#x02013;51.<pub-id pub-id-type="pmid">32374147</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR137"><label>137.</label><citation-alternatives><element-citation id="ec-CR137" publication-type="journal"><person-group person-group-type="author"><name><surname>Olsman</surname><given-names>M</given-names></name><name><surname>Sereti</surname><given-names>V</given-names></name><name><surname>Andreassen</surname><given-names>K</given-names></name><name><surname>Snipstad</surname><given-names>S</given-names></name><name><surname>van Wamel</surname><given-names>A</given-names></name><name><surname>Eliasen</surname><given-names>R</given-names></name><etal/></person-group><article-title>Ultrasound-mediated delivery enhances therapeutic efficacy of MMP sensitive liposomes</article-title><source>J Control Release</source><year>2020</year><volume>325</volume><fpage>121</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.06.024</pub-id><pub-id pub-id-type="pmid">32621827</pub-id>
</element-citation><mixed-citation id="mc-CR137" publication-type="journal">Olsman M, Sereti V, Andreassen K, Snipstad S, van Wamel A, Eliasen R, et al. Ultrasound-mediated delivery enhances therapeutic efficacy of MMP sensitive liposomes. J Control Release. 2020;325:121&#x02013;34.<pub-id pub-id-type="pmid">32621827</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR138"><label>138.</label><citation-alternatives><element-citation id="ec-CR138" publication-type="journal"><person-group person-group-type="author"><name><surname>AlSawaftah</surname><given-names>NM</given-names></name><name><surname>Paul</surname><given-names>V</given-names></name><name><surname>Kosaji</surname><given-names>D</given-names></name><name><surname>Khabbaz</surname><given-names>L</given-names></name><name><surname>Awad</surname><given-names>NS</given-names></name><name><surname>Husseini</surname><given-names>GA</given-names></name></person-group><article-title>Ultrasound-sensitive cRGD-modified liposomes as a novel drug delivery system</article-title><source>Artif Cells Nanomed Biotechnol</source><year>2022</year><volume>50</volume><issue>1</issue><fpage>111</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1080/21691401.2022.2074439</pub-id><pub-id pub-id-type="pmid">35543613</pub-id>
</element-citation><mixed-citation id="mc-CR138" publication-type="journal">AlSawaftah NM, Paul V, Kosaji D, Khabbaz L, Awad NS, Husseini GA. Ultrasound-sensitive cRGD-modified liposomes as a novel drug delivery system. Artif Cells Nanomed Biotechnol. 2022;50(1):111&#x02013;20.<pub-id pub-id-type="pmid">35543613</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR139"><label>139.</label><citation-alternatives><element-citation id="ec-CR139" publication-type="journal"><person-group person-group-type="author"><name><surname>de Matos</surname><given-names>MBC</given-names></name><name><surname>Deckers</surname><given-names>R</given-names></name><name><surname>van Elburg</surname><given-names>B</given-names></name><name><surname>Lajoinie</surname><given-names>G</given-names></name><name><surname>de Miranda</surname><given-names>BS</given-names></name><name><surname>Versluis</surname><given-names>M</given-names></name><etal/></person-group><article-title>Ultrasound-sensitive liposomes for triggered Macromolecular Drug Delivery: Formulation and in Vitro characterization</article-title><source>Front Pharmacol</source><year>2019</year><volume>10</volume><fpage>1463</fpage><pub-id pub-id-type="doi">10.3389/fphar.2019.01463</pub-id><pub-id pub-id-type="pmid">31866867</pub-id>
</element-citation><mixed-citation id="mc-CR139" publication-type="journal">de Matos MBC, Deckers R, van Elburg B, Lajoinie G, de Miranda BS, Versluis M, et al. Ultrasound-sensitive liposomes for triggered Macromolecular Drug Delivery: Formulation and in Vitro characterization. Front Pharmacol. 2019;10:1463.<pub-id pub-id-type="pmid">31866867</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR140"><label>140.</label><citation-alternatives><element-citation id="ec-CR140" publication-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>WO</given-names></name><name><surname>Wiley</surname><given-names>Z</given-names></name></person-group><article-title>COVID-19 vaccines</article-title><source>Infect Dis Clin North Am</source><year>2022</year><volume>36</volume><issue>2</issue><fpage>481</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2022.01.008</pub-id><pub-id pub-id-type="pmid">35636910</pub-id>
</element-citation><mixed-citation id="mc-CR140" publication-type="journal">Hahn WO, Wiley Z. COVID-19 vaccines. Infect Dis Clin North Am. 2022;36(2):481&#x02013;94.<pub-id pub-id-type="pmid">35636910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR141"><label>141.</label><citation-alternatives><element-citation id="ec-CR141" publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>TM</given-names></name><name><surname>Cullis</surname><given-names>PR</given-names></name></person-group><article-title>Liposomal drug delivery systems: from concept to clinical applications</article-title><source>Adv Drug Deliv Rev</source><year>2013</year><volume>65</volume><issue>1</issue><fpage>36</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2012.09.037</pub-id><pub-id pub-id-type="pmid">23036225</pub-id>
</element-citation><mixed-citation id="mc-CR141" publication-type="journal">Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36&#x02013;48.<pub-id pub-id-type="pmid">23036225</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR142"><label>142.</label><citation-alternatives><element-citation id="ec-CR142" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Nomakuchi</surname><given-names>T</given-names></name><name><surname>Papaleonidopoulou</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Krainer</surname><given-names>AR</given-names></name></person-group><article-title>Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy</article-title><source>Nat Commun</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>2978</fpage><pub-id pub-id-type="doi">10.1038/s41467-022-30668-y</pub-id><pub-id pub-id-type="pmid">35624092</pub-id>
</element-citation><mixed-citation id="mc-CR142" publication-type="journal">Kim YJ, Nomakuchi T, Papaleonidopoulou F, Yang L, Zhang Q, Krainer AR. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy. Nat Commun. 2022;13(1):2978.<pub-id pub-id-type="pmid">35624092</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR143"><label>143.</label><citation-alternatives><element-citation id="ec-CR143" publication-type="journal"><person-group person-group-type="author"><name><surname>Rossoll</surname><given-names>W</given-names></name><name><surname>Singh</surname><given-names>RN</given-names></name></person-group><article-title>Commentary: current status of gene therapy for spinal muscular atrophy</article-title><source>Front Cell Neurosci</source><year>2022</year><volume>16</volume><fpage>916065</fpage><pub-id pub-id-type="doi">10.3389/fncel.2022.916065</pub-id><pub-id pub-id-type="pmid">35656408</pub-id>
</element-citation><mixed-citation id="mc-CR143" publication-type="journal">Rossoll W, Singh RN. Commentary: current status of gene therapy for spinal muscular atrophy. Front Cell Neurosci. 2022;16:916065.<pub-id pub-id-type="pmid">35656408</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR144"><label>144.</label><citation-alternatives><element-citation id="ec-CR144" publication-type="journal"><person-group person-group-type="author"><name><surname>Makani</surname><given-names>J</given-names></name><name><surname>Luzzatto</surname><given-names>L</given-names></name></person-group><article-title>Of mice and men: from hematopoiesis in mouse models to curative gene therapy for sickle cell disease</article-title><source>Cell</source><year>2022</year><volume>185</volume><issue>8</issue><fpage>1261</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2022.03.031</pub-id><pub-id pub-id-type="pmid">35385685</pub-id>
</element-citation><mixed-citation id="mc-CR144" publication-type="journal">Makani J, Luzzatto L. Of mice and men: from hematopoiesis in mouse models to curative gene therapy for sickle cell disease. Cell. 2022;185(8):1261&#x02013;5.<pub-id pub-id-type="pmid">35385685</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR145"><label>145.</label><citation-alternatives><element-citation id="ec-CR145" publication-type="journal"><person-group person-group-type="author"><name><surname>Leebeek</surname><given-names>FWG</given-names></name><name><surname>Miesbach</surname><given-names>W</given-names></name></person-group><article-title>Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues</article-title><source>Blood</source><year>2021</year><volume>138</volume><issue>11</issue><fpage>923</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1182/blood.2019003777</pub-id><pub-id pub-id-type="pmid">34232980</pub-id>
</element-citation><mixed-citation id="mc-CR145" publication-type="journal">Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. 2021;138(11):923&#x02013;31.<pub-id pub-id-type="pmid">34232980</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR146"><label>146.</label><citation-alternatives><element-citation id="ec-CR146" publication-type="journal"><person-group person-group-type="author"><name><surname>Zu</surname><given-names>H</given-names></name><name><surname>Gao</surname><given-names>D</given-names></name></person-group><article-title>Non-viral vectors in Gene Therapy: recent development, challenges, and prospects</article-title><source>Aaps j</source><year>2021</year><volume>23</volume><issue>4</issue><fpage>78</fpage><pub-id pub-id-type="doi">10.1208/s12248-021-00608-7</pub-id><pub-id pub-id-type="pmid">34076797</pub-id>
</element-citation><mixed-citation id="mc-CR146" publication-type="journal">Zu H, Gao D. Non-viral vectors in Gene Therapy: recent development, challenges, and prospects. Aaps j. 2021;23(4):78.<pub-id pub-id-type="pmid">34076797</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR147"><label>147.</label><citation-alternatives><element-citation id="ec-CR147" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>A</given-names></name><name><surname>Aljarbou</surname><given-names>AN</given-names></name><name><surname>Aldebasi</surname><given-names>YH</given-names></name><name><surname>Allemailem</surname><given-names>KS</given-names></name><name><surname>Alsahli</surname><given-names>MA</given-names></name><name><surname>Khan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fatty acid synthase (FASN) siRNA-Encapsulated-Her-2 targeted Fab&#x02019;-Immunoliposomes for gene silencing in breast Cancer cells</article-title><source>Int J Nanomed</source><year>2020</year><volume>15</volume><fpage>5575</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.2147/IJN.S256022</pub-id></element-citation><mixed-citation id="mc-CR147" publication-type="journal">Khan A, Aljarbou AN, Aldebasi YH, Allemailem KS, Alsahli MA, Khan S, et al. Fatty acid synthase (FASN) siRNA-Encapsulated-Her-2 targeted Fab&#x02019;-Immunoliposomes for gene silencing in breast Cancer cells. Int J Nanomed. 2020;15:5575&#x02013;89.</mixed-citation></citation-alternatives></ref><ref id="CR148"><label>148.</label><citation-alternatives><element-citation id="ec-CR148" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Tian</surname><given-names>C</given-names></name><name><surname>Sun</surname><given-names>Q</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis</article-title><source>Int J Pharm</source><year>2017</year><volume>529</volume><issue>1&#x02013;2</issue><fpage>102</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.06.071</pub-id><pub-id pub-id-type="pmid">28642204</pub-id>
</element-citation><mixed-citation id="mc-CR148" publication-type="journal">Chen X, Zhang Y, Tang C, Tian C, Sun Q, Su Z, et al. Co-delivery of paclitaxel and anti-survivin siRNA via redox-sensitive oligopeptide liposomes for the synergistic treatment of breast cancer and metastasis. Int J Pharm. 2017;529(1&#x02013;2):102&#x02013;15.<pub-id pub-id-type="pmid">28642204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR149"><label>149.</label><citation-alternatives><element-citation id="ec-CR149" publication-type="journal"><person-group person-group-type="author"><name><surname>Safaei</surname><given-names>M</given-names></name><name><surname>Khosravian</surname><given-names>P</given-names></name><name><surname>Kazemi Sheykhshabani</surname><given-names>S</given-names></name><name><surname>Mardani</surname><given-names>G</given-names></name><name><surname>Elahian</surname><given-names>F</given-names></name><name><surname>Mirzaei</surname><given-names>SA</given-names></name></person-group><article-title>Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells</article-title><source>Toxicol Appl Pharmacol</source><year>2022</year><volume>441</volume><fpage>115989</fpage><pub-id pub-id-type="doi">10.1016/j.taap.2022.115989</pub-id><pub-id pub-id-type="pmid">35314202</pub-id>
</element-citation><mixed-citation id="mc-CR149" publication-type="journal">Safaei M, Khosravian P, Kazemi Sheykhshabani S, Mardani G, Elahian F, Mirzaei SA. Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells. Toxicol Appl Pharmacol. 2022;441:115989.<pub-id pub-id-type="pmid">35314202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR150"><label>150.</label><citation-alternatives><element-citation id="ec-CR150" publication-type="journal"><person-group person-group-type="author"><name><surname>Mai</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity</article-title><source>Cell Immunol</source><year>2020</year><volume>354</volume><fpage>104143</fpage><pub-id pub-id-type="doi">10.1016/j.cellimm.2020.104143</pub-id><pub-id pub-id-type="pmid">32563850</pub-id>
</element-citation><mixed-citation id="mc-CR150" publication-type="journal">Mai Y, Guo J, Zhao Y, Ma S, Hou Y, Yang J. Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity. Cell Immunol. 2020;354:104143.<pub-id pub-id-type="pmid">32563850</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR151"><label>151.</label><citation-alternatives><element-citation id="ec-CR151" publication-type="journal"><person-group person-group-type="author"><name><surname>Dolgin</surname><given-names>E</given-names></name></person-group><article-title>The tangled history of mRNA vaccines</article-title><source>Nature</source><year>2021</year><volume>597</volume><issue>7876</issue><fpage>318</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/d41586-021-02483-w</pub-id><pub-id pub-id-type="pmid">34522017</pub-id>
</element-citation><mixed-citation id="mc-CR151" publication-type="journal">Dolgin E. The tangled history of mRNA vaccines. Nature. 2021;597(7876):318&#x02013;24.<pub-id pub-id-type="pmid">34522017</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR152"><label>152.</label><mixed-citation publication-type="other">Zeng C, Zhang C, Walker PG, Dong Y. Formulation and Delivery technologies for mRNA vaccines. Curr Top Microbiol Immunol; 2020.</mixed-citation></ref><ref id="CR153"><label>153.</label><citation-alternatives><element-citation id="ec-CR153" publication-type="journal"><person-group person-group-type="author"><name><surname>Samaridou</surname><given-names>E</given-names></name><name><surname>Heyes</surname><given-names>J</given-names></name><name><surname>Lutwyche</surname><given-names>P</given-names></name></person-group><article-title>Lipid nanoparticles for nucleic acid delivery: current perspectives</article-title><source>Adv Drug Deliv Rev</source><year>2020</year><volume>154&#x02013;155</volume><fpage>37</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2020.06.002</pub-id><pub-id pub-id-type="pmid">32526452</pub-id>
</element-citation><mixed-citation id="mc-CR153" publication-type="journal">Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv Drug Deliv Rev. 2020;154&#x02013;155:37&#x02013;63.<pub-id pub-id-type="pmid">32526452</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR154"><label>154.</label><citation-alternatives><element-citation id="ec-CR154" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name></person-group><article-title>mRNA vaccine Era-Mechanisms, drug platform and clinical prospection</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><fpage>18</fpage><pub-id pub-id-type="doi">10.3390/ijms21186582</pub-id></element-citation><mixed-citation id="mc-CR154" publication-type="journal">Xu S, Yang K, Li R, Zhang L. mRNA vaccine Era-Mechanisms, drug platform and clinical prospection. Int J Mol Sci. 2020;21:18.</mixed-citation></citation-alternatives></ref><ref id="CR155"><label>155.</label><citation-alternatives><element-citation id="ec-CR155" publication-type="journal"><person-group person-group-type="author"><name><surname>Kowalski</surname><given-names>PS</given-names></name><name><surname>Rudra</surname><given-names>A</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name></person-group><article-title>Delivering the Messenger: advances in technologies for therapeutic mRNA delivery</article-title><source>Mol Ther</source><year>2019</year><volume>27</volume><issue>4</issue><fpage>710</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2019.02.012</pub-id><pub-id pub-id-type="pmid">30846391</pub-id>
</element-citation><mixed-citation id="mc-CR155" publication-type="journal">Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the Messenger: advances in technologies for therapeutic mRNA delivery. Mol Ther. 2019;27(4):710&#x02013;28.<pub-id pub-id-type="pmid">30846391</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR156"><label>156.</label><citation-alternatives><element-citation id="ec-CR156" publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>KJ</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name></person-group><article-title>Recent insights into factors affecting remnant lipoprotein uptake</article-title><source>Curr Opin Lipidol</source><year>2010</year><volume>21</volume><issue>3</issue><fpage>218</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1097/MOL.0b013e328338cabc</pub-id><pub-id pub-id-type="pmid">20463470</pub-id>
</element-citation><mixed-citation id="mc-CR156" publication-type="journal">Williams KJ, Chen K. Recent insights into factors affecting remnant lipoprotein uptake. Curr Opin Lipidol. 2010;21(3):218&#x02013;28.<pub-id pub-id-type="pmid">20463470</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR157"><label>157.</label><citation-alternatives><element-citation id="ec-CR157" publication-type="journal"><person-group person-group-type="author"><name><surname>Mennati</surname><given-names>A</given-names></name><name><surname>Rostamizadeh</surname><given-names>K</given-names></name><name><surname>Manjili</surname><given-names>HK</given-names></name><name><surname>Fathi</surname><given-names>M</given-names></name><name><surname>Danafar</surname><given-names>H</given-names></name></person-group><article-title>Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line</article-title><source>Int J Biol Macromol</source><year>2022</year><volume>200</volume><fpage>335</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2021.12.197</pub-id><pub-id pub-id-type="pmid">34999039</pub-id>
</element-citation><mixed-citation id="mc-CR157" publication-type="journal">Mennati A, Rostamizadeh K, Manjili HK, Fathi M, Danafar H. Co-delivery of siRNA and lycopene encapsulated hybrid lipid nanoparticles for dual silencing of insulin-like growth factor 1 receptor in MCF-7 breast cancer cell line. Int J Biol Macromol. 2022;200:335&#x02013;49.<pub-id pub-id-type="pmid">34999039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR158"><label>158.</label><mixed-citation publication-type="other">Connerty P, Moles E, de Bock CE, Jayatilleke N, Smith JL, Meshinchi S et al. Development of siRNA-Loaded lipid nanoparticles targeting long non-coding RNA LINC01257 as a Novel and Safe Therapeutic Approach for t(8;21) Pediatric Acute myeloid leukemia. Pharmaceutics. 2021;13(10).</mixed-citation></ref><ref id="CR159"><label>159.</label><citation-alternatives><element-citation id="ec-CR159" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>S</given-names></name><name><surname>Luo</surname><given-names>Z</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tao</surname><given-names>J</given-names></name><name><surname>Gong</surname><given-names>C</given-names></name><etal/></person-group><source>Improving Cancer Immunotherapy Outcomes Using Biomaterials Angew Chem Int Ed Engl</source><year>2020</year><volume>59</volume><issue>40</issue><fpage>17332</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">32297434</pub-id>
</element-citation><mixed-citation id="mc-CR159" publication-type="journal">Yan S, Luo Z, Li Z, Wang Y, Tao J, Gong C, et al. Improving Cancer Immunotherapy Outcomes Using Biomaterials Angew Chem Int Ed Engl. 2020;59(40):17332&#x02013;43.<pub-id pub-id-type="pmid">32297434</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR160"><label>160.</label><citation-alternatives><element-citation id="ec-CR160" publication-type="journal"><person-group person-group-type="author"><name><surname>Cafri</surname><given-names>G</given-names></name><name><surname>Gartner</surname><given-names>JJ</given-names></name><name><surname>Zaks</surname><given-names>T</given-names></name><name><surname>Hopson</surname><given-names>K</given-names></name><name><surname>Levin</surname><given-names>N</given-names></name><name><surname>Paria</surname><given-names>BC</given-names></name><etal/></person-group><article-title>mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer</article-title><source>J Clin Invest</source><year>2020</year><volume>130</volume><issue>11</issue><fpage>5976</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1172/JCI134915</pub-id><pub-id pub-id-type="pmid">33016924</pub-id>
</element-citation><mixed-citation id="mc-CR160" publication-type="journal">Cafri G, Gartner JJ, Zaks T, Hopson K, Levin N, Paria BC, et al. mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer. J Clin Invest. 2020;130(11):5976&#x02013;88.<pub-id pub-id-type="pmid">33016924</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR161"><label>161.</label><mixed-citation publication-type="other">Zhang H, You X, Wang X, Cui L, Wang Z, Xu F et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through toll-like receptor 4 signaling. Proc Natl Acad Sci U S A. 2021;118(6).</mixed-citation></ref><ref id="CR162"><label>162.</label><citation-alternatives><element-citation id="ec-CR162" publication-type="journal"><person-group person-group-type="author"><name><surname>Kulkarni</surname><given-names>JA</given-names></name><name><surname>Cullis</surname><given-names>PR</given-names></name><name><surname>van der Meel</surname><given-names>R</given-names></name></person-group><article-title>Lipid nanoparticles enabling gene therapies: from concepts to clinical utility</article-title><source>Nucleic Acid Ther</source><year>2018</year><volume>28</volume><issue>3</issue><fpage>146</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1089/nat.2018.0721</pub-id><pub-id pub-id-type="pmid">29683383</pub-id>
</element-citation><mixed-citation id="mc-CR162" publication-type="journal">Kulkarni JA, Cullis PR, van der Meel R. Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther. 2018;28(3):146&#x02013;57.<pub-id pub-id-type="pmid">29683383</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR163"><label>163.</label><citation-alternatives><element-citation id="ec-CR163" publication-type="journal"><person-group person-group-type="author"><name><surname>LoPresti</surname><given-names>ST</given-names></name><name><surname>Arral</surname><given-names>ML</given-names></name><name><surname>Chaudhary</surname><given-names>N</given-names></name><name><surname>Whitehead</surname><given-names>KA</given-names></name></person-group><article-title>The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs</article-title><source>J Control Release</source><year>2022</year><volume>345</volume><fpage>819</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2022.03.046</pub-id><pub-id pub-id-type="pmid">35346768</pub-id>
</element-citation><mixed-citation id="mc-CR163" publication-type="journal">LoPresti ST, Arral ML, Chaudhary N, Whitehead KA. The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs. J Control Release. 2022;345:819&#x02013;31.<pub-id pub-id-type="pmid">35346768</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR164"><label>164.</label><mixed-citation publication-type="other">Masarwy R, Breier D, Stotsky-Oterin L, Ad-El N, Qassem S, Naidu GS et al. Targeted CRISPR/Cas9 lipid nanoparticles elicits therapeutic genome editing in Head and Neck Cancer. Adv Sci (Weinh). 2024:e2411032.</mixed-citation></ref><ref id="CR165"><label>165.</label><citation-alternatives><element-citation id="ec-CR165" publication-type="journal"><person-group person-group-type="author"><name><surname>Dilliard</surname><given-names>SA</given-names></name><name><surname>Cheng</surname><given-names>Q</given-names></name><name><surname>Siegwart</surname><given-names>DJ</given-names></name></person-group><article-title>On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles</article-title><source>Proc Natl Acad Sci U S A</source><year>2021</year><volume>118</volume><fpage>52</fpage><pub-id pub-id-type="doi">10.1073/pnas.2109256118</pub-id></element-citation><mixed-citation id="mc-CR165" publication-type="journal">Dilliard SA, Cheng Q, Siegwart DJ. On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles. Proc Natl Acad Sci U S A. 2021;118:52.</mixed-citation></citation-alternatives></ref><ref id="CR166"><label>166.</label><citation-alternatives><element-citation id="ec-CR166" publication-type="journal"><person-group person-group-type="author"><name><surname>Husain</surname><given-names>SR</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Au</surname><given-names>P</given-names></name><name><surname>Shannon</surname><given-names>K</given-names></name><name><surname>Puri</surname><given-names>RK</given-names></name></person-group><article-title>Gene therapy for cancer: regulatory considerations for approval</article-title><source>Cancer Gene Ther</source><year>2015</year><volume>22</volume><issue>12</issue><fpage>554</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1038/cgt.2015.58</pub-id><pub-id pub-id-type="pmid">26584531</pub-id>
</element-citation><mixed-citation id="mc-CR166" publication-type="journal">Husain SR, Han J, Au P, Shannon K, Puri RK. Gene therapy for cancer: regulatory considerations for approval. Cancer Gene Ther. 2015;22(12):554&#x02013;63.<pub-id pub-id-type="pmid">26584531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR167"><label>167.</label><citation-alternatives><element-citation id="ec-CR167" publication-type="journal"><person-group person-group-type="author"><name><surname>Rothschild</surname><given-names>J</given-names></name></person-group><article-title>Ethical considerations of gene editing and genetic selection</article-title><source>J Gen Fam Med</source><year>2020</year><volume>21</volume><issue>3</issue><fpage>37</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1002/jgf2.321</pub-id><pub-id pub-id-type="pmid">32489755</pub-id>
</element-citation><mixed-citation id="mc-CR167" publication-type="journal">Rothschild J. Ethical considerations of gene editing and genetic selection. J Gen Fam Med. 2020;21(3):37&#x02013;47.<pub-id pub-id-type="pmid">32489755</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR168"><label>168.</label><citation-alternatives><element-citation id="ec-CR168" publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>P</given-names></name></person-group><article-title>Patentability of genes: a European Union perspective</article-title><source>Cold Spring Harb Perspect Med</source><year>2014</year><volume>5</volume><issue>5</issue><fpage>a020891</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a020891</pub-id><pub-id pub-id-type="pmid">25324232</pub-id>
</element-citation><mixed-citation id="mc-CR168" publication-type="journal">Cole P. Patentability of genes: a European Union perspective. Cold Spring Harb Perspect Med. 2014;5(5):a020891.<pub-id pub-id-type="pmid">25324232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR169"><label>169.</label><citation-alternatives><element-citation id="ec-CR169" publication-type="journal"><person-group person-group-type="author"><name><surname>Druedahl</surname><given-names>LC</given-names></name><name><surname>Minssen</surname><given-names>T</given-names></name><name><surname>Price</surname><given-names>WN</given-names></name></person-group><article-title>Collaboration in times of crisis: a study on COVID-19 vaccine R&#x00026;D partnerships</article-title><source>Vaccine</source><year>2021</year><volume>39</volume><issue>42</issue><fpage>6291</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2021.08.101</pub-id><pub-id pub-id-type="pmid">34556366</pub-id>
</element-citation><mixed-citation id="mc-CR169" publication-type="journal">Druedahl LC, Minssen T, Price WN. Collaboration in times of crisis: a study on COVID-19 vaccine R&#x00026;D partnerships. Vaccine. 2021;39(42):6291&#x02013;5.<pub-id pub-id-type="pmid">34556366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR170"><label>170.</label><citation-alternatives><element-citation id="ec-CR170" publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>SN</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Kim</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>KY</given-names></name><etal/></person-group><article-title>Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model</article-title><source>Nanomedicine</source><year>2021</year><volume>37</volume><fpage>102415</fpage><pub-id pub-id-type="doi">10.1016/j.nano.2021.102415</pub-id><pub-id pub-id-type="pmid">34174421</pub-id>
</element-citation><mixed-citation id="mc-CR170" publication-type="journal">Koh J, Kim S, Lee SN, Kim SY, Kim JE, Lee KY, et al. Therapeutic efficacy of cancer vaccine adjuvanted with nanoemulsion loaded with TLR7/8 agonist in lung cancer model. Nanomedicine. 2021;37:102415.<pub-id pub-id-type="pmid">34174421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR171"><label>171.</label><citation-alternatives><element-citation id="ec-CR171" publication-type="journal"><person-group person-group-type="author"><name><surname>Mirzaei-Parsa</surname><given-names>MJ</given-names></name><name><surname>Najafabadi</surname><given-names>MRH</given-names></name><name><surname>Haeri</surname><given-names>A</given-names></name><name><surname>Zahmatkeshan</surname><given-names>M</given-names></name><name><surname>Ebrahimi</surname><given-names>SA</given-names></name><name><surname>Pazoki-Toroudi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer</article-title><source>Breast Cancer</source><year>2020</year><volume>27</volume><issue>2</issue><fpage>243</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/s12282-019-01014-w</pub-id><pub-id pub-id-type="pmid">31621052</pub-id>
</element-citation><mixed-citation id="mc-CR171" publication-type="journal">Mirzaei-Parsa MJ, Najafabadi MRH, Haeri A, Zahmatkeshan M, Ebrahimi SA, Pazoki-Toroudi H, et al. Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer. Breast Cancer. 2020;27(2):243&#x02013;51.<pub-id pub-id-type="pmid">31621052</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR172"><label>172.</label><citation-alternatives><element-citation id="ec-CR172" publication-type="journal"><person-group person-group-type="author"><name><surname>Digiacomo</surname><given-names>L</given-names></name><name><surname>Pozzi</surname><given-names>D</given-names></name><name><surname>Amenitsch</surname><given-names>H</given-names></name><name><surname>Caracciolo</surname><given-names>G</given-names></name></person-group><article-title>Impact of the biomolecular corona on the structure of PEGylated liposomes</article-title><source>Biomater Sci</source><year>2017</year><volume>5</volume><issue>9</issue><fpage>1884</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1039/C7BM00387K</pub-id><pub-id pub-id-type="pmid">28676869</pub-id>
</element-citation><mixed-citation id="mc-CR172" publication-type="journal">Digiacomo L, Pozzi D, Amenitsch H, Caracciolo G. Impact of the biomolecular corona on the structure of PEGylated liposomes. Biomater Sci. 2017;5(9):1884&#x02013;8.<pub-id pub-id-type="pmid">28676869</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR173"><label>173.</label><citation-alternatives><element-citation id="ec-CR173" publication-type="journal"><person-group person-group-type="author"><name><surname>Ke</surname><given-names>PC</given-names></name><name><surname>Lin</surname><given-names>S</given-names></name><name><surname>Parak</surname><given-names>WJ</given-names></name><name><surname>Davis</surname><given-names>TP</given-names></name><name><surname>Caruso</surname><given-names>F</given-names></name></person-group><article-title>A decade of the Protein Corona</article-title><source>ACS Nano</source><year>2017</year><volume>11</volume><issue>12</issue><fpage>11773</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1021/acsnano.7b08008</pub-id><pub-id pub-id-type="pmid">29206030</pub-id>
</element-citation><mixed-citation id="mc-CR173" publication-type="journal">Ke PC, Lin S, Parak WJ, Davis TP, Caruso F. A decade of the Protein Corona. ACS Nano. 2017;11(12):11773&#x02013;6.<pub-id pub-id-type="pmid">29206030</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR174"><label>174.</label><citation-alternatives><element-citation id="ec-CR174" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>K</given-names></name><name><surname>Yu</surname><given-names>Y</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>Tian</surname><given-names>K</given-names></name><name><surname>Guo</surname><given-names>Z</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protein corona on brain targeted nanocarriers: challenges and prospects</article-title><source>Adv Drug Deliv Rev</source><year>2023</year><volume>202</volume><fpage>115114</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2023.115114</pub-id><pub-id pub-id-type="pmid">37827336</pub-id>
</element-citation><mixed-citation id="mc-CR174" publication-type="journal">Jiang K, Yu Y, Qiu W, Tian K, Guo Z, Qian J, et al. Protein corona on brain targeted nanocarriers: challenges and prospects. Adv Drug Deliv Rev. 2023;202:115114.<pub-id pub-id-type="pmid">37827336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR175"><label>175.</label><citation-alternatives><element-citation id="ec-CR175" publication-type="journal"><person-group person-group-type="author"><name><surname>Hajipour</surname><given-names>MJ</given-names></name><name><surname>Safavi-Sohi</surname><given-names>R</given-names></name><name><surname>Sharifi</surname><given-names>S</given-names></name><name><surname>Mahmoud</surname><given-names>N</given-names></name><name><surname>Ashkarran</surname><given-names>AA</given-names></name><name><surname>Voke</surname><given-names>E</given-names></name><etal/></person-group><article-title>An overview of nanoparticle protein Corona Literature</article-title><source>Small</source><year>2023</year><volume>19</volume><issue>36</issue><fpage>e2301838</fpage><pub-id pub-id-type="doi">10.1002/smll.202301838</pub-id><pub-id pub-id-type="pmid">37119440</pub-id>
</element-citation><mixed-citation id="mc-CR175" publication-type="journal">Hajipour MJ, Safavi-Sohi R, Sharifi S, Mahmoud N, Ashkarran AA, Voke E, et al. An overview of nanoparticle protein Corona Literature. Small. 2023;19(36):e2301838.<pub-id pub-id-type="pmid">37119440</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR176"><label>176.</label><citation-alternatives><element-citation id="ec-CR176" publication-type="journal"><person-group person-group-type="author"><name><surname>Ritz</surname><given-names>S</given-names></name><name><surname>Sch&#x000f6;ttler</surname><given-names>S</given-names></name><name><surname>Kotman</surname><given-names>N</given-names></name><name><surname>Baier</surname><given-names>G</given-names></name><name><surname>Musyanovych</surname><given-names>A</given-names></name><name><surname>Kuharev</surname><given-names>J</given-names></name><etal/></person-group><article-title>Protein corona of nanoparticles: distinct proteins regulate the cellular uptake</article-title><source>Biomacromolecules</source><year>2015</year><volume>16</volume><issue>4</issue><fpage>1311</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1021/acs.biomac.5b00108</pub-id><pub-id pub-id-type="pmid">25794196</pub-id>
</element-citation><mixed-citation id="mc-CR176" publication-type="journal">Ritz S, Sch&#x000f6;ttler S, Kotman N, Baier G, Musyanovych A, Kuharev J, et al. Protein corona of nanoparticles: distinct proteins regulate the cellular uptake. Biomacromolecules. 2015;16(4):1311&#x02013;21.<pub-id pub-id-type="pmid">25794196</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR177"><label>177.</label><citation-alternatives><element-citation id="ec-CR177" publication-type="journal"><person-group person-group-type="author"><name><surname>Onishchenko</surname><given-names>N</given-names></name><name><surname>Tretiakova</surname><given-names>D</given-names></name><name><surname>Vodovozova</surname><given-names>E</given-names></name></person-group><article-title>Spotlight on the protein corona of liposomes</article-title><source>Acta Biomater</source><year>2021</year><volume>134</volume><fpage>57</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.actbio.2021.07.074</pub-id><pub-id pub-id-type="pmid">34364016</pub-id>
</element-citation><mixed-citation id="mc-CR177" publication-type="journal">Onishchenko N, Tretiakova D, Vodovozova E. Spotlight on the protein corona of liposomes. Acta Biomater. 2021;134:57&#x02013;78.<pub-id pub-id-type="pmid">34364016</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR178"><label>178.</label><citation-alternatives><element-citation id="ec-CR178" publication-type="journal"><person-group person-group-type="author"><name><surname>Corbo</surname><given-names>C</given-names></name><name><surname>Molinaro</surname><given-names>R</given-names></name><name><surname>Taraballi</surname><given-names>F</given-names></name><name><surname>Toledano Furman</surname><given-names>NE</given-names></name><name><surname>Sherman</surname><given-names>MB</given-names></name><name><surname>Parodi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Effects of the protein corona on liposome-liposome and liposome-cell interactions</article-title><source>Int J Nanomed</source><year>2016</year><volume>11</volume><fpage>3049</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.2147/IJN.S109059</pub-id></element-citation><mixed-citation id="mc-CR178" publication-type="journal">Corbo C, Molinaro R, Taraballi F, Toledano Furman NE, Sherman MB, Parodi A, et al. Effects of the protein corona on liposome-liposome and liposome-cell interactions. Int J Nanomed. 2016;11:3049&#x02013;63.</mixed-citation></citation-alternatives></ref><ref id="CR179"><label>179.</label><citation-alternatives><element-citation id="ec-CR179" publication-type="journal"><person-group person-group-type="author"><name><surname>Pozzi</surname><given-names>D</given-names></name><name><surname>Colapicchioni</surname><given-names>V</given-names></name><name><surname>Caracciolo</surname><given-names>G</given-names></name><name><surname>Piovesana</surname><given-names>S</given-names></name><name><surname>Capriotti</surname><given-names>AL</given-names></name><name><surname>Palchetti</surname><given-names>S</given-names></name><etal/></person-group><article-title>Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells</article-title><source>Nanoscale</source><year>2014</year><volume>6</volume><issue>5</issue><fpage>2782</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1039/c3nr05559k</pub-id><pub-id pub-id-type="pmid">24463404</pub-id>
</element-citation><mixed-citation id="mc-CR179" publication-type="journal">Pozzi D, Colapicchioni V, Caracciolo G, Piovesana S, Capriotti AL, Palchetti S, et al. Effect of polyethyleneglycol (PEG) chain length on the bio-nano-interactions between PEGylated lipid nanoparticles and biological fluids: from nanostructure to uptake in cancer cells. Nanoscale. 2014;6(5):2782&#x02013;92.<pub-id pub-id-type="pmid">24463404</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR180"><label>180.</label><citation-alternatives><element-citation id="ec-CR180" publication-type="journal"><person-group person-group-type="author"><name><surname>Bigdeli</surname><given-names>A</given-names></name><name><surname>Palchetti</surname><given-names>S</given-names></name><name><surname>Pozzi</surname><given-names>D</given-names></name><name><surname>Hormozi-Nezhad</surname><given-names>MR</given-names></name><name><surname>Baldelli Bombelli</surname><given-names>F</given-names></name><name><surname>Caracciolo</surname><given-names>G</given-names></name><etal/></person-group><article-title>Exploring Cellular interactions of liposomes using protein Corona fingerprints and Physicochemical Properties</article-title><source>ACS Nano</source><year>2016</year><volume>10</volume><issue>3</issue><fpage>3723</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1021/acsnano.6b00261</pub-id><pub-id pub-id-type="pmid">26882007</pub-id>
</element-citation><mixed-citation id="mc-CR180" publication-type="journal">Bigdeli A, Palchetti S, Pozzi D, Hormozi-Nezhad MR, Baldelli Bombelli F, Caracciolo G, et al. Exploring Cellular interactions of liposomes using protein Corona fingerprints and Physicochemical Properties. ACS Nano. 2016;10(3):3723&#x02013;37.<pub-id pub-id-type="pmid">26882007</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR181"><label>181.</label><citation-alternatives><element-citation id="ec-CR181" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Ganesh</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Amiji</surname><given-names>M</given-names></name></person-group><article-title>The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles</article-title><source>Nanoscale</source><year>2019</year><volume>11</volume><issue>18</issue><fpage>8760</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1039/C8NR09855G</pub-id><pub-id pub-id-type="pmid">30793730</pub-id>
</element-citation><mixed-citation id="mc-CR181" publication-type="journal">Chen D, Ganesh S, Wang W, Amiji M. The role of surface chemistry in serum protein corona-mediated cellular delivery and gene silencing with lipid nanoparticles. Nanoscale. 2019;11(18):8760&#x02013;75.<pub-id pub-id-type="pmid">30793730</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR182"><label>182.</label><citation-alternatives><element-citation id="ec-CR182" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Zhan</surname><given-names>C</given-names></name></person-group><article-title>Protein corona: challenges and opportunities for targeted delivery of nanomedicines</article-title><source>Expert Opin Drug Deliv</source><year>2022</year><volume>19</volume><issue>7</issue><fpage>833</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1080/17425247.2022.2093854</pub-id><pub-id pub-id-type="pmid">35738018</pub-id>
</element-citation><mixed-citation id="mc-CR182" publication-type="journal">Jiang Z, Chu Y, Zhan C. Protein corona: challenges and opportunities for targeted delivery of nanomedicines. Expert Opin Drug Deliv. 2022;19(7):833&#x02013;46.<pub-id pub-id-type="pmid">35738018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR183"><label>183.</label><citation-alternatives><element-citation id="ec-CR183" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Q</given-names></name><name><surname>Zoulikha</surname><given-names>M</given-names></name><name><surname>Qiu</surname><given-names>M</given-names></name><name><surname>Teng</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><etal/></person-group><article-title>The effects of protein corona on in vivo fate of nanocarriers</article-title><source>Adv Drug Deliv Rev</source><year>2022</year><volume>186</volume><fpage>114356</fpage><pub-id pub-id-type="doi">10.1016/j.addr.2022.114356</pub-id><pub-id pub-id-type="pmid">35595022</pub-id>
</element-citation><mixed-citation id="mc-CR183" publication-type="journal">Xiao Q, Zoulikha M, Qiu M, Teng C, Lin C, Li X, et al. The effects of protein corona on in vivo fate of nanocarriers. Adv Drug Deliv Rev. 2022;186:114356.<pub-id pub-id-type="pmid">35595022</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR184"><label>184.</label><citation-alternatives><element-citation id="ec-CR184" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>T</given-names></name><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>P</given-names></name><etal/></person-group><article-title>Interrogation of folic acid-functionalized nanomedicines: the Regulatory roles of plasma proteins reexamined</article-title><source>ACS Nano</source><year>2020</year><volume>14</volume><issue>11</issue><fpage>14779</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c02821</pub-id><pub-id pub-id-type="pmid">33084315</pub-id>
</element-citation><mixed-citation id="mc-CR184" publication-type="journal">Wang H, Ding T, Guan J, Liu X, Wang J, Jin P, et al. Interrogation of folic acid-functionalized nanomedicines: the Regulatory roles of plasma proteins reexamined. ACS Nano. 2020;14(11):14779&#x02013;89.<pub-id pub-id-type="pmid">33084315</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR185"><label>185.</label><citation-alternatives><element-citation id="ec-CR185" publication-type="journal"><person-group person-group-type="author"><name><surname>Salvati</surname><given-names>A</given-names></name><name><surname>Pitek</surname><given-names>AS</given-names></name><name><surname>Monopoli</surname><given-names>MP</given-names></name><name><surname>Prapainop</surname><given-names>K</given-names></name><name><surname>Bombelli</surname><given-names>FB</given-names></name><name><surname>Hristov</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface</article-title><source>Nat Nanotechnol</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>137</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1038/nnano.2012.237</pub-id><pub-id pub-id-type="pmid">23334168</pub-id>
</element-citation><mixed-citation id="mc-CR185" publication-type="journal">Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013;8(2):137&#x02013;43.<pub-id pub-id-type="pmid">23334168</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR186"><label>186.</label><citation-alternatives><element-citation id="ec-CR186" publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Luo</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Protein corona, influence on drug delivery system and its improvement strategy: a review</article-title><source>Int J Biol Macromol</source><year>2024</year><volume>256</volume><issue>Pt 2</issue><fpage>128513</fpage><pub-id pub-id-type="doi">10.1016/j.ijbiomac.2023.128513</pub-id><pub-id pub-id-type="pmid">38040159</pub-id>
</element-citation><mixed-citation id="mc-CR186" publication-type="journal">Guo F, Luo S, Wang L, Wang M, Wu F, Wang Y, et al. Protein corona, influence on drug delivery system and its improvement strategy: a review. Int J Biol Macromol. 2024;256(Pt 2):128513.<pub-id pub-id-type="pmid">38040159</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR187"><label>187.</label><citation-alternatives><element-citation id="ec-CR187" publication-type="journal"><person-group person-group-type="author"><name><surname>Kurtz-Chalot</surname><given-names>A</given-names></name><name><surname>Villiers</surname><given-names>C</given-names></name><name><surname>Pourchez</surname><given-names>J</given-names></name><name><surname>Boudard</surname><given-names>D</given-names></name><name><surname>Martini</surname><given-names>M</given-names></name><name><surname>Marche</surname><given-names>PN</given-names></name><etal/></person-group><article-title>Impact of silica nanoparticle surface chemistry on protein corona formation and consequential interactions with biological cells</article-title><source>Mater Sci Eng C Mater Biol Appl</source><year>2017</year><volume>75</volume><fpage>16</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1016/j.msec.2017.02.028</pub-id><pub-id pub-id-type="pmid">28415450</pub-id>
</element-citation><mixed-citation id="mc-CR187" publication-type="journal">Kurtz-Chalot A, Villiers C, Pourchez J, Boudard D, Martini M, Marche PN, et al. Impact of silica nanoparticle surface chemistry on protein corona formation and consequential interactions with biological cells. Mater Sci Eng C Mater Biol Appl. 2017;75:16&#x02013;24.<pub-id pub-id-type="pmid">28415450</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR188"><label>188.</label><mixed-citation publication-type="other">Kozma GT, Shimizu T, Ishida T, Szebeni J. Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals. Adv Drug Deliv Rev. 2020;154&#x02013;5:163&#x02013;75.</mixed-citation></ref><ref id="CR189"><label>189.</label><citation-alternatives><element-citation id="ec-CR189" publication-type="journal"><person-group person-group-type="author"><name><surname>Zahednezhad</surname><given-names>F</given-names></name><name><surname>Saadat</surname><given-names>M</given-names></name><name><surname>Valizadeh</surname><given-names>H</given-names></name><name><surname>Zakeri-Milani</surname><given-names>P</given-names></name><name><surname>Baradaran</surname><given-names>B</given-names></name></person-group><article-title>Liposome and immune system interplay: challenges and potentials</article-title><source>J Control Release</source><year>2019</year><volume>305</volume><fpage>194</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2019.05.030</pub-id><pub-id pub-id-type="pmid">31121278</pub-id>
</element-citation><mixed-citation id="mc-CR189" publication-type="journal">Zahednezhad F, Saadat M, Valizadeh H, Zakeri-Milani P, Baradaran B. Liposome and immune system interplay: challenges and potentials. J Control Release. 2019;305:194&#x02013;209.<pub-id pub-id-type="pmid">31121278</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR190"><label>190.</label><citation-alternatives><element-citation id="ec-CR190" publication-type="journal"><person-group person-group-type="author"><name><surname>Estap&#x000e9; Senti</surname><given-names>M</given-names></name><name><surname>de Jongh</surname><given-names>CA</given-names></name><name><surname>Dijkxhoorn</surname><given-names>K</given-names></name><name><surname>Verhoef</surname><given-names>JJF</given-names></name><name><surname>Szebeni</surname><given-names>J</given-names></name><name><surname>Storm</surname><given-names>G</given-names></name><etal/></person-group><article-title>Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement</article-title><source>J Control Release</source><year>2022</year><volume>341</volume><fpage>475</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2021.11.042</pub-id><pub-id pub-id-type="pmid">34890719</pub-id>
</element-citation><mixed-citation id="mc-CR190" publication-type="journal">Estap&#x000e9; Senti M, de Jongh CA, Dijkxhoorn K, Verhoef JJF, Szebeni J, Storm G, et al. Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement. J Control Release. 2022;341:475&#x02013;86.<pub-id pub-id-type="pmid">34890719</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR191"><label>191.</label><citation-alternatives><element-citation id="ec-CR191" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Qian</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><etal/></person-group><article-title>Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines</article-title><source>J Control Release</source><year>2021</year><volume>330</volume><fpage>493</fpage><lpage>501</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2020.12.047</pub-id><pub-id pub-id-type="pmid">33383098</pub-id>
</element-citation><mixed-citation id="mc-CR191" publication-type="journal">Zhang Z, Chu Y, Li C, Tang W, Qian J, Wei X, et al. Anti-PEG scFv corona ameliorates accelerated blood clearance phenomenon of PEGylated nanomedicines. J Control Release. 2021;330:493&#x02013;501.<pub-id pub-id-type="pmid">33383098</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR192"><label>192.</label><citation-alternatives><element-citation id="ec-CR192" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>Z</given-names></name></person-group><article-title>Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications</article-title><source>Adv Mater</source><year>2010</year><volume>22</volume><issue>9</issue><fpage>920</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1002/adma.200901407</pub-id><pub-id pub-id-type="pmid">20217815</pub-id>
</element-citation><mixed-citation id="mc-CR192" publication-type="journal">Jiang S, Cao Z. Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications. Adv Mater. 2010;22(9):920&#x02013;32.<pub-id pub-id-type="pmid">20217815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR193"><label>193.</label><citation-alternatives><element-citation id="ec-CR193" publication-type="journal"><person-group person-group-type="author"><name><surname>Schlenoff</surname><given-names>JB</given-names></name></person-group><article-title>Zwitteration: coating surfaces with zwitterionic functionality to reduce nonspecific adsorption</article-title><source>Langmuir</source><year>2014</year><volume>30</volume><issue>32</issue><fpage>9625</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1021/la500057j</pub-id><pub-id pub-id-type="pmid">24754399</pub-id>
</element-citation><mixed-citation id="mc-CR193" publication-type="journal">Schlenoff JB. Zwitteration: coating surfaces with zwitterionic functionality to reduce nonspecific adsorption. Langmuir. 2014;30(32):9625&#x02013;36.<pub-id pub-id-type="pmid">24754399</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR194"><label>194.</label><citation-alternatives><element-citation id="ec-CR194" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Yuk</surname><given-names>SA</given-names></name><name><surname>Dieterly</surname><given-names>AM</given-names></name><name><surname>Kwon</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><etal/></person-group><article-title>Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, enables systemic delivery of siRNA to solid tumors</article-title><source>ACS Nano</source><year>2021</year><volume>15</volume><issue>3</issue><fpage>4576</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1021/acsnano.0c08694</pub-id><pub-id pub-id-type="pmid">33645963</pub-id>
</element-citation><mixed-citation id="mc-CR194" publication-type="journal">Kim H, Yuk SA, Dieterly AM, Kwon S, Park J, Meng F, et al. Nanosac, a Noncationic and Soft Polyphenol Nanocapsule, enables systemic delivery of siRNA to solid tumors. ACS Nano. 2021;15(3):4576&#x02013;93.<pub-id pub-id-type="pmid">33645963</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR195"><label>195.</label><citation-alternatives><element-citation id="ec-CR195" publication-type="journal"><person-group person-group-type="author"><name><surname>G&#x000f6;ppert</surname><given-names>TM</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>RH</given-names></name></person-group><article-title>Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns</article-title><source>J Drug Target</source><year>2005</year><volume>13</volume><issue>3</issue><fpage>179</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1080/10611860500071292</pub-id><pub-id pub-id-type="pmid">16036306</pub-id>
</element-citation><mixed-citation id="mc-CR195" publication-type="journal">G&#x000f6;ppert TM, M&#x000fc;ller RH. Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: comparison of plasma protein adsorption patterns. J Drug Target. 2005;13(3):179&#x02013;87.<pub-id pub-id-type="pmid">16036306</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR196"><label>196.</label><citation-alternatives><element-citation id="ec-CR196" publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Luo</surname><given-names>K</given-names></name></person-group><article-title>Artificial intelligence aids in development of nanomedicines for cancer management</article-title><source>Semin Cancer Biol</source><year>2023</year><volume>89</volume><fpage>61</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2023.01.005</pub-id><pub-id pub-id-type="pmid">36682438</pub-id>
</element-citation><mixed-citation id="mc-CR196" publication-type="journal">Tan P, Chen X, Zhang H, Wei Q, Luo K. Artificial intelligence aids in development of nanomedicines for cancer management. Semin Cancer Biol. 2023;89:61&#x02013;75.<pub-id pub-id-type="pmid">36682438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR197"><label>197.</label><citation-alternatives><element-citation id="ec-CR197" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>Y</given-names></name><name><surname>Islam</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>S</given-names></name><etal/></person-group><article-title>Smart nanoparticles for cancer therapy</article-title><source>Signal Transduct Target Ther</source><year>2023</year><volume>8</volume><issue>1</issue><fpage>418</fpage><pub-id pub-id-type="doi">10.1038/s41392-023-01642-x</pub-id><pub-id pub-id-type="pmid">37919282</pub-id>
</element-citation><mixed-citation id="mc-CR197" publication-type="journal">Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023;8(1):418.<pub-id pub-id-type="pmid">37919282</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR198"><label>198.</label><citation-alternatives><element-citation id="ec-CR198" publication-type="journal"><person-group person-group-type="author"><name><surname>Tenzer</surname><given-names>S</given-names></name><name><surname>Docter</surname><given-names>D</given-names></name><name><surname>Kuharev</surname><given-names>J</given-names></name><name><surname>Musyanovych</surname><given-names>A</given-names></name><name><surname>Fetz</surname><given-names>V</given-names></name><name><surname>Hecht</surname><given-names>R</given-names></name><etal/></person-group><article-title>Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology</article-title><source>Nat Nanotechnol</source><year>2013</year><volume>8</volume><issue>10</issue><fpage>772</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1038/nnano.2013.181</pub-id><pub-id pub-id-type="pmid">24056901</pub-id>
</element-citation><mixed-citation id="mc-CR198" publication-type="journal">Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, et al. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013;8(10):772&#x02013;81.<pub-id pub-id-type="pmid">24056901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR199"><label>199.</label><citation-alternatives><element-citation id="ec-CR199" publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>Z</given-names></name><name><surname>Yuan</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Peng</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name></person-group><article-title>Machine learning predicts the functional composition of the protein corona and the cellular recognition of nanoparticles</article-title><source>Proc Natl Acad Sci U S A</source><year>2020</year><volume>117</volume><issue>19</issue><fpage>10492</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1073/pnas.1919755117</pub-id><pub-id pub-id-type="pmid">32332167</pub-id>
</element-citation><mixed-citation id="mc-CR199" publication-type="journal">Ban Z, Yuan P, Yu F, Peng T, Zhou Q, Hu X. Machine learning predicts the functional composition of the protein corona and the cellular recognition of nanoparticles. Proc Natl Acad Sci U S A. 2020;117(19):10492&#x02013;9.<pub-id pub-id-type="pmid">32332167</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR200"><label>200.</label><citation-alternatives><element-citation id="ec-CR200" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>M</given-names></name><name><surname>Zhuang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures</article-title><source>Nat Nanotechnol</source><year>2023</year><volume>18</volume><issue>6</issue><fpage>657</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1038/s41565-023-01323-4</pub-id><pub-id pub-id-type="pmid">36781994</pub-id>
</element-citation><mixed-citation id="mc-CR200" publication-type="journal">Zhu M, Zhuang J, Li Z, Liu Q, Zhao R, Gao Z, et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures. Nat Nanotechnol. 2023;18(6):657&#x02013;66.<pub-id pub-id-type="pmid">36781994</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR201"><label>201.</label><citation-alternatives><element-citation id="ec-CR201" publication-type="journal"><person-group person-group-type="author"><name><surname>Narang</surname><given-names>AS</given-names></name><name><surname>Chang</surname><given-names>RK</given-names></name><name><surname>Hussain</surname><given-names>MA</given-names></name></person-group><article-title>Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems</article-title><source>J Pharm Sci</source><year>2013</year><volume>102</volume><issue>11</issue><fpage>3867</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1002/jps.23691</pub-id><pub-id pub-id-type="pmid">24037829</pub-id>
</element-citation><mixed-citation id="mc-CR201" publication-type="journal">Narang AS, Chang RK, Hussain MA. Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. J Pharm Sci. 2013;102(11):3867&#x02013;82.<pub-id pub-id-type="pmid">24037829</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR202"><label>202.</label><citation-alternatives><element-citation id="ec-CR202" publication-type="journal"><person-group person-group-type="author"><name><surname>Teli</surname><given-names>MK</given-names></name><name><surname>Mutalik</surname><given-names>S</given-names></name><name><surname>Rajanikant</surname><given-names>GK</given-names></name></person-group><article-title>Nanotechnology and nanomedicine: going small means aiming big</article-title><source>Curr Pharm Des</source><year>2010</year><volume>16</volume><issue>16</issue><fpage>1882</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.2174/138161210791208992</pub-id><pub-id pub-id-type="pmid">20222866</pub-id>
</element-citation><mixed-citation id="mc-CR202" publication-type="journal">Teli MK, Mutalik S, Rajanikant GK. Nanotechnology and nanomedicine: going small means aiming big. Curr Pharm Des. 2010;16(16):1882&#x02013;92.<pub-id pub-id-type="pmid">20222866</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR203"><label>203.</label><citation-alternatives><element-citation id="ec-CR203" publication-type="journal"><person-group person-group-type="author"><name><surname>Caracciolo</surname><given-names>G</given-names></name><name><surname>Pozzi</surname><given-names>D</given-names></name><name><surname>Capriotti</surname><given-names>AL</given-names></name><name><surname>Cavaliere</surname><given-names>C</given-names></name><name><surname>Piovesana</surname><given-names>S</given-names></name><name><surname>La Barbera</surname><given-names>G</given-names></name><etal/></person-group><article-title>The liposome-protein corona in mice and humans and its implications for in vivo delivery</article-title><source>J Mater Chem B</source><year>2014</year><volume>2</volume><issue>42</issue><fpage>7419</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1039/C4TB01316F</pub-id><pub-id pub-id-type="pmid">32261967</pub-id>
</element-citation><mixed-citation id="mc-CR203" publication-type="journal">Caracciolo G, Pozzi D, Capriotti AL, Cavaliere C, Piovesana S, La Barbera G, et al. The liposome-protein corona in mice and humans and its implications for in vivo delivery. J Mater Chem B. 2014;2(42):7419&#x02013;28.<pub-id pub-id-type="pmid">32261967</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>